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Non-elevation acute myocardial infarction (NSTEMI) is one of the commonest 
phenotype of acute coronary syndrome (ACS) and associated with significant 
morbidity and mortality at the short and long term. An invasive strategy in the form 
of coronary angiography (CA) or percutaneous coronary intervention (PCI) allows 
an early assessment of coronary anatomy, identify culprit lesions and plan further 
management. While the effectiveness of the invasive strategy is well documented in 
clinical trials, there is limited data regarding the changes in demographics, risk 
profile and comorbidity burden of patients receiving invasive strategy in 
contemporary practice. Furthermore, the opinion is divided regarding the optimal 
timing of invasive strategy in this cohort and it is unclear how risk stratification 
guides the utilisation of invasive strategy in a real world setting.  
Consequently, this thesis was designed to determine, 1) changes in characteristics, 
risk profile and comorbidity burden of patients admitted with a diagnosis of an 
NSTEMI and how this relates to the use of an invasive strategy in different 
subgroups of patients 2) optimal timing of invasive strategy in different subgroups 
of patients 3) guidelines recommended risk stratification and how this translates into 
the use of invasive strategy  4) availability of cardiac catheter laboratory facilities, 
use of invasive strategy and clinical outcomes and  5) optimal access site practice to 
perform invasive strategy.  
This thesis addresses the aforementioned aims in mainly three parts. Part 1 relates to 
results in chapter 4 and 5 which systematically looked at the use of an invasive 
strategy in different subgroups of patients. Chapter 4 demonstrates a temporal 
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increase in the utilisation of invasive strategy albeit slower adoption was noted in 
older, women and more comorbid patients. Furthermore, the results from chapter 5 
showed that despite the increase in the use of early invasive strategy within 24hours, 
there were significant disparities in utilisation of an early invasive strategy in 
Women, African Americans, admission day and older patients. Part 2 of the thesis 
shows that an invasive strategy for management of NSTEMI is not delivered 
according to international guidelines recommendations. Specifically, the disconnect 
between baseline risk and utility of invasive strategy increases with increasing risk 
and women achieve even slower access than men to the invasive strategy, so that 
overall their care is even more discrepant with the guidelines. Chapter 7 highlights 
important differences in both the utilisation of invasive strategy and subsequent 
management of NSTEMI patients according to admitting hospital cardiac catheter 
laboratory facilities. These variations are important particularly in the high-risk 
NSTEMI where patients admitted to ‘diagnostic’ hospitals had a greater risk of in-
hospital mortality. Finally, part 3 of the thesis showed that left radial access offers a 
very safe and effective alternative access site route for performing invasive strategy 
and may also help to reduce procedure related stroke complications.  
Overall, this thesis has demonstrated that there are significant inequalities in the use 
of invasive strategy in clinical practice in that elderly, women, ethnic minorities, and 
more comorbid patients. Furthermore, there is a significant disconnect between 
guidelines recommended risk stratification criteria and use of invasive strategy. 
There are also significant institutional variations in the adoption of an invasive 
strategy which may be associated with poor outcomes in high-risk patients.  Clinical 
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Chapter 1  
 





This thesis is concerned with the invasive management of Non-ST Elevation Acute 
Myocardial Infarction (NSTEMI) and investigates various factors associated with 
utilisation of an invasive strategy in the form of Coronary Angiography (CA) or 
Percutaneous Coronary Intervention (PCI) in this cohort. On the whole, the thesis is 
divided into three parts, in order to study the three main aspects of the use of an 
invasive strategy in the management of NSTEMI as illustrated in Figure 1.1. 
Figure 1.1 Pictorial demonstration of the three main phases of the thesis.  
 
1.2 Objectives 
The main objectives of this thesis were to investigate the following:  
 The utilisation of an invasive strategy in the form of CA or PCI in the 
management of patients admitted with a diagnosis of NSTEMI and its 
association with clinical outcomes. 
 Trends in the utilisation of an invasive strategy at different time points from 




associated with use 


















 Appropriate use of guidelines recommended risk stratification in clinical 
practice and its relationship with the use of an invasive strategy.  
 Influence of hospital cardiac catheterisation facilities on the use of an invasive 
strategy in patients admitted with the diagnosis of NSTEMI and association with 
clinical outcomes. 
 Radial access and access site choice in patients undergoing an invasive strategy 
(PCI) following admission with NSTEMI and its association with clinical 
outcomes. 
1.3 Chapter 2 
The chapter reviews the pathophysiology, clinical presentation and overall management 
of different types of Acute Coronary Syndrome (ACS). Furthermore, various aspects of 
invasive management of ACS patients are discussed and gaps in the literature are 
identified. 
1.4 Chapter 3 
This chapter describes the datasets used in this PhD, namely, National Inpatient Sample 
(NIS), Myocardial Ischaemia National Audit Project (MINAP) and the British 
Cardiovascular Intervention Society (BCIS) dataset. In addition to cohort selection, the 
general methodology used in this thesis for descriptive analyses and complex modelling 
strategies is described in detail.  
1.5 Chapter 4  
This chapter addresses the objective one of the thesis. In this chapter, temporal trends in 
the characteristics of patients receiving an invasive strategy are examined. I also 
explored the secular trends in the use of an invasive strategy and differences in the use 
29 
 
of an invasive strategy in NSTEMI patients stratified according to age, sex, ethnicity, 
comorbidity burden and hospital characteristics. 
1.6 Chapter 5 
This chapter addresses objective two of the thesis. In this chapter, I studied the temporal 
trends in timing to an invasive strategy and also described the changes in the profile of 
patients undergoing early, intermediate and late invasive strategy following admission 
with an NSTEMI over the past decade in the United States. 
1.7 Chapter 6  
 Objective three of this thesis was studied in this chapter, to study the adoption of 
guidelines recommended risk stratification in clinical practice and association with the 
use of an invasive strategy. 
1.8 Chapter 7 
This chapter addresses objective four of the thesis, to examine the relationship between 
the presence of different types of cardiac catheter laboratory facilities and utilisation of 
an invasive strategy in patients admitted with the diagnosis of NSTEMI.  
1.9 Chapter 8 
In line with objective four of the thesis, this chapter studies the procedural aspect of an 
invasive strategy. Current practice is to perform PCI using radial access but there is 
limited data on the difference between using right or left radial access. Therefore, this 
chapter investigated the differences between the use of left and right radial access in 
performing PCI, and clinical outcomes in all patients admitted following ACS. 
Furthermore, access site crossover practice was described in patients receiving the first 
procedure from right radial access. 
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1.10 Chapter 9  
This chapter summarises the overall findings of the thesis and the potential clinical 






Chapter 2  
 
This chapter provides an introduction to Acute Coronary Syndromes and overview of 
invasive strategies used in the management of Acute Coronary Syndromes.
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2.1 Acute coronary syndrome 
This thesis focuses on the invasive management of NSTEMI, the most common 
presentation of ACS. ACS, an umbrella term that denotes the presence of acute 
myocardial injury and raised cardiac biomarkers in the setting of acute myocardial 
ischemia or infarction
1
. Pathologically, the majority of ACS is caused by 
atherothrombotic coronary artery disease and are usually precipitated by an acute plaque 
rupture or erosion culminating in prolonged myocardial ischemia and myocardial cell 
death. This type is also referred as type 1 Myocardial Infarction (MI), however, there 
are 4 other types of MIs which may occur due to a variety of reasons ranging from 
oxygen supply/demand imbalance (type 2 MI) to procedure-related MI (type 3-5 MI)
1
. 
Hereafter, all the discussion in this thesis is related to ACS or type 1 MI. 
 For clinical purposes and allocation of appropriate treatment strategies, all types of 
ACS are mainly divided into two groups, namely ST-elevation Acute Myocardial 
Infarction (STEMI) and NSTEMI. STEMI occurs when there is complete occlusion of 
one or more coronary vessels and is diagnosed by the presence of an acute ST-segment 
elevation in two contiguous leads or a new bundle branch block on the 
electrocardiogram (ECG) in presence of cardiac chest pain. As the artery is completely 
occluded and diagnosis is evident on the ECG, the treatment is therefore based on the 
principle “time is muscle” i.e. open the blocked artery soon as possible by performing a 
procedure called PCI in order to minimise the irreversible myocardial injury. PCI is an 
invasive procedure, where an interventional cardiologist injects contrast dye into the 
coronary arteries using a small catheter, to establish if there is any narrowing/ blockages 
inside the arteries and can then treat them with balloons or metal tubes (stents) during 
the procedure if necessary. In contrast, NSTEMI usually occurs due to a sudden 
reduction in blood supply to the heart muscle from rupture of a plaque without complete 
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occlusion of the coronary vessel. Therefore, diagnosis is often reliant on carrying a 
number of investigations such as ECG and blood tests (cardiac enzyme biomarkers) to 
detect damage to the myocardium. As the artery is only partially blocked, performing 
immediate intervention in the form of PCI is usually not mandated and these patients 
are often managed by giving appropriate combination of medications such as 
antiplatelets, (aspirin, clopidogrel etc), antithrombotics (heparin, glycoprotein 2b3a 
inhibitors) before a decision about an invasive strategy is made. As such, the use of an 
invasive strategy is determined by various patient and hospital level factors, which will 
be discussed in details later on in this chapter.  
2.2 Management of NSTEMI  
The management of NSTEMI entails a detailed assessment of the patient’s presentation, 
risk-stratification using validated risk scores such as Global Registry of Acute Coronary 
Events (GRACE) risk score
2
, pharmacological treatment including administration of 
antiplatelets, anticoagulants, antithrombotics and invasive strategies in the form of 
invasive CA followed by the PCI or Coronary Artery Bypass Graft (CABG) surgery if 
indicated
3,4
. The overall goal of all these treatment strategies is to minimise further 
myocardial muscle damage, prevent future adverse events and improve survival in 
patients admitted with NSTEMI.  
2.2.1 Risk stratification 
As described earlier, patients presenting with STEMI usually have complete occlusion 
of one or more coronary arteries affecting a larger territory of the myocardium. 
Therefore, in contemporary practice, patients presenting with chest pain and diagnosed 
with STEMI are now urgently triaged to hospitals having facilities to perform urgent 
primary PCI (PPCI) in order to open the blocked artery and restore myocardial 





. However, when PPCI facilities are not readily available or located beyond the 
recommended timeframe of 90 minutes, thrombolytic therapy is administered
5-7
. 
Thrombolytic therapy, also known as clot-busting therapy, includes administration of 
potent blood thinners in the form of tissue plasminogen activator to allow immediate 
desolation of thrombus inside the coronary arteries
6
. These patients may then be 
transferred to a PCI capable hospital to perform invasive CA followed by PCI or CABG 
if required. Immediate risk stratification in STEMI patients is infrequent particularly 
due to the widespread use of PPCI to treat these patients. Regional pathways now offer 
urgent PPCI once clinical and diagnostic criteria of ECG is met, therefore it is unlikely 
that a STEMI risk stratification score would alter decision making and treatment 
offered. Guidelines from national bodies also encourage rapid assessment, early 




In contrast to STEMI, the treatment pathways for patients admitted with an NSTEMI 
are more diverse. National bodies emphasise the use of a pharmaco-invasive approach 
for NSTEMI patients which includes an initial period of intense medical therapy with 
antiplatelet, anti-coagulant and anti-ischemic agents followed by an invasive strategy in 
the form of an invasive CA with adjuvant PCI or CABG if indicated 
3,4,8
. Compared to 
STEMI, the patients presenting with an NSTEMI are also likely to be much more 
complex, older and comorbid, making them challenging to diagnose and treat
9-11
. 
Therefore, a quantitative risk stratification plays a pivotal role in enabling physicians to 
identify patients at higher risk of adverse events and target treatments accordingly
2
. 
Risk stratification is a predictive tool based on a number of independent factors of 
patients on presentation which are used to calculate a score to help physicians stratify 
the patients. A number of risk stratification scores have been reported in the literature 
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but the two most widely used in daily practice are the GRACE risk score and TIMI 
(Thrombolysis In Myocardial Infarction) scores
2,12
. The GRACE risk score is a scoring 
system to risk stratify patients diagnosed with ACS to estimate their in-hospital and 6-
month to 3-year mortality
2
. The GRACE risk score clinical application tool is a web-
based downloadable application and is available at http://www.outcomes-
umassmed.org/grace. The GRACE risk score is based on the patient's age, heart rate or 
pulse, systolic blood pressure, creatinine, cardiac arrest at admission, ST-segment 
changes on the ECG, elevated cardiac enzymes and the Killip class, which is a surrogate 
for the degree of acute heart failure. An overall score is then calculated by imputing all 
these parameters, which is then divided into three different risk categories, low risk 
(score <109), intermediate risk (score 109-140) and high-risk (score >140). Depending 
upon the risk profile of the patient, the risk of in-hospital death ranges from 0-2% in 
low-risk GRACE to more than 20% in high-risk GRACE category 
2
(Figure 2.3). 





The second most commonly used risk score for risk stratification of NSTEMI patients is 
TIMI score. This score is also derived using patient factors such as age, presence of 3 or 
more coronary artery disease risk factors, known coronary artery disease, aspirin use in 
the past seven days, severe angina defined as two or more episodes in last 24 hours, ST-
segment changes on the ECG and elevated cardiac enzymes 
12
. One point is given for 
the presence of each factor and totals score ranges from 0-7, which is then used to 
predict the risk of in-hospital death, new or recurrent myocardial infarction, or severe 
recurrent ischemia requiring urgent revascularisation in the first 14-days of admission 
(Figure 2.4). Although both scores are widely used in clinical practice, GRACE score is 
preferred over TIMI score due to its superior discriminative accuracy and accurate risk 
stratification both on admission and discharge
13,14
. 
Figure 2.2 TIMI risk calculator for NSTEMI/UA (adapted from HTTP:// www.timi.org) 
 
2.2.2 Pharmacological treatments 
The pharmacological treatment of NSTEMI includes administration of anti-ischemic, 
antiplatelets and lipid lower agents in all patients. After the acute phase, a continuation 
of these medications is also recommended as secondary prevention beyond the acute 
phase
3,4,15
. The main goal of anti-ischemic medications is to relieve the symptoms of 
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ischemia by reducing the myocardial oxygen demand or increase the oxygen supply to 
the myocardium. Beta-blockers and nitrates have excellent anti-ischemic properties, 
whereas administration of oxygen is also recommended particularly in patients with 
oxygen saturation lower than 90%
4
. Antiplatelet medications such as aspirin, 
clopidogrel, ticagrelor and prasugrel are pivotal in inhibition of platelet activation and 
aggregation and prevent thrombus formation after acute plaque rupture
16-19
. Current 
guidelines advocate administration of aspirin along with one of the P2Y12 inhibitors 
such as clopidogrel or ticagrelor or prasugrel for up to 12 months. It is also 
recommended that lipid-lowering statin therapy should be initiated in all patients soon 
after the admission and continued beyond the discharge
3,4
.  
2.2.3 Invasive strategy  
An invasive strategy in the context of NSTEMI is defined as an initial assessment of 
coronary anatomy using a procedure called “coronary angiography (CA)” followed by 
revascularisation in the form of PCI or CABG if indicated. CA is a non-surgical 
procedure, where a catheter is inserted into the coronary arteries via either the femoral 
or radial artery, allowing the operator to visualise the extent of coronary obstruction by 
injecting a contrast dye into the coronary arteries under x-ray guidance. CA is the most 
commonly performed medical procedure, to investigate the extent of coronary disease 
and identify the culprit lesions in the vessel that contributed to the NSTEMI. More 
importantly, the information from CA helps to decide the further course of treatment in 
the form of medical management, PCI or surgical revascularisation in the form of 
CABG surgery. As described earlier, PCI includes treating the narrowing in the 
coronary arteries mechanically either with a balloon or a stent. In the context of STEMI, 
the majority of the patients end up needing PCI in order to achieve coronary reperfusion 
as soon as possible. However, in NSTEMI patients, the decision to undertake an 
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invasive strategy in the form of CA or PCI requires a careful assessment of patient’s 
clinical presentation, comorbidities, risk stratification as outlined in 1.2.1, the risk 
associated with the invasive procedure and prognostic impact of any potential treatment 
on patient’s survival
3,4
. Nevertheless, very often a proportion of patients receive CA and 
PCI as one procedure instead of a staged procedure depending upon the availability of 
facilities of admitting hospital and clinical indication. In this thesis, from hereafter, an 
invasive strategy is defined use of either coronary angiography or PCI.  
2.3 Determinants of use of an invasive strategy in NSTEMI 
As described earlier, an invasive strategy plays a central role in the invasive 
management of patients admitted with NSTEMI. The information obtained from the CA 
helps physicians to confirm the diagnosis of ACS, identify the culprit lesions and 
establish the indication of revascularisation in the form of PCI or CABG. However, 
given the invasive nature of the procedure and associated complications, the decision to 
undertake an invasive strategy must also be weighed against the potential risks of the 
procedure, costs, resource utilisation and impact on patient outcomes. There are several 
factors which may influence the utilisation of an invasive strategy and clinical outcomes 
in NSTEMI patients as discussed below. 
2.3.1 Patient-related factors 
Patient characteristics such as age, gender, ethnicity and presence of comorbidities are 
known determinants of receipt of an invasive strategy 
20-24
. It is widely reported in the 
literature that younger patients admitted with NSTEMI are more likely to receive an 
invasive strategy compared to older patients. A similar bias towards the lower threshold 
to adopt an invasive strategy in men compared to women has been reported
25
. This is 
probably because physicians are likely to opt for a more conservative approach in 
complex and higher-risk patients such as elderly and women compared to lower-risk 
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young and male patients. Presence of comorbidities is also an important determinant of 
the use of an invasive strategy. Due to changes in population demographics, a 
significant proportion of patients with NSTEMI are older and have cardiac and non-
cardiac comorbidities
9,11
. Presence of these comorbidities not only influence outcomes 
of patients but are also likely to play a major role in decision making and planning 
treatments. For instance, current guidelines place special emphasis on the early use of 
an invasive strategy in patients with known cardiovascular risk factors such as the 
history of diabetes, chronic renal disease, heart failure and hypertension
3,4,15
. Whilst 
cardiovascular risk factors such as hypertension, hyperlipidemia, smoking, diabetes are 
prevalent in patients presenting with NSTEMI, with the changing population 
demographics, these patients often have a broad spectrum of cardiac and non-cardiac 
comorbidity conditions
9
. It is not clear how clustering of multiple chronic comorbidities 
influence decision making in terms of the use of an invasive strategy in patients 
admitted with NSTEMI. In order to study the association between clustering of the 
different comorbid condition and use of an invasive strategy, it is important to focus on 
an overall comorbidity burden of the patient using a recognised measure. The Charlson 
comorbidity index (CCI) is a well-recognised measure of quantifying the prognostic 
impact of 22 comorbidity conditions individually by means of a score, which can then 
be used to estimate the prognosis of the patients with these conditions. In a previously 
published meta-analysis, I reported that every point increase in CCI score was 
associated with an increased risk of mortality in patients with ACS and a two-fold 
increase in the risk of mortality in patients with a CCI score of 2 or more
9
. However, it 
is not clear what factors drive the increased risk of mortality with an increasing burden 
of comorbidities. It is plausible that patients with multiple comorbidities are less likely 
to receive an invasive strategy and more likely to be managed conservatively. 
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Similarly, sex differences in clinical outcomes of patients presenting with NSTEMI are 
widely reported in the literature
26-31
. The unfavourable outcomes in women have often 
been attributed to the delayed or atypical presentation, older age, less aggressive 
management and higher comorbidity burden 
9,32-35
. However, more contemporary data 
suggest that differences in clinical characteristics and presentation only partially 
contribute towards the higher mortality amongst women
36,37
. A recent analysis of the 
Myocardial Infarction National Audit Project (MINAP) registry showed that women in 
England and Wales were less likely to receive guidelines indicated care and had 
significantly higher mortality than men following AMI. These data highlight the need 
for greater understanding of factors driving these differences in outcomes and 




2.3.2 Healthcare system-related factors 
Healthcare system related factors such as the presence of cardiac catheter laboratory 
facilities is another important factor, which may influence the utilisation of an invasive 
strategy in patients with NSTEMI. Patients meeting the diagnostic criteria of STEMI are 
usually transferred immediately to the nearest PCI capable hospital for urgent 
reperfusion in the form of PPCI. Evidence from multiple randomised control trials, 
suggests that PPCI performed in a timely fashion improves outcomes in this cohort of 
patients by reducing mortality by approximately 30% and is the current gold standard 
treatment modality
39,40
. Consequently, there has been a great expansion in the provision 
of PCI programmes in the majority of the healthcare systems across Europe, UK and 
USA. For example, the use of thrombolysis for treatment of STEMI has steadily 





In contrast, the use of an invasive strategy in patients admitted with NSTEMI may be 
different across hospitals with different types of cardiac catheter laboratory facilities. 
For instance, patients admitted to a hospital without on-site cardiac catheter laboratory 
facilities may be less likely to receive an invasive strategy or have to wait longer before 
being transferred to another hospital with facilities to perform CA or PCI. Conversely, 
previous studies have shown that patients admitted to hospital with onsite cardiac 
catheter laboratory facilities are more likely to receive invasive coronary 
procedures
42,43
. However, the use of an invasive strategy may be variable according to 
different types of cardiac catheter laboratory facilities at the first admitting hospital. For 
example, patients admitted to hospitals with facilities to perform diagnostic coronary 
angiography only, may receive CA locally but then will need to be transferred to PCI 
capable hospital in case of needing PCI, whereas this may not be relevant to patients 
admitted directly to the PCI capable hospitals. It is also not known if different types of 
cardiac catheter laboratory facilities at the admitting hospital influence outcomes in 
NSTEMI cohort. 
2.3.3 Timing of an invasive strategy 
As discussed earlier, STEMI usually develops because of acute plaque rupture or 
erosion, triggering platelet aggregation and fibrin deposition and leading to the 
formation of an occlusive thrombus and complete vessel occlusion. Therefore, patients 
presenting with STEMI are treated with an immediate invasive strategy to minimise 
myocardial injury and improve patient outcomes. STEMI care pathways are designed 
around 24/7 emergency services to minimise time delays and offer PCI in the 
recommended time of fewer than 90 minutes 
3,4,15
. Health services have been structured 
in a way to offer immediate PCI 24/7 and there is little variation in services offered / 
access to PCI either nationally or internationally.  
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 In contrast, the timing of an invasive strategy for patients with NSTEMI varies 
greatly according to national and regional practices. For example, in UK practice, 
National Institute of Clinical Excellence (NICE) recommends that an invasive strategy 
in the form of CA should be undertaken within 96 hours following admission with 
NSTEMI
8
. In contrast, the European Society of Cardiology (ESC) advocates offering an 
invasive strategy within 72 hours to low-risk patients and within 24 hours to patients 
with high-risk features defined as GRACE score >140 
4
. Lastly, the American Heart 
Association/ American College of Cardiology (AHA/ACC) has also recommended three 
different points for performing CA whilst acknowledging the fact that optimal timing to 
an invasive strategy remains inconclusive
3
. An immediate invasive strategy (within 2 
hours) is recommended by both ESC and AHA/ACC guidelines in patients with 
hemodynamic instability, signs of new heart failure or recurrent angina despite 
maximum medical therapy, early approach (within 24h) for patients with changes in 
cardiac biomarker or ECG changes and a late approach for patients with low GRACE 
score (109-140). However, the integration of guidelines into clinical practice is variable 
and often delayed due to a variety of potential barriers such as clinician’s bias, lack of 
infrastructure or financial restraints 
44-46
. Therefore, it is important to describe the 
utilisation of an invasive strategy based on guidelines recommended risk and whether 
the receipt of an invasive strategy is based on guidelines-based risk criteria.  
 There is also strong evidence that the time/day of presentation does not 
influence outcomes in patients following STEMI, due to the fact that STEMI care 
pathways are designed around a 24/7 emergency service where an ECG meeting the 
diagnostic criteria of STEMI will trigger the same pathway regardless the time or day of 
presentation
47,48
. As a result, the patients are directly taken to the catheter laboratory for 
immediate revascularisation regardless of their time or day of presentation whereas 
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patient admitted after NSTEMI are usually admitted and treated medically first before a 
decision is made about further invasive strategy or conservative management. 
Therefore, optimal timing to an invasive strategy in patients admitted following 
NSTEMI remains inconclusive as reflected in heterogeneity in current national practices 
and national societies guideline recommendations
3,4
. In general, there are two 
viewpoints regarding optimal timing to perform an invasive strategy; early invasive (i,e 
within 24 hours of admission) or delayed invasive (i,e within 72 hours of admission). 
The use of an early invasive approach in the form of CA followed by revascularisation 
is supported by some, but not all
49-51
 randomised control trials (RCT) data that has 
shown that an early invasive strategy reduces the risk of adverse events and improves 







. Additionally, an early invasive strategy also 
facilitates early risk stratification, timely treatment in the form PCI or CABG and 
speedy discharge but this can also place greater logistic demands on limited resources of 
a healthcare system. The early invasive strategy is also associated with increased risk of 
procedure-related complications such as major bleeding, stroke and procedure-related 
myocardial infarction 
55
. To minimise this hazard, a second expert consensus is to 
passivate plaque activity by means of extended medical therapy for up to 72 hours 
before undertaking any invasive intervention
56
. The delayed strategy obviously has 
disadvantages in that it increases the risk of further complications of NSTEMI such as 
re-infarction that could ensue during medical therapy and longer hospital stays. 
Therefore, optimal timing to an invasive strategy in patients admitted following 
NSTEMI remains an area of uncertainty and it is unclear whether it should be offered as 
early as possible after admission or it could be delayed safely until patient receives 
medical therapy to allow plaque passivation
57-59
. An earlier meta-analysis of four RCTs 
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illustrated that an early invasive strategy was superior in preventing recurrent ischemia 
and reducing major bleeding complications. However, this protective impact of early 
invasive therapy did not translate into any significant benefit in reducing mortality or 
major cardiovascular events
59
. A very recent updated meta-analysis of all the 10 RCTs 
conducted to date on this subject showed that patients undergoing an early invasive 
strategy have less recurrent ischemia or refractory angina but no overall survival benefit 
in reducing mortality and adverse cardiovascular events 
60
. The confidence intervals 
around estimates of mortality and myocardial infarction were very wide despite the fact 
that 3 more trials (almost 1,000) were added in the latest meta-analysis. This is an 
important limitation of current literature highlighting the fact that randomised trials 
have so far failed to provide a conclusive answer to the question of whether one strategy 
is better than other. In conclusion, the currently available evidence does not provide 
definitive evidence around the optimal timing of performing an invasive strategy in 
patients admitted with NSTEMI. 
2.3.4 Procedural aspects of the invasive strategy 
Transradial and transfemoral access are the two commonest access sites used in the 
performing CA and PCI. In transradial access, the operator punctures the radial artery in 
the wrist of the patient to get access to coronary arteries whereas, in transfemoral 
access, one of the femoral arteries is used as an access site. The radial artery is much 
smaller in diameter and easily compressible against the distal radius bone, hence much 
easier to achieve haemostasis and has lesser propensity to bleed compared to the 
femoral artery. The adoption of transradial access has increased significantly over the 
past decade and is certainly a default access site in many countries such as UK, Europe 
and many countries in Asia
61-63
. Data from randomised control trials and observational 
studies also show that transradial access is associated with reduced risk of major 
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adverse cardiac events, mortality, major bleeding, access site related complications
64-73
. 
However, transradial access is not without challenges such as difficult technique, longer 
learning curve, radial artery spasm and occlusion
74,75
. I have previously published a 
large meta-analysis of 68 studies summarising the incidence of radial artery occlusion in 
patients undergoing PCI
75
. The results showed that the rate of radial occlusion varied 
from <1% to 33% depending upon the timing of assessment of radial artery patency 
after the procedure. Nevertheless, once the radial artery is occluded, it precludes the use 
of radial access for any future intervention and the operator may need to perform the 
following procedure via the femoral artery. Given the aforementioned benefits of radial 
access over the femoral access, it is not only important to minimise the occurrence of 
radial artery occlusion but may also need to explore alternatives access site such as left 
radial access instead of switching to femoral access. Previous studies comparing the use 
of left radial access with right radial access report that use of left radial access may be 
associated with reduced procedure time, radiation dose and quicker learning
76-79
. This 
may be due to more favourable anatomy of subclavian artery on the left side compared 
to the right side. The right common carotid artery which supplies blood to the brain 
originates from the right innominate artery whereas on the left common carotid artery 
originates directly from the aortic arch as shown in Figure 2.5. Therefore, on the right 
side, the catheter needs to manipulated from the right subclavian artery into the 
innominate artery and aortic arch which requires more manipulation and an increased 
theoretical risk of plaque embolisation into the right common carotid artery which in 
return may also increase the risk of procedure-related stroke. It is plausible that using 
left radial access may result in reduced risk of procedure-related stroke compared to 
right radial access. 




2.4 Gaps in Evidence and rationale for thesis  
NSTEMI is the commonest manifestation of ACS. An invasive strategy in the form of 
coronary angiography remains a gold standard investigation, to investigate the cause of 
NSTEMI and plan further management. Due to a large diversity in underlying 
pathophysiology, clinical presentation and risk of adverse events in patients presenting 
with NSTEMI, it is very difficult to tailor the use of an invasive strategy in these 
patients. Furthermore, due to changing population demographics, patients presenting 
with an NSTEMI are getting older, multimorbid and they are at increased risk of 
adverse events. There are several limitations of current literature which are summarised 
below,  
1. There is a significant change in population demographics and comorbidity 
burden of the patients over the past decade. My previous work illustrates the 
rising burden of co-existing comorbidities in all patients presenting with ACS
9
. 
These changes in population demographics may relate to differences in receipt 
of an invasive strategy in different subgroups of patients admitted following 
NSTEMI. It is therefore important to study if there are any systematic biases in 
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the utilisation of an invasive strategy in particular subgroups of patients. This 
thesis will study the secular trends in the use of an invasive strategy based on 
age, gender, ethnicity, comorbidity burden and types of admitting hospital.  
2. Despite the fact that the best treatment option for most patients with an NSTEMI 
is angiography guided revascularisation, regardless of the primary success of 
medical treatment, the optimal timing for the invasive strategy remains unclear 
and opinion remains divided amongst the interventional cardiology community. 
Current guidelines advocate different time points about the time of invasive 
angiography depending upon the patient's baseline risk on presentation.
3,4
. It is 
therefore important to study if there are any inequalities in the timing of an 
invasive strategy and whether the timing of invasive strategy is related to the 
baseline risk as defined by the guidelines in real-world practice. Further studies 
will also be framed to investigate if there is any relationship between the timing 
of invasive strategy and outcomes in patients with an NSTEMI in this thesis. 
3. Availability of services is an important driver of the utilisation of resources. For 
instance, the presence of on-site cardiac catheter laboratory facilities has been 
noted to have a positive association with increased utilisation of invasive cardiac 
procedures. However, it is not known how different types of cardiac catheter 
facilities may influence the physician's decision making and use of an invasive 
strategy. It is also not known if these differences are associated with differences 
in outcomes in patients admitted with NSTEMI to hospitals with different types 
of cardiac catheter laboratory facilities. 
4. Finally, despite the fact the radial access is the preferred the choice of access site 
in patients undergoing coronary angiography, there is limited regarding the 
association between choice of the radial access site and clinical outcomes. 
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the best procedural practices in routine use of an invasive strategy, it is important to 
study the alternative access site in these patients. Therefore, the research question 
about whether the left radial access offers a similar procedural and clinical safety 
compared to right radial access will also be investigated in the thesis. 
In summary, the main rationale for this thesis is to describe different patient, hospital 
and procedural factors influencing the use of an invasive strategy and how they are 




Chapter 3  
 
Description of datasets and general methodology.
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3.1 Introduction  
This chapter describes each dataset utilised to study different aspects of invasive 
management of patients admitted with NSTEMI. Firstly, a brief description of the 
source of each dataset, the context in which information is collected in the dataset, type 
of coding system, description of variables used and strengths and limitations of the 
dataset. Secondly, an outline of the general methodology used in this thesis and an 
overview of statistical methods is described. As each chapter has its own specific aims 
and study material, full details of methods will be discussed specifically in the relevant 
section of subsequent chapters.  
3.2 Study datasets 
3.2.1 Myocardial Infarction National Audit Project (MINAP) dataset  
Myocardial Infarction National Audit Project (MINAP) is a comprehensive national 
clinical database of patients hospitalised with an ACS in England and in Wales. 
Participation in the audit is mandated by the Department of Health for all National 
Health Service (NHS) acute hospitals in England and in Wales. Data are collected 
prospectively at each participating hospital and encrypted electronically before transfer 
to central database servers at the National Institute for Cardiovascular Research 
Outcomes (NICOR). It captures consecutive patients admitted with a diagnosis of an 
ACS across all the acute NHS hospitals in England and in Wales. MINAP amasses 
almost 85 000 episodes of patients with an overall sample size of close to a million 
records in 2018
41
. Data entry is subject to routine error checking such as range and 
consistency checks. In addition, a mandatory annual data validation exercise is 
conducted where participating hospitals are requested to re-enter data for 20 fields from 
20 randomly selected patients using a data validation tool. The completeness of 20 key 
fields including the NHS number, patient’s demographics, discharge diagnosis, hospital 
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mortality and secondary medication at discharge is closely monitored and is generally 
above 95%. In other fields, the completeness of data entry, as recorded in 2008, was 
generally over 80% and has been improving constantly since MINAP's inception
80
. 
All patients in the dataset are identified and tracked from their unique NHS number, 
which is pseudo-anonymised to protect the patient’s identity. MINAP does not record 
patient’s full postal address but does record other patient identifiers such as hospital 
numbers, dates of birth and postcodes area. These are encrypted before transmission to 
the central database. Researchers do not have access to the patient’s sensitive data, and 
hospital identity is also strictly protected. However, age at the time of the index event is 
provided and eastings and northings of the centroid of the output area of residence, 
shared between one and 80 addresses, can be made available for geographical mapping 
with the necessary permissions.  
The MINAP dataset contains 123 separate fields under the groups of; patient 
demographics, medical history mainly encompassing known cardiovascular risk factors, 
drug treatment before admission, admission method/route, clinical characteristics and 
important relevant cardiac investigations carried out whilst being in-patient, in-hospital 
drug treatments, primary reperfusion treatment details, interventional treatments, 
clinical complications, in-hospital outcomes, diagnosis on discharge and discharge 
(secondary prevention) treatments. Thus each entry provides a complete overview of the 
patient journey from the first contact to medical services, in-hospital treatment and 
discharge. Follow up data is not collected in the dataset and the linkage to the Office of 
National Statistics (ONS) for long term mortality is only available for audit purposes 
due to recent changes in data governance. Therefore, the outcome of interest will be 
restricted to in-hospital all-cause mortality, cardiac mortality, major bleeding and re-
infarction complications. Ethical approval for using this dataset for research is not 
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required as secondary use of anonymised MINAP dataset for research purposes is 
authorised under the NHS research governance arrangements and further supported 
under section 251 of NHS act 2006 (NIGB: ECC1-06(d)/2011), which allows 
researchers to use patient information collected within the dataset for medical research 
without patient consent. The size and national reach of the MINAP registry underpin its 
value as an audit and research tool. The representativeness to the whole of England and 
Wales is a key strength and provides an excellent first time opportunity to study the 
invasive management of patients admitted with NSTEMI within the scope of this PhD. 
Using the detailed information around the time of admission, time of invasive 
procedures, patient clinical characteristics and risk profile, the association between the 
presence of onsite hospital cardiac catheterisation facilities and clinical outcomes were 
examined. Furthermore, the granularity of data around the patient’s risk profile and 
laboratory results allowed to study implications of guidelines recommended risk 
stratification and timing of invasive management of patients admitted with an NSTEMI 
in a national cohort.  
3.2.2 British Cardiovascular Intervention Society (BCIS) dataset 
The BCIS dataset is an obligatory national audit, which collects information about 
almost every PCI procedure performed across all NHS hospitals in the UK. Although 
private hospitals are not obliged to participate in the registry, some of the private 
hospitals also contribute to the data collection. Overall, BCIS captures >99% PCI 
activity within UK
81
. All consecutive patients undergoing PCI for treatment of coronary 
artery disease are recorded in the dataset. The data collected in the BCIS registry have 
the same section 251 approval of NHS Act 2006 as MINAP, thus allowing the use of 
dataset for medical research and audit purposes without seeking patient consent. Full 
details about the data protection and security are available at 
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(www.ucl.ac.uk/nicor/patients/security). The audit project is funded by the central 
government through the Department of Health (DoH), however, the funding is now 
managed by the Healthcare Quality Improvement Partnership (HQIP). The logistic 
support, data monitoring and analysis are managed by a project manager along with a 
team of support staff, analyst and statisticians at NICOR under the supervision of an 
audit lead from BCIS
82
.  
All patients within the dataset are tracked by using their unique NHS number which is a 
unique 10-digit number issued to all patients registered within NHS, with an exception 
of Scotland where name and date of birth are used for tracking. Some other relevant 
patient identifiers such as date of birth, postcode, hospital number and present or past 
geographical location are also collected within the dataset. These identifiers are then 
encrypted before transmission to the central database. Although NICOR has access to 
these patient identifiers and is able to contact patients for audit and research purposes, 
these data fields are protected from access to researchers. 
The BCIS registry is designed to collect data of all consecutive adults undergoing PCI 
for stable angina or ACS in the UK from time of admission to discharge. The 
information about diagnostic CA is not collected as the main aim of BCIS registry to 
improve the quality of PCI activity in the UK. There are approximately 113 variables in 
the BCIS dataset which collect information about patient’s baseline demographics, 
presentation, important cardiovascular risk factors, previous cardiac intervention, 
indication for PCI, details about technical aspects of PCI, access site, pharmacology, 
operator details and any in-hospital adverse outcomes. In addition to in-hospital 
mortality, particular emphasis is placed on the recording of peri-procedural 
complications such as stroke, myocardial infarction, bleeding, access site related 
complications and stent thrombosis. BCIS endeavours to collect information about 
55 
 
every single PCI procedure undertaken in the United Kingdom and the nationwide 
participation from all NHS hospitals in the UK adds to its national representation
81
. 
With close to a million PCI procedure records in the dataset, the BCIS dataset offers a 
great opportunity for the researchers to study procedural aspects, access site practice 
and some of the rare complications of PCI procedures and compare treatments/ 
strategies in a different cohort of patients which will not be possible in a randomised 
control trial. I utilised these strengths of the BCIS registry to study the procedural 
aspects such as optimal access site strategy to perform PCI in patients admitted 
following ACS in the United Kingdom. 
3.2.3 National Inpatient Sample (NIS) dataset 
National Inpatient Sample also formally called the Nationwide Inpatient Sample (NIS) 
database is one of the largest publically available all-payer inpatient healthcare database 
in the United States. It is developed by Healthcare Cost and Utilization Project 
(HCUP)
83
 and sponsored by the Agency for Healthcare Research and Quality (AHRQ). 
The NIS contains information about the inpatient hospital stays which is gleaned from 
billing data submitted by hospitals to state-wide data organizations. This information in 
the inpatient data includes clinical and resource use information which can easily be 
derived from discharge level abstracts. NIS collects discharge level data from 
approximately 1000 hospitals, including 20% of all community hospitals in the US, 
with over 7 million unweighted hospital admissions added each year making it truly one 
the largest datasets of its kind worldwide. Discharge weights are used to determine 
national estimates and weighted data contains over 35 million hospital records 
representative of a large national sample. NIS is a publically available database with no 
identifiable patient, state or hospital level information; therefore, ethical approval is not 
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needed. However, HCUP requires a data user agreement and mandatory online training 
completion from all research applicants.  
Each record within NIS contains granularity of information about patient demographics, 
ethnicity, primary payer, 29 Elixhauser comorbidity conditions, in-patient procedure 
information, in-hospital complications such as bleeding, stroke, cardiac complications, 
mortality, length of stay and cost on hospitalisation. The data elements are stored using 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes. Additionally, HCUP has developed a Clinical Classification of Software 
(CCS) scheme which contains over 14,000 diagnosis and 3,900 procedure codes 
condensed into small categories. The CCS scheme is also based on ICD-9-CM codes, 
however, it enables the analysis of a much larger number of diagnosis or procedures 
more efficiently and accurately. For instance, all the ICD-9-CM codes for any type of 
in-hospital gastrointestinal bleeding are collapsed into a single CCS diagnosis code.  
Although NIS contains comprehensive information around medical history, comorbidity 
burden, in-patient procedural treatment and in-hospital outcomes, it lacks information 
about pharmacology and lab results. Nevertheless, NIS offers an excellent opportunity 
to study secular trends, changes in patient’s characteristics, comorbidity burden, 
invasive procedural aspects of patients admitted with a diagnosis of an NSTEMI in the 
United States over a decade.  
3.3 Statistical methods  
 As described above, this thesis has used three different data sources and each chapter 
aimed to investigate a specific aspect of invasive management of patients admitted with 
the diagnosis of an NSTEMI. As each chapter has its own comprehensive details of 
relevant methods, therefore specifics of methods are not discussed here. Rather, this 
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chapter aims to describe an overview of the general methodology and different 
statistical methods used. 
3.3.1 Data cleaning  
Before starting the analysis of each dataset, I examined the data for completeness, 
accuracy and consistency, to identify the scope of and the limitations of data analysis. 
After evaluating descriptive statistics for each variable, erroneous values for individual 
data were checked by evaluating frequency distributions and checking lower and upper 
outliers for entries beyond the acceptable range. For instance, the age variable with age 
defined > 110 years or <18years were removed. Similarly, unknown gender was 
excluded. Any patients with duplicate admission during the study time period were 
excluded from the analysis to prevent survivorship bias both in MINAP and BCIS 
dataset analyses. However, as the NIS lack information on individual patient ID and 
merely represents records of each hospitalisation with ACS, individual patient level 
analyses were not done from NIS. 
3.3.2 Descriptive methods  
After the initial exploratory analyses and cleaning, the total number of admissions with 
a diagnosis of NSTEMI in each dataset were identified. Study variables were finalised 
based on literature search, prior clinical knowledge and supervisory team input. 
Data for continuous variables were presented as either means (with standard deviation) 
if normally distributed or medians with interquartile ranges if not normally distributed. 
To assess the normality of the continuous data, distribution curves and quantile-quantile 
(QQ) plots were used. Similarly, categorical or ordinal variables are reported as 
numbers and percentages. Where the interest lay in comparing the two means, student’s 
t-tests were used for normally distributed continuous variables based on the assumption 
58 
 
that observations are normally distributed with equal variance
84,85
. However, when 
observations were not normally distributed or with equal variance, Mann Whitney or 
Wilcoxon Rank sum tests were used
84,85
. In the instance of comparing more than two 
groups, one-way analysis of variances (ANOVA) for normally distributed data was used 
whereas or when data was not uniformly or normally distributed Kruskal-Wallis tests 
were used. 
The categorical variables were compared using Pearson’s Chi-Squared test. Due to the 
large sample size, clinically important effects and association rather than sole statistical 
significant p values were described
86
.  
3.3.3 Framework for dealing with missing data  
Following on from descriptive analysis, multivariable models were developed to predict 
the outcomes of interest based on the aims and objectives of each study chapter. It is, 
however, important to deal with the missing data. Therefore, the missing data for each 
variable has been reported in the relevant section of each chapter with a consideration of 
whether there are significant variations based on outcome variables. In order to deal 
with the missing data, multiple imputations using chained equations (MICE) were used, 
wherein all variables used in the analytic models, as well as the outcomes of interest, 
were included. Patient age, gender, exposure and outcomes variables were included in 
the MICE after removing missing information. Multiple imputation techniques are used 
to account for the missing data and protect against the biases arising from missing 
data
87,88
. One of the fundamental assumptions of multiple imputations is that the data 
are missing at random (MAR)
87
 which were examined by using data distributions 
curves of each variable included in the analysis. Although levels of missingness are 
high for certain variables, it has been previously shown that multiple imputation 
frameworks are robust even when levels of missingness are extremely high, while they 
59 
 
can offer some protection when data are missing not at random (MNAR)
89
. During this 
process, missing values in each variable were replaced with predictions from multiple 
imputation model plus a random error by using multivariable regression models. 
Overall, three different types of models namely logistic regression for binary variables, 
linear regression for continuous variables and ordinal or multinomial logistic regression 
for ordinal variables were used. Ten imputed datasets were generated in this process. 
Full details of variables and models are discussed in the methodology of the relevant 
chapters. In the instances where missing information was very low, complete case 
analyses were undertaken as a sensitivity analysis to confirm the findings.  
3.3.4 Modelling strategy  
In this thesis, the study outcomes were binary therefore multivariable logistic regression 
models were used to study the associations between exposure variables and study 
outcomes. Firstly, data quality, distribution, missingness, prior clinical knowledge and 
prognostic relevance of each variable was used to determine model covariates. All 
variables were included in the models in order to fully adjust for all potential 
confounders This method is widely recommended and practised in conducting large 
scale epidemiology studies
90,91
. However, as a sensitivity analysis, a backward stepwise 
approach was used where a non-significant variable was removed from the model at a 
time to reach a final model and the final results were compared with the first full model. 
The goodness of fit for each model was assessed using the area under the curve and 
likelihood ratio tests
92
. Multi-collinearity between the variables was assessed using 
Variance Inflation factors. All results are reported as odds ratios (OR) along with their 
associated 95% confidence intervals and p values. More specifics of study design, 




Chapter 4  
 




4.1 Introduction  
This chapter addresses the first research question set in part one of the thesis by 
investigating the patient’s level factors associated with the use of invasive strategy. The 




NSTEMI including unstable angina is estimated to account for almost two-thirds of the 
total hospital admissions for ACS in the United States and Europe
94-97
. Although 
patients with the STEMI have a worse prognosis in the short term, the long-term 
outcomes of NSTEMI are worse 
20,98-100
. The most likely explanation for this is an 
ageing population, increased burden of comorbidities and variation in the use of an early 
invasive strategy in this cohort of patients
9,21,101,102
. Consequently, despite 
improvements in treatments and the provision of guideline-recommended care, 
NSTEMI remains the most vulnerable phenotype of ACS.  
As described in the introduction chapter (1.0) of this thesis, an invasive strategy in the 
form of CA is an important tool to diagnose the extent and severity of obstructive 
coronary artery disease and enable treatment of the underlying lesions that has 
contributed to the NSTEMI through PCI or CABG surgery. Guidelines from national 
bodies emphasise the use of an invasive strategy in patients presenting with an NSTEMI 
particularly in clinically unstable or high-risk patients
4,103
 with data from observational 
and randomised control trials forming the evidence basis of improved outcomes in 
patients receiving an early invasive strategy
57,104-106
.  
Despite the established benefit of an early invasive strategy in this cohort, significant 
variations in the utilisation of an invasive strategy both at regional and national level 
remain
107,108
. These variations may be related to hospital level factors such as the 
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availability of cardiac catheterisation laboratory facilities (which will be explored 
further in chapter 7.0 of this thesis) or patient level factors. The decision to undertake an 
invasive strategy followed by revascularisation requires careful consideration of the 
patient’s baseline risk profile and coexisting comorbidities
3,4
. In order to answer the first 
research question as set out in part 1 of this thesis, it is important to investigate how the 
patient’s baseline risk profile and coexisting comorbidities have changed over time, and 
in particular how these are related to the utilisation of an invasive strategy in the 
management of patients admitted with an NSTEMI in a real-world setting. 
4.2 Objectives 
The main objectives of this chapter are to study  
I. Overall secular trends in utilisation of an invasive strategy in a national cohort of 
patients admitted with a diagnosis of an NSTEMI in the United States.  
II. Investigate the receipt of an invasive strategy in contemporary practice in 
different subgroups of patients stratified according to age, sex, ethnicity, and 
comorbidity burden and hospital characteristics.  
III. Compare the characteristics of patients receiving an invasive strategy to those 
receiving medical management and how these have changed over time. 
IV. Examine the independent predictors of receipt of an invasive strategy. 
V. Study the association between use of an invasive strategy and in-hospital clinical 
outcomes.  
4.3 Methods 
National Inpatient Sample (NIS) dataset was used for this study. Full details about the 
NIS dataset are already described in chapter 3. 
4.3.1 Study design  
This study is a retrospective cohort study of the prospectively collected NIS dataset.  
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4.3.2 Study population  
Within NIS dataset, all patients admitted with a diagnosis of an NSTEMI age >18years 
between 1
st
 January 2004 to 31
st
 December 2014 were included in the study. 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes of 4111 and 4107 were used to identify all admissions with a primary 
diagnosis of an NSTEMI during the study period. Patients admitted with the records of 
elective admission were excluded as these are unlikely to represent a true diagnosis of 
an NSTEMI. Elective admissions were also excluded as they were likely to be patients 
admitted for a different diagnosis or procedure electively and then they may have had a 
diagnosis of NSTEMI whilst as an inpatient. A typical example of this would be a 
patient admitted for elective knee arthroscopy and who may have suffered from an 
NSTEMI. These records don’t represent the patients admitted with a primary diagnosis 
of an NSTEMI and are likely to confound the analysis. This approach has been utilised 
in previous studies using NIS for research about ACS
109-113
. Similarly, the diagnosis 
field was only limited to primary diagnosis within the NIS dataset to represent the true 
diagnosis of NSTEMI. These inclusion criteria were rationalised on the basis of 
previous studies using the NIS database and Agency of Healthcare Research and 
Quality (AHRQ) recommendations
83,114-119
.   
4.3.3 Study outcomes 
The main outcomes of interest were in-hospital all-cause mortality, Major Adverse 
Cerebrovascular Complications (MACCE), adverse cardiac complications, major 
bleeding, and any vascular complications. Adverse cardiac complications were a 
composite of cardiac tamponade, pericardiocentesis, iatrogenic cardiac complication 
requiring emergency coronary artery bypass graft (CABG) surgery and 
hemopericardium. Major bleeding was a composite of gastrointestinal, retroperitoneal, 
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intracranial or unspecified haemorrhage, and requirement of blood transfusion. Vascular 
complications were defined as procedure-related vascular injury. MACCE was a 
composite of acute ischemic stroke, in-hospital mortality and adverse cardiac 
complications. All complications were identified using ICD-9-CM codes in any of the 
secondary diagnosis fields within the NIS database (Table 4.1). The ICD-9-CM codes 
utilised in this study were based on a thorough literature search of previous studies 
using NIS dataset
10,114,116,120-126
. In order to maximise the capture of accurate codes, all 
the clinical conditions extracted from NIS dataset were also searched in the ICD-9-CM 
database at www.findacode.com to look for any additional unpublished codes. After 
extracting the information from the NIS database using these codes, the estimates for all 
main conditions such as diagnosis of NSTEMI were matched with national discharged 
estimates published at AHRQ website (https://www.ahrq.gov/).  
Table 4.1 ICD-9-CM codes used for driving post procedural complications 
Post-procedural Complication ICD-9-CM or CCS codes 
Bleeding complication  
Gastrointestinal CCS 153 
Unspecified haemorrhage 459.0 
Retroperitoneal haemorrhage 568.81, 998.1 
Intracranial haemorrhage 430-432x 
Post-op haemorrhage requiring transfusion 99.0 (procedure) 
Blood transfusion V58.2 
Vascular complications  
Vascular injury 900-904, 998.2, 447, 868.04, 999.7 
(diagnosis) 
39.31, 39.41, 39.49, 39.52, 39.53, 39.56 - 
39.59 39.79 (procedure) 
Cardiac complications  
Iatrogenic cardiac complications 997.1 
Pericardial complications 423.0, 423.3 (diagnosis) 47.0 (procedure) 
Coronary artery dissection 414.12 
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Requiring CABG surgery 36.1x, 36.2, 36.31, 36.32, 36.9x 
CABG= coronary artery bypass graft surgery 
4.3.4 Study covariates  
Use of an invasive strategy was derived from procedure codes provided in the NIS 
dataset. NIS captures up to 15 procedure codes in the dataset. Invasive strategy in the 
form of CA was defined as ICD-9-CM procedure codes 88.53, 88.54, 88.55, 88.56 
37.22 and 37.23, with or without PCI (ICD-9-CM procedure codes 00.66, 360.1, 360.2, 
360.5, 360.6 and 360.7
114,124-128
. Data regarding patient baseline demographics 
including age, sex, race, primary expected payer, admission day of the week and 
cardiovascular risk factors (known coronary artery disease (CAD), family history of 
premature CAD, smoking, dyslipidaemias, previous myocardial infarction (MI), history 
CABG, previous PCI, previous stroke or transient ischemic attack) and chronic 
hypertension were also collected. The ICD-9-CM codes or clinical classification 
software (CCS) codes used to identify any additional comorbidities are provided in 
Table 4.2.  
Table 4.2 List of the ICD-9-CM and clinical classification software (CCS) codes used 
for identifying additional comorbidities 
Comorbidities Source Codes 











































IHD= ischemic heart disease, CABG= coronary artery bypass graft, PCI= percutaneous 
coronary intervention 
 
The overall comorbidity burden was defined as per the Charlson Comorbidity Index 
(CCI) which was determined using information from 29 Elixhauser comorbidities as 
defined by AHRQ in the NIS
129
. The CCI is a recognized measure of comorbidity 
burden and quantifies the prognostic impact of 22 comorbid conditions based on their 
number and individual prognostic impact by means of a score
130
. It is a useful tool for 
estimating prognosis in patients with multiple co-existing illnesses. CCI was derived 
using a point-based system with scores ranging from 1 to 6, with each value weighted 
depending on the prognostic impact of the comorbidity
130
. These scores were then 
summated to classify overall comorbidity burden into mild, moderate and severe 
categories with CCI score of 0,1,2 and 3 or more respectively
131,132
 (Table 4.3). 
Table 4.3 Deyo’s modification of Charlson’s comorbidity index (CCI) 
Reported ICD-9 codes Condition Charlson 
score 
412 Previous myocardial infarction 1 
428 – 428.9 Congestive heart failure 1 
433.9, 441 – 441.9, 785.4 V43.4 Peripheral vascular disease 1 
V12.54, 438.x Previous cerebrovascular disease 1 
290 – 290.9 Dementia 1 
490 – 496, 500 –505, 506.4 Chronic pulmonary disease 1 
710.0, 710.1, 710.4, 714 – 714.2, 
714.81, 725 
Rheumatologic disease 1 
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531 – 534.9 Peptic ulcer 1 
571.2, 571.5, 571.6, 571.4 –
571.49 
Mild liver disease 1 
250 – 250.3, 250.7 Diabetes 1 
250.4 – 250.6 Diabetes with chronic 
complications 
2 
344.1, 342 – 342.9 Hemiplegia or paraplegia 2 
582 – 582.9, 583 – 583.7, 585, 
586, 588 – 588.9 
Renal Disease 2 
140 – 172.9, 174 –195.8, 200 – 
208.9 
Any malignancy including 
leukaemia and lymphoma 
2 
572.2 – 572.8  Moderate or severe liver disease 3 
196 – 199.1 Metastatic solid tumour 6 




Finally, data regarding the hospital characteristics including the bed size, location, 
region and teaching status were also collected. The hospital bed size within NIS are 
defined using different regions of the US and ranges from 1-249 beds for a small 
hospital, 25-449 for a medium hospital and 50+ to 450+ for a large size hospital. 
4.3.5 Statistical analysis  
All statistical analyses were conducted using Stat 14.0 (College Station, Texas, USA). 
Complete case analysis strategy was used in this study as the missing information in the 
study variables were less than 3%. Given the overall sample size of close to 4.3 million 
patients, it was felt that using multiple imputations to account for a small proportion of 
patients with missing data information is unlikely to change the findings. Records with 
missing information on the age (n=395), gender (n=954), length of stay (n=20), Median 
Zip code (n=109,088) and in-hospital mortality (n=2008) were excluded. The total 
number of records which were excluded from the main analysis were only n=112,465 
which is approximately 2.3% of the total sample size. The elective admissions were not 
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excluded due to missing information but due to the reason explained above (elective 
admissions are unlikely to represent true admissions with NSTEMI). (Figure 4.1).  
 
Figure 4.1 Flow diagram of included/excluded records 
 
Descriptive statistics were used to compare differences in baseline demographics, 
hospital characteristic and crude outcome rates of patients who received an invasive 
strategy compared to those managed medically. For all analyses, the survey estimation 
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commands were used (by using the svy prefix in analyses conducted in Stata), this 
followed the recommendations from AHRQ for analysis of survey data to account for 
the complex survey design of the NIS database. The use of sampling weights is required 
because the design of the study means that different observations may have different 
probabilities of selection. Due to records being sampled by hospitals rather than 
individuals, clustering of records within hospitals was taken into account in the survey 
estimation. This was done by defining each hospital to be the primary sampling unit. 
For calculation of national estimates and correct variances, sampling weights for each 
individual discharge that were provided by the AHRQ were used.  
Continuous variables were reported as median and interquartile ranges to account for 
the skewness of data. Categorical variables were presented as a number and a 
percentage. Chi-square and t-tests were used to determine the statistical difference 
between patients who received an invasive strategy compared to those who were 
managed medically for categorical or continuous variables respectively, while the 
“nptrend” package was used to assess the statistical significance of changes in the trend 
across ordered groups. Multivariable analyses were undertaken to determine the 
association between the use of an invasive strategy and outcomes of interest. Logistic 
regression models were fitted using maximum likelihood estimation and were adjusted 
for all potential and measured confounders including age, sex, year of procedure, 29 
Elixhasuer comorbidities, ethnicity, median income, weekend/weekday admission, 
cardiovascular risk factors and hospital characteristics. In order to better control for any 
differences in the baseline characteristics of the patients in the two groups, a sensitivity 
analysis using the propensity score matching was conducted. The average treatment 
effects (ATE) were calculated using the “teffects” package and included all the 
variables as described in the multivariable logistic regression models. Full details of 
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multivariable logistic and propensity score matching algorithm have been described in 
the methodology (chapter 3). 
4.4 Results  
4.4.1 Patient and hospital characteristics 
A total of 4,380,827 patients were admitted with a primary diagnosis of an NSTEMI 
between 2004 and 2014 out of which 2,518,704 (57.5%) received an invasive strategy 
as an in-patient. Baseline difference between patients receiving an invasive strategy 
compared to those managed medically are presented in Table 1. Patients receiving an 
invasive strategy, in general, were younger (median age 65 vs 72 years, p<0.001), had 
worse cardiovascular profile such as history of smoking (37.9% vs 22.4%, p<0.001), 
dyslipidaemia (56.4% vs 37.5%, p<0.001), previous history of PCI (11.5% vs 7.7%, 
p<0.001) and IHD (81.7% vs 42.6%, p<0.001). Conversely, medically managed patients 
were more likely to be female (51.3% vs 39.3%, p<0.001), had higher proportions of 
co-existing comorbidities as defined by CCI (CCI ≥3 53.9% vs 46.1%, p<0.001) and 
were likely to be admitted on weekend (26.8% vs 25.0%, p<0.001). Patients admitted to 
a small hospital were more likely to be medically managed (16.3% vs 8.0%, p<0.001), 
compared to the patients admitted to large hospitals who were more likely to receive an 
invasive strategy (70.3% vs 55.4%, p<0.001). Similar trends were noted based on the 
location/teaching status of the hospitals where patients admitted to rural hospitals were 
more likely to be medically managed (18.0% vs 6.6%, p<0.001) and patients admitted 
to urban teaching hospitals had higher rates of receipt of an invasive strategy (54.4% vs 
34.8%, p<0.001). Medically managed patients had higher unadjusted in-hospital 
mortality (6.6% vs 1.9%, p<0.001) and bleeding complications (11.9% vs 10.7%, 
p<0.001). However, patients receiving an invasive strategy had higher rates of 
procedure related vascular (1.4% vs 0.3%, p<0.001) and cardiac complications (2.1% vs 
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0.5%, p<0.001). The median length of stay was similar in both groups (3 (IQR 2-6) 
days)) whereas receipt of the invasive strategy was associated with greater costs 
compared to medically managed patients. (Median total charge $51433 (IQR $31694-
$85583) vs $18078 (IQR $9841-$34417)).  
Table 4.4 Baseline characteristics of patients receiving medical management compared 
to those receiving an invasive strategy 




Number of Cases weighted (%age) 1,862,123 (42.5%) 2,518,704 (57.5%) 
Age (year), Median IRQ) 72 (63-85) 65 (46-75) 
Men % 49.7% 61.7% 
Ethnicity   
White 63.2% 63.3% 
Black 10.0% 9.0% 
Hispanic 6.4% 6.2% 
Asian/Pacific Islander 1.8% 1.6% 
Native American 0.4% 0.5% 
Other 2.2% 2.7% 
Missing Race 16.0% 16.7% 
Weekend admission 26.8% 25.0% 
Primary expected payer, %   
Medicare 72.2% 53.3% 
Medicaid 5.7% 6.6% 
Private Insurance 16.2% 30.3% 
Self-pay 3.6% 6.2% 
No charge 0.3% 0.7% 
other 1.9% 2.9% 
Median Household Income (percentile)   
0-25
th
 30.2% 29.2% 
26-50
th
 27.0% 27.7% 
51-75
th
 22.7% 23.9% 
76-100
th
 20.1% 19.2% 
Comorbidities, %   
Dyslipidaemia 37.5% 56.4% 
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Smoking 22.4% 37.9% 
Previous AMI 9.5% 9.4% 
Previous PCI 7.7% 11.5% 
Previous CABG 10.1% 5.8% 
Previous CVA 4.0% 3.1% 
Family history of CAD 3.7% 8.0% 
Valvular heart disease 0.4 0.1 
Peripheral vascular disease 11.9% 11.9% 
Use of assist devise or IABP 0.5% 4.2% 
Shock 2.2% 2.6% 
AIDS 0.12% 0.13% 
Alcohol abuse 2.4% 2.9% 
Deficiency anaemias 20.3% 13.2% 




Congestive heart failure 1.3% 0.5% 
Chronic pulmonary disease 25.4% 20.6% 
Coagulopathy 4.4% 4.2% 
Depression 7.8% 6.8% 
Diabetes 30.1% 30.3% 
Diabetes with complications 7.5% 6.1% 
Drug abuse 1.8% 2.2% 
Hypertension 68.2% 70.9% 
Hypothyroidism 12.6% 9.4% 
Liver disease 1.4% 1.2% 
Lymphomas 0.7% 0.4% 
Fluid and electrolyte disturbances 25.1% 16.1% 
Other neurological disorders 9.1% 4.0% 
Obesity 9.1% 14.6% 
Paralysis 2.6% 1.2% 
Psychoses 2.7% 1.9% 
Pulmonary circulation disorder 0.2% 0.06% 
Renal failure (chronic) 24.8% 15.0% 
Peptic ulcer disease 0.05% 0.04% 
Weight loss 3.2% 1.5% 
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Solid tumour without Mets 2.0% 1.1% 
Metastatic cancer 1.5% 0.4% 
Dementia 12.9% 2.5% 
Charlson Comorbidity Index   
0 23.0% 34.5% 
1 31.5% 32.8% 
2 24.6% 19.5% 
≥3 20.9% 13.1% 
Hospital bed size   
Small 16.3% 8.0% 
Medium 28.3% 21.7% 
Large 55.4% 70.3% 
Hospital Region   
Northeast 25.8% 17.9% 
Midwest 20.1% 24.4% 
South 38.8% 42.4% 
West 15.2% 15.3% 
Location/ Teaching status   
Rural 18.0% 6.6% 
Urban-non teaching 47.2% 39.0% 
Urban- teaching 34.8% 54.4% 
Length of stay, Median (IQR) 3 (2-6) 3 (2-6) 
Total charge,$, Median (IQR) 18078 (9841-34417) 51433 (31694-85583) 
Bleeding complications 11.9% 10.7% 
Vascular complications 0.3% 1.4% 
Cardiac complication 0.5% 2.1% 
In-hospital mortality 6.6% 1.9% 
IQR=interquartile range, AIDS= acquired immunodeficiency syndrome, AMI=acute 
myocardial infarction, CVA= cerebrovascular accident, PCI= percutaneous coronary 
intervention, CABG= coronary artery bypass graft, CAD= coronary artery disease, 
IABP= intra-aortic balloon pump, RA= rheumatoid arthritis. 
4.4.2 Temporal trends 
There was a significant increase in the utilisation of an invasive strategy from 48.5% in 
2004 to 65.1% (Ptrend <0.001) in 2014 (Figure 4.2). PCI procedures performed in this 
population increased from 23.5% in 2004 to 35.3% (p trend<0.001) in 2014, whilst 
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CABG procedures declined from 8.6% to 7.7% during the same period (Ptrend <0.001) 
(Figure 4.3).  
Figure 4.2 Temporal trends in utilisation of an invasive strategy from 2004-2014. 
 
Figure 4.3 Temporal trends in utilisation of invasive strategy, percutaneous coronary 
intervention and coronary artery bypass procedures from 2004-2014 
 
Table 4.5 and 4.6 present the temporal changes in baseline demographics and hospital 
characteristics, comorbidities and crude outcomes in patients receiving an invasive 
strategy and those who were medically managed respectively. The prevalence of risk 
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factors for coronary artery disease such smoking, dyslipidemia, previous AMI, previous 
PCI, hypertension, previous CABG and peripheral vascular disease has increased in 
both groups however a greater proportional increase was observed in the invasive 
strategy group from 2004 to 2014. Patients receiving an invasive strategy were 
consistently younger and less comorbid across all years compared to medically 
managed patients. Crude in-hospital mortality decreased from 2.2% in 2004 to 1.9% 
(Ptrend <0.001) in 2014. Conversely, in addition to increasing age, a greater proportional 
increase in the non-cardiac comorbidities was observed in medically managed patients. 
For instance, the prevalence of renal failure increased from 10.8% to 34.0%, 
(Ptrend<0.001) and prevalence of dementia increased from 8.9% to 15.4%, (Ptrend<0.001) 
during the study period. 
The unadjusted in-hospital mortality decreased from 2.2% in 2004 to 1.9% in 
2014, (Ptrend <0.001) in patients receiving invasive strategy, whilst it remained static in 
the medically managed group during the study period (6.8% to 6.7%, Ptrend =0.84).  
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Table 4.5: Demographics of patients receiving invasive strategy for each year included in the study, from 2004 – 2014. 
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Number of records 195,071 203,011 217,748 203,537 221,160 241,979 228,890 235,603 251,015 255,390 265,300 
























Men % 60.1% 61.3% 61.5% 61.0% 61.0% 61.5% 61.7% 61.8% 62.1% 62.5% 62.5% 
Ethnicity            
White 56.4% 58.1% 55.8% 54.5% 59.4% 62.3% 65.4% 66.4% 70.8% 70.3% 71.0% 
Black 7.3% 5.6% 7.1% 8.0% 7.8% 8.2% 10.6% 10.5% 10.7% 10.6% 10.6% 
Hispanic 4.8% 5.7% 5.8% 5.6% 5.3% 5.9% 6.4% 6.6% 7.0% 7.7% 7.4% 
Asian/Pacific 
Islander 1.1% 1.2% 1.1% 1.6% 1.6% 1.6% 1.7% 1.6% 1.8% 2.0% 2.0% 
Native American 0.2% 0.3% 0.3% 0.6% 0.9% 0.5% 0.8% 0.4% 0.6% 0.4% 0.5% 
Other 2.0% 2.5% 2.7% 2.2% 3.1% 3.0% 2.1% 3.1% 3.3% 2.8% 2.9% 
Missing Race 28.2% 26.6% 27.2% 27.3% 21.8% 18.5% 13.1% 11.4% 5.8% 6.2% 5.5% 
Weekend 
admission 
24.0% 24.4% 24.2% 24.3% 25.0% 24.7% 25.7% 25.7% 25.0% 25.9% 25.6% 
Primary expected 
payer 
           
Medicare 53.3% 54.0% 52.2% 51.9% 51.7% 52.2% 51.8% 54.5% 54.7% 55.0% 55.0% 
Medicaid 5.7% 6.1% 5.7% 5.5% 6.1% 6.1% 7.2% 6.9% 6.9% 6.9% 8.8% 
Private Insurance 32.8% 31.8% 32.8% 32.5% 32.3% 30.2% 30.7% 28.5% 27.5% 27.2% 27.8% 
Self-pay 5.0% 5.2% 5.4% 6.0% 6.0% 6.8% 6.8% 6.4% 7.0% 7.0% 5.2% 
No charge 0.6% 0.6% 0.7% 0.7% 0.6% 0.6% 0.5% 0.7% 0.6% 0.8% 0.6% 
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other 2.6% 2.4% 3.0% 3.4% 3.3% 3.1% 3.0% 2.9% 3.2% 3.1% 2.5% 
Median Household 
Income (percentile 
           
0-25
th
 26.4% 28.3% 26.4% 28.2% 28.3% 28.8% 31.1% 29.5% 32.1% 30.7% 30.3% 
26-50
th
 28.1% 26.2% 26.6% 27.3% 29.4% 28.9% 28.0% 26.0% 26.5% 27.7% 29.5% 
51-75
th
 23.3% 25.6% 25.1% 24.1% 22.9% 24.3% 23.2% 25.8% 22.8% 23.6% 22.5% 
76-100
th
 22.2% 19.9% 21.9% 20.4% 19.3% 18.0% 17.7% 18.7% 18.6% 18.0% 17.7% 
Comorbidities, %            
Dyslipidaemia 46.7% 48.6% 50.4% 53.1% 54.3% 56.9% 58.7% 60.7% 61.5% 62.1% 61.8% 
Smoking 27.8% 30.7% 32.0% 33.8% 35.1% 38.6% 39.1% 40.9% 42.7% 44.1% 46.7% 
Previous AMI 7.8% 7.6% 8.1% 8.3% 8.5% 9.4% 9.7% 10.4% 10.8% 11.0% 11.4% 
History of IHD 80.8% 80.5% 80.6% 80.4% 82.0% 83.3% 82.3% 83.1% 82.3% 81.6% 81.0% 
Previous PCI 7.3% 7.7% 8.9% 9.4% 10.0% 11.3% 12.2% 13.7% 13.8% 14.4% 15.3% 
Previous CABG 5.6% 5.3% 5.3% 5.1% 5.4% 5.5% 5.6% 6.3% 6.2% 6.3% 6.5% 
Previous CVA No data No data No data 0.5% 2.8% 3.8% 4.2% 4.9% 4.7% 5.2% 5.5% 
Family history of 
CAD 
5.0% 6.4% 5.9% 6.5% 6.8% 8.2% 9.4% 9.2% 9.3% 9.7% 10.0% 
Valvular heart 
disease 
0.2% 0.2% 0.2% 0.1% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.1% 
Peripheral vascular 
disease 
9.7% 9.5% 10.6% 11.6% 12.1% 12.6% 11.5% 13.1% 12.8% 13.0% 13.1% 
Use of assist devise 
or IABP 
4.1% 4.4% 4.0% 4.1% 4.5% 4.3% 4.2% 4.2% 4.3% 3.9% 3.9% 
Shock 1.8% 2.0% 2.1% 2.1% 2.5% 2.7% 2.7% 3.0% 2.9% 2.9% 3.2% 
AIDS 0.1% 0.1% 0.13% 0.13% 0.11% 0.16% 0.14% 0.16% 0.12% 0.14% 0.14% 
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Alcohol abuse 2.3% 2.3% 2.7% 2.7% 2.8% 2.9% 3.2% 3.1% 3.2% 3.3% 3.4% 
Deficiency 
anaemias 
8.9% 9.3% 10.0% 12.2% 13.5% 14.2% 13.9% 15.8% 15.0% 14.9% 14.9% 
Chronic Blood loss 
anaemia 




1.6% 1.8% 1.9% 2.0% 2.2% 2.2% 2.2% 2.5% 2.4% 2.6% 2.6% 
Congestive heart 
failure 
0.7% 0.6% 0.6% 0.4% 0.4% 0.5% 0.6% 0.5% 0.5% 0.4% 0.4% 
Chronic pulmonary 
disease 
18.7% 20.1% 20.2% 20.9% 20.1% 20.5% 19.8% 21.1% 21.4% 21.4% 21.8% 
Coagulopathy 3.1% 3.2% 3.2% 3.3% 3.6% 4.2% 4.5% 5.1% 5.0% 5.3% 5.2% 
Depression 4.0% 4.6% 5.0% 5.5% 6.3% 6.8% 7.2% 7.8% 8.3% 8.4% 8.7% 
Diabetes 26.7% 26.5% 27.8% 28.3% 29.7% 30.0% 30.6% 32.2% 32.8% 33.2% 33.2% 
Diabetes with 
complications 
4.5% 4.8% 4.9% 5.6% 5.6% 5.8% 6.1% 6.8% 7.1% 7.3% 7.7% 
Drug abuse 1.3% 1.5% 1.9% 2.1% 1.9% 2.0% 2.2% 2.4% 2.5% 2.7% 2.8% 
Hypertension 62.0% 62.6% 66.2% 67.1% 70.0% 70.9% 72.6% 74.6% 75.5% 76.5% 77.2% 
Hypothyroidism 6.9% 7.1% 7.4% 8.3% 9.1% 9.5% 9.5% 10.7% 10.8% 11.0% 11.5% 
Liver disease 0.7% 0.8% 0.8% 1.0% 1.1% 1.1% 1.2% 1.3% 1.5% 1.5% 1.8% 









2.8% 3.0% 3.3% 3.7% 4.0% 4.2% 3.9% 4.5% 4.5% 4.8% 4.9%% 
Obesity 8.9% 9.7% 9.9% 11.7% 13.7% 15.1% 14.6% 16.9% 18.1% 19.1% 19.9% 
Paralysis 0.9% 0.9% 1.0% 1.0% 1.4% 1.2% 1.2% 1.3% 1.2% 1.2% 1.3% 
Psychoses 1.2% 1.2% 1.2% 1.4% 2.0% 2.0% 2.0% 2.3% 2.3% 2.5% 2.5% 
Pulmonary 
circulation disorder 
0.03% 0.03% 0.03% 0.04% 0.1% 0.1% 0.1% 0.08% 0.07% 0.06% 0.07% 
Renal failure 
(chronic) 
6.4% 8.0% 12.7% 14.4% 14.4% 15.7% 16.5% 18.2% 17.8% 18.3% 19.1% 
Peptic ulcer 
disease 
0.07% 0.04% 0.06% 0.04% 0.04% 0.02% 0.02% 0.04% 0.03% 0.03% 0.02% 
Weight loss 0.6% 0.8% 0.9% 1.0% 1.4% 1.7% 1.6% 2.1% 2.1% 2.1% 2.0% 
Solid tumour 
without Mets 
0.9% 1.0% 1.0% 1.1% 1.1% 1.2% 1.0% 1.1% 1.1% 1.2% 1.1% 
Metastatic cancer 0.3% 0.3% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 




           
0 38.4% 38.6% 38.4% 37.2% 35.6% 34.7% 34.2% 32.2% 31.6% 31.1% 30.2% 
1 33.9% 33.9% 33.9% 33.7% 34.0% 32.8% 32.9% 31.8% 32.1% 31.3% 31.6% 
2 18.4% 18.2% 18.2% 18.6% 19.0% 19.3% 19.8% 20.3% 20.4% 21.0% 21.0% 
≥3 9.3% 9.3% 9.3% 10.5% 11.4% 13.2% 13.1% 15.6% 15.9% 16.6% 17.2% 
Hospital bed size            
Small 8.1% 3.6% 8.7% 8.0% 7.5% 5.9% 8.6% 7.0% 8.4% 8.4% 12.7% 
80 
 
Medium 19.6% 21.5% 21.4% 22.1% 20.0% 18.5% 18.8% 21.2% 24.3% 24.2% 28.9% 
Large 72.3% 74.9% 69.9% 69.9% 72.5% 75.6% 72.6% 71.8% 67.3% 67.4% 58.3% 
Hospital Region            
Northeast 22.0% 20.9% 18.8% 18.3% 16.4% 17.5% 17.4% 16.1% 16.7% 16.3% 17.0% 
Midwest 24.1% 23.2% 22.2% 24.3% 25.3% 23.9% 26.1% 23.6% 23.8% 23.9% 24.1% 
South 39.1% 40.7% 44.3% 40.4% 42.5%% 42.7% 38.8% 42.7% 42.9% 43.0% 42.2% 
West 14.8% 15.3% 14.7% 17.0% 15.7% 15.9% 17.7% 17.6% 16.6% 16.8% 16.7% 
Location/ Teaching 
status 
           
Rural 5.2% 5.2% 4.4% 7.3% 7.8% 7.2% 10.1% 5.8% 6.8% 7.1% 5.7% 
Urban-non 
teaching 
38.2% 42.5% 39.6% 39.0% 40.5% 40.1% 40.3% 41.7% 38.2% 37.9% 27.5% 
Urban- teaching 56.6% 52.3% 56.0% 53.7% 51.7% 52.7% 49.6% 52.5% 55.0% 55.0% 66.8% 
Length of stay, 
Median (IQR) 






































11.5% 11.6% 11.3% 11.8% 11.7% 12.2% 10.5% 10.5% 10.0% 9.2% 8.5% 
Vascular 
complications 
1.4% 1.7% 1.5% 1.6% 1.5% 1.5% 1.1% 1.4% 1.1% 1.2% 1.1% 
Cardiac 
complication 
2.5% 2.5% 2.3% 2.3% 2.6% 2.3% 2.0% 1.7% 1.8% 1.8% 1.9% 




IQR=interquartile range, AIDS= acquired immunodeficiency syndrome, AMI=acute myocardial infarction, CVA= cerebrovascular 
accident, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft, CAD= coronary artery disease, IABP= intra 
aortic balloon pump, RA= rheumatoid arthritis. 
 
Table 4.6: Demographics of patients not receiving invasive strategy for each year included in the study, from 2004 – 2014. 
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Number of records 207,084 189,955 184,979 175,428 182,214 169,948 158,144 160,538 148,900 142,474 142,455 
























Men % 49.0% 49.2% 49.4% 49.2% 49.3% 49.9% 49.3% 49.6% 50.0% 50.8% 51.2% 
Ethnicity            
White 56.6% 58.6% 57.2% 57.4% 62.7% 64.1% 65.5% 67.9% 71.1% 70.2% 70.9% 
Black 9.4% 7.1% 8.7% 8.9% 8.5% 9.3% 12.4% 11.7% 11.3% 12.1% 12.1% 
Hispanic 5.8% 5.3% 6.9% 5.6% 5.5% 6.6% 6.2% 7.2% 7.4% 7.7% 7.5% 
Asian/Pacific 
Islander 1.5% 1.0% 1.7% 1.6% 1.8% 1.7% 2.3% 1.5% 2.3% 2.3% 2.1% 
Native American 0.3% 0.2% 0.4% 0.5% 0.5% 0.5% 0.6% 0.4% 0.5% 0.4% 0.5% 
Other 1.9% 2.3% 1.5% 1.8% 2.3% 3.0% 2.1% 2.1% 2.6% 2.2% 2.6% 
Missing Race 24.5% 25.5% 23.6% 24.3% 18.6% 14.9% 10.8% 9.2% 4.7% 5.0% 4.3% 
Weekend admission 26.6% 26.7% 26.0% 26.9% 27.2% 27.2% 27.3% 26.6% 26.5% 27.1% 26.9% 
Primary expected 
payer, % 
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Medicare 68.6% 71.5% 70.5% 70.7% 72.0% 71.9% 72.9% 74.6% 75.1% 74.8% 74.4% 
Medicaid 6.0% 5.3% 5.2% 4.9% 5.5% 5.5% 5.8% 5.7% 6.1% 6.0% 7.5% 
Private Insurance 19.4% 17.6% 18.2% 18.4% 17.1% 16.4% 15.1% 14.1% 13.0% 13.2% 13.3% 
Self-pay 4.0% 3.7% 4.0% 3.6% 3.1% 4.0% 3.7% 3.3% 3.6% 3.4% 2.8% 
No charge 0.3% 0.3% 0.3% 0.4% 0.2% 0.2% 0.4% 0.3% 0.3% 0.4% 0.3% 
other 1.8% 1.6% 1.8% 1.8% 2.1% 2.0% 2.0% 2.0% 1.9% 2.2% 1.7% 
Median Household 
Income (percentile 
           
0-25
th
 31.1% 29.5% 30.1% 29.9% 28.9% 30.3% 30.5% 31.1% 31.7% 30.0% 30.3% 
26-50
th
 27.8% 26.2% 26.7% 26.5% 28.5% 26.9% 26.9% 25.7% 25.6% 27.4% 27.0% 
51-75
th
 21.2% 23.5% 22.3% 23.4% 21.8% 23.1% 23.2% 23.6% 22.6% 22.7% 22.7% 
76-100
th
 20.0% 20.7% 20.9% 20.3% 20.8% 19.7% 19.4% 19.6% 20.1% 19.8% 20.0% 
Comorbidities, %            
Dyslipidaemia 28.6% 30.6% 32.3% 35.1% 35.5% 38.9% 40.4% 42.2% 44.9% 45.9% 46.8% 
Smoking 15.3% 16.6% 17.9% 19.2% 19.3% 22.6% 24.1% 26.3% 27.9% 30.0% 33.9% 
Previous AMI 7.3% 7.5% 7.8% 8.4% 8.4% 9.8% 10.6% 11.4% 11.7% 11.5% 11.9% 
History of IHD 36.2% 37.8% 38.7% 40.4% 42.1% 44.1% 44.7% 46.7% 47.7% 47.8% 47.9% 
Previous PCI 4.6% 4.9% 5.1% 6.3% 6.3% 7.8% 8.6% 10.1% 11.0% 11.3% 12.4% 
Previous CABG 8.4% 8.4% 8.6% 8.6% 8.9% 10.6% 10.7% 12.1% 11.9% 11.9% 12.5% 
Previous CVA No data No data No data 0.6% 3.8% 5.6% 6.5% 7.0% 7.6% 8.0% 8.6% 
Family history of 
CAD 
2.6% 2.6% 2.8% 3.3% 2.9% 3.3% 3.7% 4.0% 3.9% 4.1% 4.5% 
Valvular heart 
disease 





8.4% 8.8% 9.4% 10.7% 11.3% 12.3% 12.5% 13.6% 13.8% 14.1% 14.6% 
Use of assist devise 
or IABP 
0.3% 0.4% 0.5% 0.4% 0.5% 0.5% 0.4% 0.6% 0.7% 0.8% 0.9% 
Shock 1.6% 1.5% 1.7% 1.8% 1.7% 2.3% 2.2% 2.9% 2.9% 3.1% 3.4% 
AIDS 0.14% 0.11% 0.08% 0.13% 0.12% 0.11% 0.15% 0.1% 0.11% 0.11% 0.15% 
Alcohol abuse 2.0% 2.1% 2.2% 2.2% 2.4% 2.4% 2.4% 2.6% 2.7% 2.8% 2.9% 
Deficiency 
anaemias 
13.9% 14.7% 15.7% 18.3% 20.9% 22.1% 22.7% 24.6% 25.3% 25.2% 25.1% 
Chronic Blood loss 
anaemia 




1.8% 1.9% 2.0% 2.1% 2.3% 2.4% 2.7% 2.7% 2.8% 2.9% 2.9% 
Congestive heart 
failure 
1.3% 1.2% 1.0% 1.1% 1.3% 1.6% 1.6% 1.4% 1.2% 1.2% 1.2% 
Chronic pulmonary 
disease 
23.5% 24.8% 24.9% 25.2% 24.9% 24.9% 24.9% 26.5% 26.7% 26.7% 27.0% 
Coagulopathy 2.8% 2.9% 3.2% 3.7% 3.7% 4.4% 4.6% 5.4% 6.1% 6.2% 6.7% 
Depression 5.4% 5.7% 6.3% 7.3% 7.8% 8.0% 8.6% 9.4% 9.6% 9.8% 10.1% 
Diabetes 27.2% 27.6% 28.4% 29.3% 29.7% 30.4% 31.1% 31.6% 32.7% 32.7% 33.2% 
Diabetes with 
complications 
5.9% 6.2% 6.4% 7.2% 7.3% 7.5% 7.6% 8.1% 8.5% 9.2% 9.7% 
Drug abuse 1.3% 1.4% 1.6% 1.7% 1.5% 1.7% 1.8% 1.8% 2.0% 2.2% 2.6% 
Hypertension 59.1% 61.3% 63.5% 65.3% 67.6% 70.4% 71.4% 72.6% 74.5% 76.1% 76.4% 
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Hypothyroidism 9.0% 9.8% 10.3% 11.4% 12.7% 13.0% 13.7% 14.8% 15.7% 15.8% 16.0% 
Liver disease 1.1% 1.1% 1.2% 1.2% 1.2% 1.3% 1.5% 1.6% 1.8% 1.9% 2.2% 




19.3% 21.3% 21.5% 23.3% 25.1% 25.5% 26.1% 28.3% 29.1% 30.4% 30.8% 
Other neurological 
disorders 
7.0% 7.3% 7.9% 8.7% 9.6% 10.0% 10.0% 10.4% 10.4% 10.3% 10.2% 
Obesity 6.1% 6.6% 6.8% 7.8% 8.5% 9.5% 9.2% 10.8% 11.7% 12.6% 13.6% 
Paralysis 2.2% 2.1% 2.3% 2.4% 3.1% 2.7% 2.8% 2.7% 2.7% 2.6% 2.7% 
Psychoses 1.9% 1.9% 2.1% 2.2% 2.7% 2.7% 3.1% 3.2% 3.3% 3.5% 3.5% 
Pulmonary 
circulation disorder 
0.06% 0.06% 0.06% 0.08% 0.2% 0.3% 0.2% 0.3% 0.2% 0.2% 0.2% 
Renal failure 
(chronic) 
10.8% 14.0% 21.1% 24.1% 24.5% 27.3% 29.1% 31.6% 32.4% 33.6% 34.0% 
Peptic ulcer disease 0.07% 0.04% 0.05% 0.07% 0.04% 0.04% 0.06% 0.05% 0.02% 0.02% 0.03% 
Weight loss 1.8% 1.7% 1.9% 2.4% 3.1% 3.6% 3.8% 4.4% 4.6% 4.7% 4.6% 
Solid tumour 
without Mets 
1.7% 1.8% 1.8% 2.1% 2.2% 2.0% 2.3% 2.2% 2.2% 2.3% 2.2% 
Metastatic cancer 1.2% 1.4% 1.3% 1.5% 1.6% 1.8% 1.5% 1.7% 1.6% 1.7% 1.8% 




           
0 28.4% 26.6% 26.8% 25.4% 23.6% 22.3% 21.0% 20.2% 19.0% 18.0% 17.6% 
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1 32.8% 33.2% 33.6% 32.8% 32.4% 31.2% 30.8% 29.7% 29.5% 29.8% 28.7% 
2 23.2% 24.0% 23.9% 24.0% 24.8% 24.7% 25.3% 24.7% 25.5% 25.6% 25.6% 
≥3 15.6% 16.2% 15.7% 17.8% 19.2% 21.8% 22.9% 25.3% 26.0% 26.6% 28.1% 
Hospital bed size            
Small 15.9% 13.9% 16.7% 14.7% 16.0% 15.0% 13.7% 14.7% 16.4% 16.3% 22.3% 
Medium 28.6% 28.1% 27.9% 27.4% 26.5% 27.0% 27.2% 28.2% 29.1% 29.1% 31.3% 
Large 55.5% 58.0% 55.4% 57.9% 57.5% 59.0% 59.1% 57.1% 54.5% 54.6% 46.4% 
Hospital Region            
Northeast 26.9% 29.7% 28.6% 26.8% 24.5% 25.0% 24.9% 26.4% 25.5% 24.6% 24.7% 
Midwest 21.5% 19.1% 19.0% 20.6% 21.1% 20.9% 21.8% 20.6% 20.2% 19.9% 20.4% 
South 38.1% 38.3% 38.3% 38.3% 39.5% 39.6% 38.5% 37.3% 37.6% 38.2% 37.9% 
West 13.5% 12.9% 14.1% 14.3% 14.9% 14.5% 14.8% 15.7% 16.7% 17.3% 17.0% 
Location/ Teaching 
status 
           
Rural 21.6% 21.0% 19.6% 18.3% 17.9% 18.5% 17.9% 17.8% 16.0% 15.6% 13.7% 
Urban-non teaching 50.5% 50.1% 45.6% 50.0% 50.1% 47.5% 48.1% 47.3% 45.0% 44.0% 32.8% 
Urban- teaching 27.9% 28.9% 34.8% 31.7% 32.0% 34.0% 34.0% 34.9% 39.0% 40.4% 53.5% 
Length of stay, 
Median (IQR) 






































11.2% 11.8% 11.7% 12.7% 12.7% 12.5% 12.2% 11.9% 11.9% 11.8% 10.6% 






0.3% 0.4% 0.5% 0.4% 0.4% 0.6% 0.4% 0.4% 0.5% 0.6% 0.6% 
In-hospital 
mortality 
6.8% 6.9% 6.6% 6.3% 6.7% 6.4% 6.4% 6.5% 7.0% 6.7% 6.7% 
IQR=interquartile range, AIDS= acquired immunodeficiency syndrome, AMI=acute myocardial infarction, CVA= cerebrovascular 
accident, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft, CAD= coronary artery disease, IABP= intra 
aortic balloon pump, RA= Rheumatoid arthritis. 
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Temporal trends in the comorbidity burden of patients receiving an invasive strategy as 
defined by the Charlson score are shown in Figure 4.4. An increase in the use of the 
invasive strategy was noted across all four categories of Charlson score, albeit with the 
lowest uptake in patients with the highest comorbidity burden. From 2004 to 2014, the 
use of an invasive strategy increased from 55.9% to 75.6% (Ptrend <0.001) in patients 
with no comorbidity (CCI=0), from 48.7% to 66.4% (Ptrend <0.001) in CCI=1 category, 
from 42.3% to 59.9% (Ptrend <0.001) in CCI=2 and 35.3% to 53.9% (Ptrend <0.001) in 
CCI≥3 category respectively. Very interestingly, the delta between all four curves 
seems to remain stable throughout the study periods showing persistent disparities.  
Figure 4.4 Temporal trends in proportions of patients receiving invasive strategy 






















































Similar disparities were observed in the use of an invasive strategy when patients were 
stratified according to age group, gender, ethnicity and hospital location/teaching status. 
For instance, patients age ≤60 years showed a higher proportional increase in the 
utilisation of an invasive strategy (59.0% to 77.9%, Ptrend <0.001) compared to patients 
age≥81(27.2% to 37.9%, Ptrend <0.001) between the study period. (Figure 4.5) 
Figure 4.5 Temporal trends in proportions of patients receiving an invasive strategy 
according to their age category from 2004-2014 
 
Similarly, a greater proportional increase in the use of an invasive strategy was observed 
in Native Americans (33.3% to 65.4%, Ptrend <0.001) compared to the Whites (48.3% to 
65.1%, Ptrend <0.001). In contrast, the use of an invasive strategy remained lowest in the 
African American group throughout the study periods compared to all other ethnicities 
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Figure 4.6 Temporal trends in proportions of patients receiving invasive strategy 
according to their Ethnicity from 2004-2014 
 
Although, there was an increase in the proportion of the women receiving an invasive 
strategy from 41.9% to 58.9%, Ptrend <0.001 the overall adoption of the invasive strategy 
lagged behind in women compared to men (53.9% to 69.4%, Ptrend <0.001). (Figure 4.7)  
Figure 4.7 Temporal trends in proportions of patients receiving invasive strategy 
according to their gender from 2004-2014 
a) Women  
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b) Men  
 
Finally, whilst there has been a steady increase in use of an invasive strategy in teaching 
hospitals (65.1% to 69.8%, Ptrend <0.001), a greater increase was noted in patients 
admitted to urban non-teaching (42.1% - 64.2%, Ptrend <0.001) and rural hospitals 
(19.9% to 43.9%, Ptrend <0.001) (Figure 4.8). 
Figure 4.8 Temporal trends in proportions of patients receiving an invasive strategy 
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4.4.3 Independent predictors of receipt of an invasive strategy  
The predictors of receipt of an invasive strategy are shown in Table 4.7. The 
independent predictors of an invasive strategy receipt included the history of smoking 
(OR 1.17 95%CI 1.16-1.19), dyslipidemia (OR 1.39 95%CI 1.37-1.40), and history of 
IHD (OR 6.21 95%CI 6.13-6.29). Notably, patient characteristics which are known to 
be related to adverse outcomes in NSTEMI such as increasing age (OR 0.96 95%CI 
0.960-0.961), prior history of CABG (OR 0.35 95%CI 0.35-0.36), prior PCI (OR 0.84 
95%CI 0.83-0.86), history of diabetes (OR 0.88 95%CI 0.87-0.89), diabetes with 
complications (OR 0.85 95%CI 0.83-0.87) and previous history of AMI (OR 0.65 
95%CI 0.64-0.67) had a strong inverse relationship with receipt of invasive strategy. 
Certain non-cardiac comorbidities which are also associated with poor outcomes such as 
metastatic cancer (OR 0.33 95%CI 0.31-035), dementia (OR 0.32 95%CI 0.31-0.33) 
and chronic renal failure (OR 0.66 95%CI 0.65-0.67) were also independently 
associated with lower odds of receipt of an invasive strategy. Finally, patients treated at 
large bed or teaching hospital had approximately 3 and a 5-fold increase in odds of 
receiving invasive strategy (large hospital bed size (OR 3.05 95%CI 2.99-3.11) and 
urban hospital teaching status (OR 5.51 95%CI 5.39-5.62)) respectively.  
Table 4.7 Independent Variables associated with the invasive strategy after excluding 
for in-hospital mortality and association between the use of an invasive strategy and 
clinical outcomes. 
Predictors Odds Ratio 95% Confidence 
Interval  
P Value 
Age  0.96 0.960-0.961 <0.001 
Weekend admission  0.92 0.91-93 <0.001 
Female  0.91 0.90-0.92 <0.001 
AIDS 0.79 0.67-0.93 <0.001 
Alcohol abuse 0.88 0.85-0.91 <0.001 
Deficiency anaemias 0.82 0.81-0.83 <0.001 
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Chronic Blood loss anaemia 0.72 0.68-0.76 <0.001 
Congestive heart failure 0.53 0.49-0.57 <0.001 
Chronic pulmonary disease 0.85 0.84-0.86 <0.001 
Coagulopathy 1.12 1.08-1.15 <0.001 
Depression 0.86 0.84-0.86 0.009 
Diabetes 0.88 0.87-0.89 <0.001 
Diabetes with complications 0.85 0.83-0.87 <0.001 
Drug abuse 0.66 0.63-0.68 <0.001 
Hypertension 1.02 1.00-1.03 0.001 
Hypothyroidism 0.92 0.91-0.94 <0.001 
Liver disease 0.76 0.72-0.80 <0.001 
Fluid and electrolyte 
disturbances 
0.85 0.83-0.86 <0.001 
Other neurological disorders 0.79 0.76-0.81 <0.001 
Obesity 1.09 1.07-1.11 <0.001 
Paralysis 0.61 0.58-0.64 <0.001 
Psychoses 0.67 0.64-0.70 <0.001 
Renal failure (chronic) 0.66 0.65-0.67 <0.001 
Weight loss 0.80 0.77-0.83 <0.001 
Solid tumour without Mets 0.67 0.64-0.70 <0.001 
Metastatic cancer 0.33 0.31-0.35 <0.001 
Dementia 0.32 0.31-0.33 <0.001 
Dyslipidaemia 1.39 1.37-1.40 <0.001 
Smoking 1.17 1.16-1.19 <0.001 
Previous AMI 0.65 0.64-0.67 <0.001 
Previous PCI 0.84 0.83-0.86 <0.001 
Previous CABG 0.35 0.35-0.36 <0.001 
Previous CVA 0.82 0.79-0.84 <0.001 
Family history of CAD 1.30 1.27-1.34 <0.001 
Peripheral vascular disease 1.12 1.10-1.14 <0.001 
Shock 2.16 2.06-2.26 <0.001 
Hospital bed size(Ref small)    
Medium 1.56 1.52-1.59 <0.001 
Large 3.05 2.99-3.11 <0.001 
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Location/ Teaching status 
(Ref Rural) 
   
Urban-non teaching 2.58 2.53-2.63 <0.001 
Urban- teaching 5.51 5.39-5.62 <0.001 
4.4.4 Clinical outcomes 
 Association between the use of an invasive strategy and in-hospital outcomes are 
reported in Table 4.8. In the multivariate adjusted analysis, the use of an invasive 
strategy was associated with a significantly decreased odds of in-hospital death (OR 
0.38 95%CI 0.36-0.40). There was a significant increase in the incidence of major 
bleeding (OR 1.23 95%CI 1.16-1.31), vascular complications (OR 3.96 95%CI 3.09-
5.07), cardiac complications (OR 4.77 95%CI 3.88-5.87) and MACCE (OR 0.76 95%CI 
0.74-0.79) in patients receiving an invasive strategy. 
Table 4.8 Association between the use of an invasive strategy and clinical outcomes  





In hospital mortality 0.38 0.36-0.40 <0.001 
Cardiac Complications 4.77 3.88-5.87 <0.001 
Major Bleeding 1.23 1.16-1.31 <0.001 
Vascular Complications 3.96 3.09-5.07 <0.001 
MACCE 0.76 0.74-0.79 <0.001 
94 
 
4.5 Discussion  
In this analysis of over 4.3 million patients admitted with a diagnosis of an NSTEMI in 
the United States, there was a gradual increase in uptake of an invasive strategy for 
management of NSTEMI over an 11-year period. The results show that there is a 
paradigm shift in the demographics and risk profile of patients presenting with an 
NSTEMI resulting in a significant increase in case mix complexity, comorbidity burden 
in an increasingly older population. Consequently, treating physicians are required to 
make decisions about the adoption of an invasive strategy in an elderly and more 
comorbid cohort of patients who have a higher prevalence of both cardiac and non-
cardiac comorbidities. There was marked heterogeneity in invasive strategy practices 
according to patient’s baseline cardiovascular profile, comorbidities and hospital 
characteristics. The use of an invasive strategy remained relatively confined to patients 
with lower baseline risk such as young age, males, lesser comorbid burden and those 
admitted to large bed size or teaching hospitals during the study period. In addition, 
there was a strong inverse relationship between receipt of an invasive strategy and 
known risk factors of coronary artery disease such as the history of diabetes, 
hypertension, prior history of CABG, PCI, or AMI. Finally, the use of an invasive 
strategy was associated with a significant reduction in in-hospital mortality and 
increased odds of major bleeding, vascular and cardiac complications and trends 
remained consistent across all years during the study period.  
This study demonstrates that clinical spectrum, baseline characteristics and 
comorbidity status of patients presenting with an NSTEMI has changed significantly 
over the past decade reflecting and ageing demographics in the United States. The 
utilisation of an invasive strategy in this cohort increased from 48.5% to 65.1% during 
the study period; however, there were significant disparities in invasive strategy 
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practices. Previous studies have reported that the use of an invasive strategy ranges from 




, and France respectively
20
. 
This lower utilisation of invasive strategy in the United States may be attributed to 
inequalities in uniform health coverage by the insurance-based system and differences 
in the associated comorbid burden of the patients. More importantly, there was 
significant heterogeneity in the utilisation of an invasive strategy in different patient 
groups stratified according to gender, age, ethnicity and hospital characteristics. For 
instance, the higher proportional increase in the utilisation of an invasive strategy was 
noted in young patients aged ≤60 years compared to elderly patients (age ≥81) despite a 
progressive increase in the average age of this NSTEMI cohort. More importantly, there 
was significant heterogeneity in the utilisation of an invasive strategy in different 
patient groups stratified according to sex, age, ethnicity and hospital characteristics. A 
higher proportional increase in the utilisation of an invasive strategy was noted in young 
patients aged ≤60 years compared to elderly patients (aged ≥81) despite a progressive 
increase in the average age of NSTEMI population. The inequalities in the use of an 
invasive strategy were also evident in women and African Americans wherein adoption 
of an invasive strategy has been particularly slower in comparison to men and Native 
Americans respectively. African Americans and Asians were almost 30% less likely to 
receive an invasive strategy. Teaching hospital status was associated with higher use of 
an invasive strategy compared to rural hospitals despite the expansion of cardiac 
catheter laboratory services in rural hospitals
134
.  
The delay in uniform adoption of an invasive approach across the whole 
spectrum of NSTEMI patients may be related to a complex web of underlying factors 
including local practice, service availability and inequalities in uniform health coverage 
by the insurance-based system. It is important to note that the under-utilisation of both 
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invasive and medical therapies in women and the elderly have been widely described 
which in part has been related to the increased perception of adverse outcomes in 
women and older patients
97,135,136
. Increase knowledge and understanding of important 
factors which influence clinician’s decision-making about the use of an invasive 
strategy is required to ensure a uniform and effective use of invasive management in 
this underserved group of patients.  
This analysis also allowed to study the temporal changes in the clinical 
characteristics and associated comorbidities of the patients receiving an invasive 
strategy compared to those medically managed in much greater details. Previous studies 
have mainly reported on the cardiovascular comorbid burden of NSTEMI patients such 
as history of hypertension, dyslipidaemias, smoking, and diabetes
20,21,97,133,137
. However, 
the granularity of comorbidity data in NIS facilitates the study of both cardiac and non-
cardiac comorbidities in decision making in much greater detail. The findings from this 
study illustrate that non-cardiac comorbid burden has increased considerably in patients 
with NSTEMI over the last decade. There was a significantly higher prevalence of non-
cardiac comorbidities such as dementia, chronic obstructive airway disease, renal 
disease and cancer in patients not receiving an invasive strategy. For instance, the 
prevalence of dementia was significantly higher in patients not receiving an invasive 
strategy (12.9% vs 2.5% p<0.001) and it was a strong negative predictor of receiving an 
invasive strategy (OR 0.32 95%CI 0.31-0.33, p<0.001). Furthermore, there were 
significant disparities in selection for invasive strategy and global measures for the 
severity of comorbidity burden. The utilisation of an invasive strategy remained lower 
in patients with a higher Charlson score category (CCI≥3) compared to no comorbidity 
(CCI=0) group throughout the study time period. There is a paucity of data on the 
utilisation of invasive management in patients with multimorbidity as these patients are 
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often excluded from randomised control trials
9
. It is conceivable that treating physicians 
may adopt a more conservative approach in older, frailer and multimorbid patients due 
to the perceived increased risk of adverse events. However, previous studies have 
shown that impact on mortality with invasive therapies for ACS is not attenuated with 
age 
136
 and patients with higher comorbidities may have even greater gains from 
guidelines recommended treatment
23,138
. Therefore, age alone or the presence of 
comorbidities should not deter the physician from offering an invasive strategy to these 
patients. Women have often been denied an early invasive approach
139,140
 but recent 
data from Ontario, Canada showed that women had worse outcomes after undergoing an 
early invasive strategy after an NSTEMI when compared to men
141
. Women had more 
bleeding complications after undergoing invasive strategy but it was also seen that 
women were less likely than men to undergo any revascularisation even after 
undergoing an invasive strategy. Younger women were less likely to undergo an 
invasive strategy in this population but there were no noted sex-differences in outcomes 
in those receiving medical management rather than an invasive approach. These 
observational data may bias the management of female patients, where an invasive 
strategy continues to be underutilised in women.  
Current guidelines advocate a risk-based approach for offering an invasive 
strategy in the setting of an NSTEMI which includes several parameters such as age, 
history of renal insufficiency, prior history of CABG or PCI and presence of coronary 
disease risk factors such as diabetes
3,4
. This study shows that patient features which are 
known to be associated with increased risk of adverse events in NSTEMI such as age, 
diabetes with complications, prior history of CABG, PCI or AMI actually have a strong 
inverse relationship with receipt of an invasive strategy. In a previous analysis of the 
CRUSADE registry, Cohen et al reported that patients with the greatest probability of 
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having severe coronary artery disease were least likely to have invasive strategy
137
. 
Patients with prior CABG, severe comorbidities and advanced age were excluded from 
this analysis. This study adds new knowledge to this literature by using granular data 
from both cardiac and non-cardiac comorbidities, older age, racial and institutional 
factors thus representing a truly real-world population elucidating a persistent treatment-
risk paradox. More importantly, this is the first national analysis spanning over a decade 
where there have been major changes in clinical practice with advancements in both 
diagnostic and therapeutic tools to diagnose and manage patient admitted with an 
NSTEMI. For example, the use of highly sensitive troponin assays has significantly 
increased the diagnostic accuracy of an NSTEMI and therefore increase utilisation of 
invasive strategy. More importantly, such disparities in the invasive strategy practices 
have not been described in the literature from the contemporary era and underline the 
importance to develop focused efforts for a homogenous and risk-assessment based 
utilisation of the invasive strategy.  
One final finding worthy of discussion in this investigation was the association of an 
invasive strategy with in-hospital mortality, major bleeding, vascular and cardiac 
complications. the invasive strategy was associated with significantly decreased odds of 
in-hospital mortality (OR 0.38 95%CI 0.36-0.40) albeit at the expense of a slight 
increase in relative risk of major bleeding, vascular and cardiac complications. 
Procedure safety and risk profile have improved significantly over the past decade due 
to improvement in procedural skills, changes in access site practice from femoral to 
radial access, operator volume, and better equipment and as a result, the absolute risk of 
such procedure-related adverse events has declined
142-144
. Nevertheless, the main 
finding in the outcome analysis is a significant reduction in in-hospital mortality in 
patients receiving an invasive strategy which corroborates the results of previously 
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reported better outcomes of patients receiving routine invasive approach compared to 
conservative or selective invasive approach
11,57,104,145
, thus providing reassurance about 
the accuracy of the overall findings.  
4.6 Study strengths and limitations 
The strengths of this study findings arise from the use of comprehensive, unselected, 
national records that are derived from an obligatory administrative database which are 
representative of true real-world practice. The granularity of comorbidity data, diversity 
in geographic, racial and hospital characteristic information within the NIS dataset 
allowed to study the disparities in the invasive strategy practices.  
Nevertheless, this work must be interpreted within the context of certain limitations. 
First, this work is observational in nature and the possibility of unmeasured confounders 
cannot be ruled out. Secondly, important clinical information such as medication 
history, frailty, ECG and cardiac biomarker information is not captured within the NIS 
database. Cardiac biomarkers, ECG changes, and hemodynamic parameters are 
important for risk stratification and may influence a physician’s decision on whether to 
adopt an invasive approach
146,147
. The information regarding onsite facility to perform 
angiography is not available in the database which may have limited the estimation of 
the utilisation of an invasive strategy. Finally, as with any administrative database, there 
is a potential for coding error for diagnoses or procedure codes 
4.7 Conclusion  
In summary, for the first time in literature, this study in over 4 million inpatient 
admissions of NSTEMI across the United States from 2004 – 2014 demonstrates a 
steady rise in the use of an invasive strategy. There was significant heterogeneity in the 
utilisation of an invasive strategy across different patient groups stratified according to 
age, gender, race, comorbidity burden and hospital characteristics wherein severe 
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comorbidity burden as defined by Charlson score (CCI>3), female, elderly and Native 
Americans were less likely to receive an invasive strategy. Although, utilisation of an 
invasive strategy was associated with decreased odds of in-hospital mortality, patients 
who are more likely to benefit such as elderly, diabetic and previous PCI or AMI were 
least likely to receive it. Future strategies need to focus on identification of factors 
associated with these disparities and developing pathways for a uniform uptake of 




Chapter 5  
 
Trends and outcomes in the timing of an invasive strategy in the management of non-ST 
elevation acute myocardial infarction  
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5.1 Introduction  
In line with part 1 of this thesis to investigate patient level factors associated with the 
use of an invasive strategy, this study was designed to further understand how timing of 
an invasive strategy varies amongst different subgroup of patients, secular trends in the 
timing of an invasive strategy and association with clinical outcomes to further augment 
the findings presented in chapter 4. The findings from this chapter have been published 
in Coronary Artery Disease Journal (impact factor 1.7). 
A routine invasive strategy has been shown to be associated with a reduced risk 
of re-infarction, repeat hospitalisation, and improved survival compared to a selective 
invasive or conservative approach, particularly in high-risk NSTEMI such as those who 
are troponin positive or high GRACE risk score >140
52,104,146
. An invasive strategy 
plays a pivotal role in the early diagnosis and management of patients admitted 
following an NSTEMI. Time to an invasive strategy for patients with NSTEMI varies 
greatly according to national and regional practices. In the UK, NICE recommends that 
the invasive strategy should be undertaken within 96 hours following admission with an 
NSTEMI in patients that are intermediate to high risk per GRACE risk score 
8
. In 
contrast, the European Society of Cardiology advocates offering an invasive strategy 
within 72 hours to low-risk patients and within 24 hours to patients with high-risk 
features defined as GRACE score >140. However, patients presenting with 
haemodynamic instability, cardiac arrest, cardiogenic shock or acute heart failure are 
advised to undergo an immediate invasive strategy within 2 hours according to expert 
consensus
148
. Lastly, the AHA/ACC has recommended three different points for 
invasive strategy whilst acknowledging the fact that the optimal timing of an invasive 
strategy is not known
3
. An immediate invasive strategy (within 2 hours) is 
recommended in patients with hemodynamic instability, signs of new heart failure or 
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recurrent angina despite maximum medical therapy, an early approach (within 24h) for 
patients with changes in cardiac biomarker or ECG changes and a late invasive 
approach (>24 hours) for patients with low GRACE score (109-140). Although an 
invasive approach during the index admission is now routinely practised for 
management of NSTEMI, the optimal timing of the procedure remains contentious due 
to conflicting data derived from the previous studies
51,59,60
. The ISAR-COOL study was 
the first trial with a relatively smaller sample size of 410 patients which compared early 
(3h) with delayed (72h) invasive strategy in patients admitted with NSTEMI. Patients 
were randomly allocated to antithrombotic pre-treatment for 3 to 5 days or to early 
intervention after pre-treatment for less than 6 hours. At 30 days, the cumulative 
incidence of primary endpoints (large AMI or death) was significantly different between 
the two groups (early intervention 5.9% vs late intervention 11.6%, p=0.04) 
demonstrating that an early invasive approach resulted in a reduction in MI or death 
149
. 
The authors concluded that late invasive strategy is associated with significant cardiac 
complications, costs related to a prolonged hospital stay and does not reduce the risk of 
subsequent revascularisation procedures. More recently, two other smaller RCTs tested 
the hypothesis if treating NSTEMI with an immediate invasive strategy like STEMI 
improves cardiovascular outcomes 
51,105
. The LIPSIA-NSTEMI trial randomised the 
patients to immediate (<2h) versus early (10-48h) or delayed selective invasive 
approach (>48h) 
51
. They concluded that immediate invasive approach did not offer any 
advantage over the early or delayed selective high invasive approach in reducing 
myocardial infarction as defined by peak CKMB activity level. More interestingly, a 
very recent study of 323 NSTEMI patients reported a greater benefit of immediate 
invasive approach in reducing death or new MI at short to medium term follow up, 





. Meta-analyses of RCTs and observational 
studies reveal that an early invasive strategy does not reduce mortality compared with a 
delayed invasive strategy in all patients with NSTEMI, but there may be a benefit in 
high-risk patients such as those with GRACE risk score >140 
60,149-151
. Moreover, the 
timing of an invasive strategy has changed significantly in the last decade due to 
expansion in services and changes in guideline recommendations around the cut off for 
an invasive approach
3,4
. There are limited data in contemporary practice and in national 
cohorts regarding temporal trends and changing characteristics of patients undergoing 
an invasive strategy following an NSTEMI diagnosis at different time points. 
5.2 Objectives 
The main objectives of this chapter were as follows 
I. To investigate the temporal trends in timing to an invasive strategy 
stratified into early, intermediate and late. 
II.  To describe changes in the profile of patients undergoing early, 
intermediate and late invasive strategy following admission with 
NSTEMI over the past decade in the United States.  
III. To study these trends stratified according to age, ethnicity, gender, 
weekday versus weekend admission and comorbidity burden.  
IV. To investigate the independent predictors of an early invasive strategy. 
V.  To study the association of in-hospital mortality, Major Adverse 
Cardiovascular & Cerebrovascular Events(MACCE) and major bleeding 
with different time points of an invasive strategy. 
5.3 Methods 
Full details of NIS dataset and methods have already been described in chapter 3. 
However, a brief summary of methods is provided here.  
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5.3.1 Study design 
This study was a retrospective analysis of prospectively collected data from NIS. The 
NIS is one of the largest publically available all-payer inpatient healthcare database 
sponsored by the Agency for Healthcare Research and Quality (AHRQ) as a part of 
Healthcare Cost and Utilisation Project (HCUP)
83
. NIS collects discharge level 
anonymised data encompassing more than 7 million yearly hospital records. Patient 
ethical approval was not required for this study as NIS is publically available 
anonymised data. 
5.3.2 Study population  
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) code of 4111and 4107 were used to identify patients admitted with a primary 
diagnosis of NSTEMI from 2004 to 2014. Data were restricted to urgent or emergency 
diagnoses thereby excluding elective admissions, as they do not represent a true 
diagnosis of NSTEMI. the invasive strategy was defined as ICD-9-CM procedure codes 
8853, 8854, 8855, 8856 3722 and 3723, with or without PCI (ICD-9-CM procedure 
codes 0066, 3601, 3602, 3605, 3606 and 3607. Time to the invasive strategy was 
defined as the number of days from admission date to procedure date provided within 
the NIS dataset. It was then categorised into early (day 0, 1), intermediate (day 2) and 
late (day ≥3). Patients who did not undergo an invasive strategy comprise the 
conservative (comparison) group. 
5.3.3 Study covariates 
The information on patient demographics, including age, sex, race, median household 
income by zip code, primary expected payer, weekend admission and comorbidities 
using Elixhasuer comorbidities, as defined by AHRQ were also collected. The length of 
stay and total cost of hospitalisation for each admission were recorded. The cost of 
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hospitalisation was calculated using cost to conversion ratio to convert the reported 
charges into the actual cost for the primary payer. Additionally, hospital characteristics 
such as region, location, teaching status and bed size were also included. Finally, 
information around cardiovascular risk factors and other important relevant diagnoses 
such as the history of smoking, hyperlipidaemia, coronary artery disease, family history 
of ischemic heart disease, previous myocardial infarction or CABG, and dementia were 
also extracted using ICD-9-CM codes provided in the Appendix Table 1. The ICD-9-
CM coded used for calculating the Charlson comorbidity index are given in the 
Appendix Table 2. The ICD-9-CM codes utilised in this study were based on a thorough 




5.3.4 Study outcomes  
The in-hospital mortality is collected in the NIS database as DIED variable. Whereas, 
other in-hospital outcomes including major bleeding, acute ischemic stroke, adverse 
cardiac complications, and MACCE; a composite of acute ischemic stroke, in-hospital 
mortality and adverse cardiac complications were obtained using ICD-9-CM codes 
provided in the Appendix Table 3. 
5.3.5 Statistical analysis  
The differences in the baseline, hospital characteristics, and crude outcomes of interest 
across all four categories were made using descriptive statistics. Continuous variables 
were reported as the median and interquartile range to account for the skewness of the 
data whereas categorical variables were presented as a number and percentage. All the 
analyses were undertaken using the survey estimation command as recommended by 
AHRQ in order to account for the complex survey design of the NIS database as 
described before in chapter 3. The updated AHRQ trend weights for years 2004-2011 
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(TRENDWT) and existing discharge weights for years 2012-2014 (DISCHWT) were 
used to produce national discharge-level estimates for trends analysis. Multivariable 
logistic regression models were fitted to investigate the independent predictors of early 
invasive strategy (0,1 day) and determine the association between time to invasive 
strategy category with the aforementioned clinical outcomes. The following covariates 
were adjusted for in all analyses: age, sex, elective admission, weekend admission, 
primary expected payer, median household income, dyslipidaemia, smoking status, 
previous acute myocardial infarction, previous CABG, history of IHD, previous PCI, 
previous CVA, family history of CAD, use of assist device or IABP, shock during 
hospitalisation, dementia, bed size of hospital, region of hospital, location/teaching 
status of hospital and 29 AHRQ comorbidities. All odds ratios (ORs) are adjusted for 
the aforementioned covariates and presented with the corresponding 95% confidence 




5.4 Results  
5.4.1 Patient and hospital characteristics 
A total of 4,380,827 records with a diagnosis of NSTEMI were identified between 2004 
and 2014, of which 1,862,123 (42.5%) were managed medically and 2,518,704 (57.5%) 
received invasive strategy. After excluding the records with missing information on 
time to invasive strategy (12%), the patients that received an invasive strategy, 
1,574,342 (62.5%), 302,668 (12.0%), 340,054 (13.5%) were categorised into early (day 




Figure 5.1: Flow diagram of included/excluded records 
Age – 395 missing  
Gender – 954 missing 
Elective procedure excluded – 337,469 
Length of Stay – 20 missing 
Median Zip code income – 109,088 missing 
Death – 2008 missing 
Total charge – 110,376 charge missing 
Primary payer –  8192 missing 
  
All records taken from NIS 
database from 2004 - 2014 
Excluded records with 
covariate information that was 
missing (n=4,949,329) 
 
Weighted 4,949,522 records 
were identified with NSTEMI 
diagnosis. 
. 
Restricted to Adult over the 
age of 18 (n=4,949,329) 
Identified records with a primary 
diagnosis of NSTEMI using ICD-9 
codes including 410.7x, 411.1x 
Final records with a diagnosis 
of NSTEMI included in 


















Invasive strategy time – 301,640 missing  





There were significant differences in the profile of the patient undergoing an invasive 
strategy at different time points. Patients receiving early invasive strategy were younger 
(median age 64 vs 70 years), more likely to be men (63.7% vs 55.3%) and of white 
ethnic background (68.7% vs 64.7%) compared to late invasive strategy group. 
Conversely, patient in the late invasive strategy group were more likely to be women 
(44.7% vs 26.3%), had higher proportions of co-existing comorbidities such as COPD 
(28.5% vs 18.2%), complicated diabetes (11.6% vs 4.8%), fluid and electrolyte 
disturbances (27.5% vs 13.2%), CCI score ≥3 (24.2% vs 10.4%), and were more likely 
to be admitted on weekend (25.1% vs 19.4%). Finally, patients with private insurance 
were more likely to have an early invasive strategy (33.5%) than late invasive strategy 
(16.7%), while patients on Medicare were more likely to have a late invasive strategy 
(66.4%) than early invasive strategy (49.5%). More than half of all patients treated 
conservatively (54.2%) were on Medicare, while only 30.8% had private insurance 
(Table 5.1). 
Table 5.1: Baseline characteristics of patients receiving an invasive strategy at different 
time points compared to medically managed patients. 
Timing of invasive strategy Early Intermediate Late Conservative 
approach  








Age (year), Median IRQ 64 (54-74) 67 (57-77) 70 (60-
78) 
66 (56-75) 
Men % 63.7% 58.6% 55.3% 49.7% 
Ethnicity     
White 68.7% 66.8% 64.7% 63.3% 
Black 8.9% 11.2% 12.7% 10.0% 
Hispanic 6.4% 7.7% 8.3% 6.4% 
Asian/Pacific Islander 1.7% 1.7% 2.0% 1.8% 
Native American 0.5% 0.5% 0.4% 0.4% 
Other 3.1% 2.7% 2.7% 2.2% 
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Missing Race 10.8% 9.4% 9.2% 16.0% 
Weekend admission 19.4% 53.0% 25.1% 26.8% 
Primary expected payer, %     
Medicare 49.5% 58.2% 66.4% 54.2% 
Medicaid 6.6% 6.8% 7.2% 5.7% 
Private Insurance 33.5% 25.9% 16.7% 30.8% 
Self-pay 6.6% 5.7% 4.5% 5.8% 
No charge 0.7% 0.7% 0.6% 0.5% 
other 3.1% 2.7% 2.3% 1.9% 
Median Household Income (percentile)     
0-25
th
 28.2% 30.5% 31.9% 30.3% 
26-50
th
 27.5% 27.8% 26.7% 27.0% 
51-75
th
 23.9% 23.5% 22.8% 22.7% 
76-100
th
 20.4% 18.2% 18.6% 20.0% 
Comorbidities, %     
Dyslipidaemia 60.1% 55.5% 45.0% 37.6% 
Smoking 40.8% 35.8% 29.6% 22.4% 
Previous AMI 9.5% 10.4% 9.3% 9.5% 
History of IHD 83.9% 80.0% 73.7% 42.6% 
Previous PCI 12.1% 12.4% 10.0% 7.7% 
Previous CABG 5.5% 6.9% 7.0% 10.1% 
Previous CVA 3.1% 3.7% 3.8% 4.0% 
Family history of CAD 9.2% 6.7% 4.0% 3.4% 
Valvular heart disease 0.1% 0.2% 0.3% 0.4% 
Peripheral vascular disease 10.7% 13.4% 16.0% 11.5% 
Multivessel PCI  10.8% 8.3% 7.6% 0% 
Use of assist devise or IABP 4.4% 2.4% 2.8% 0.5% 
Shock 2.7% 1.6% 2.7% 2.2% 
AIDS 0.13% 0.14% 0.18% 0.12% 
Alcohol abuse 2.9% 3.0% 3.4% 2.4% 
Deficiency anaemias 10.8% 15.6% 23.2% 20.3% 
Chronic Blood loss anaemia 0.6% 0.8% 1.8% 1.6% 
RA/collagen vascular 
diseases 
2.1% 2.4% 2.5% 2.4% 
Congestive heart failure 0.3% 0.4% 0.9% 1.3% 
Chronic pulmonary disease 18.2% 22.6% 28.5% 25.4% 
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Coagulopathy 3.8% 4.2% 6.0% 4.4% 
Depression 6.6% 7.4% 7.4% 7.8% 
Diabetes 29.6% 32.4% 33.6% 30.1% 
Diabetes with complications 4.8% 7.3% 11.6% 7.4% 
Drug abuse 2.2% 2.3% 2.3% 1.8% 
Hypertension 71.0% 73.5% 71.8% 68.3% 
Hypothyroidism 9.1% 10.4% 11.2% 12.7% 
Liver disease 1.1% 1.3% 1.8% 1.4% 
Lymphomas 0.4% 0.5% 0.6% 0.6% 
Fluid and electrolyte disturbances 13.2% 17.9% 27.5% 25.1% 
Other neurological disorders 3.6% 4.7% 5.8% 9.1% 
Obesity 14.9% 15.1% 14.3% 9.1% 
Paralysis 1.0% 1.3% 2.0% 2.5% 
Psychoses 1.7% 2.1% 2.6% 2.7% 
Pulmonary circulation disorder 0.05% 0.07% 0.1% 0.2% 
Renal failure (chronic) 11.8% 18.3% 28.6% 24.8% 
Peptic ulcer disease 0.03% 0.05% 0.05% 0.05% 
Weight loss 1.2% 1.6% 3.0% 3.2% 
Solid tumour without mets 1.0% 1.2% 1.7% 2.0% 
Metastatic cancer 0.4% 0.5% 0.7% 1.5% 
Dementia 2.1% 3.1% 4.4% 13.0% 
Charlson Comorbidity Index     
0 38.9% 29.3% 18.8% 23.0% 
1 33.3% 32.8% 30.2% 31.5% 
2 17.4% 22.0% 26.8% 24.6% 
≥3 10.4% 15.9% 24.2% 20.9% 
Hospital bed size     
Small 7.7% 7.2% 7.7% 15.9% 
Medium 22.3% 23.3% 23.1% 28.1% 
Large 70.0% 69.5% 69.8% 56.0% 
Hospital Region     
Northeast 20.3% 20.1% 23.6% 26.3% 
Midwest 21.3% 19.5% 17.7% 20.5% 
South 42.1% 46.2% 46.2% 38.4% 
West 16.3% 14.2% 12.4% 14.9% 
Location/ Teaching status     
112 
 
Rural 6.3% 6.5% 5.7% 18.2% 
Urban-non teaching 38.3% 40.9% 40.0% 46.9% 
Urban- teaching 55.4% 52.6% 54.3% 34.9% 
Length of stay, Median (IQR) 2 (2-4) 4 (3-6) 6 (4-10) 3 (2-6) 












AMI= acute myocardial infarction, IHD, ischemic heart disease, PCI= percutaneous coronary 
intervention, CABG= coronary artery bypass graft, CVA= cerebrovascular accident, CAD= coronary 
artery disease, IABP= intra-aortic balloon pump, AIDS= acquired immunodeficiency syndromes, RA= 
Rheumatoid arthritis, IQR= interquartile range. 
 
 The prevalence of risk factors for coronary artery disease including smoking (31.5%, 
47.5% vs 35.4% in 2004 to 47.1%, 42.8% vs 39.6% in 2014), dyslipidaemia (51.6%, 
47.5% vs 35.4% in 2004 to 64.0%, 60.1% vs 53.1% in 2014), previous AMI (8.0%, 
8.5% vs 7.6% in 2004 to 11.0%, 12.4% vs 11.1%), hypertension (61.9%, 65.5% vs 
62.5% in 2004 to 76.1%, 79.4% vs 78.0% in 2014), and peripheral vascular disease 
(8.5%, 10.8% vs 12.2% in 2004 to 11.3%, 14.0% vs 18.5% in 2014) has increased in 
both early and intermediate groups, but with a greater proportional increase observed in 
the early invasive strategy group. In contrast, patients undergoing late invasive strategy 
had a greater proportional increase in the non-cardiac comorbidities such as COPD 
(26.1% vs 15.5% in 2004 to 30.2% vs 19.4% in 2014), hypothyroidism (7.9% vs 6.5% 
in 2004 to 13.5% vs 10.8% in 2014) and chronic renal failure (13.2% vs 4.0% in 2004 
to 35.3% vs 14.7% in 2014) compared to the early invasive strategy group throughout 




Table 5.2: Temporal trends in baseline and hospital characteristics of patients stratified according to different cut off of time to an invasive 
strategy  
Year  2004 2005-2006 2007-2008 
Timing of invasive strategy Early Interm. Late Early Interm. Late Early  Interm. late 




































Men % 63.8% 58.2% 55.7% 63.7% 58.5% 54.6% 63.2% 58.2% 54.2% 
Ethnicity          
White 64.6% 62.0% 60.2% 63.9% 63.9% 62.2% 66.2% 64.0% 62.7% 
Black 7.1% 9.6% 11.3% 6.2% 8.3% 9.6% 8.5% 10.1% 11.4% 
Hispanic 4.7% 6.4% 7.4% 5.8% 7.1% 8.5% 5.9% 7.8% 7.8% 
Asian/Pacific Islander 1.2% 1.2% 1.5% 1.2% 1.4% 1.6% 1.7% 1.8% 2.1% 
Native American 0.2% 0.3% 0.2% 0.2% 0.2% 0.2% 0.8% 0.9% 0.8% 
Other 2.3% 2.1% 2.2% 3.7% 1.7% 1.9% 3.3% 2.8% 2.9% 
Missing Race 19.8% 18.3% 17.3% 18.9% 17.3% 16.0% 13.6% 12.6% 12.3% 
Weekend admission 17.1% 50.2% 25.8% 17.8% 51.5% 26.0% 18.7% 53.7% 24.8% 
Primary expected payer, %          
Medicare 48.0% 55.8% 66.8% 48.6% 58.0% 66.4% 47.7% 56.5% 65.4% 
Medicaid 5.8% 5.8% 6.1% 5.7% 6.2% 6.5% 5.7% 6.3% 6.9% 
Private Insurance 37.7% 30.3% 21.0% 36.5% 27.5% 19.7% 35.7% 27.8% 19.8% 
Self-pay 5.4% 5.0% 3.8% 5.7% 5.0% 4.2% 6.4% 5.6% 4.4% 
No charge 0.5% 0.7% 0.6% 0.7% 0.8% 0.8% 0.8% 0.8% 0.8% 
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other 2.6% 2.2% 1.6% 2.9% 2.5% 2.3% 3.7% 3.0% 2.7% 
Median Household Income (percentile)          
0-25
th
 25.9% 28.3% 30.4% 26.0% 28.8% 31.4% 26.4% 30.5% 31.6% 
26-50
th
 28.0% 28.3% 26.6% 26.5% 27.1% 26.0% 28.3% 28.3% 26.9% 
51-75
th
 21.9% 22.6% 21.4% 25.0% 24.5% 23.1% 23.2% 23.1% 22.9% 
76-100
th
 24.2% 20.8% 21.6% 22.4% 19.6% 19.5% 22.1% 18.1% 18.6% 
Comorbidities, %          
Dyslipidaemia 51.6%% 47.5%% 35.4% 54.1% 49.5% 37.2% 57.9% 53.0% 40.3% 
Smoking 31.5% 26.4% 19.7% 34.0% 29.9% 21.7% 37.7% 32.0% 24.4% 
Previous AMI 8.0% 8.5% 7.6% 7.7% 9.0% 7.7% 8.6% 8.7% 7.9% 
History of IHD 84.4% 80.1% 72.0% 84.1% 79.1% 71.0% 84.0% 79.4% 72.4% 
Previous PCI 7.8% 7.7% 6.0% 9.0% 9.1% 6.6% 10.3% 10.2% 7.6% 
Previous CABG 5.5% 6.2% 6.4% 5.3% 6.3% 6.0% 5.2% 6.4% 6.0% 
Previous CVA NA NA NA NA NA NA 1.7% 2.1% 2.1% 
Family history of CAD 6.3% 4.3% 2.6% 7.2% 5.3% 2.8% 7.9% 5.1% 2.4% 
Valvular heart disease 0.1% 0.2% 0.4% 0.1% 0.1% 0.3% 0.1% 0.2% 0.3% 
Peripheral vascular disease 8.5% 10.8% 12.2% 9.2% 11.5% 12.3% 10.9% 14.0% 16.1% 
Multivessel PCI  10.6% 8.0% 6.9% 12.0% 9.1% 7.8% 10.4% 7.2% 6.5% 
Use of assist devise or IABP 3.8% 2.0% 2.0% 4.2% 2.0% 2.0% 4.4% 2.6% 2.7% 
Shock 1.8% 0.6% 1.4% 2.1% 1.1% 1.6% 2.3% 1.4% 2.6% 
AIDS 0.11% 0.17% 0.15% 0.1% 0.13% 0.16% 0.1% 0.17% 0.14% 
Alcohol abuse 2.1% 2.6% 2.7% 2.4% 2.4% 2.8% 2.8% 2.7% 3.0% 
Deficiency anaemias 6.8% 10.3% 13.8% 7.7% 10.6% 15.0% 10.9% 15.3% 22.0% 





1.7% 1.4% 1.9% 1.7% 2.4% 1.9% 2.0% 2.4% 2.4% 
Congestive heart failure 0.4% 0.3% 1.0% 0.3% 0.3% 0.8% 0.3% 0.6% 0.9% 
Chronic pulmonary disease 15.5% 20.0% 26.1% 17.2% 21.2% 27.7% 18.1% 22.1% 28.4% 
Coagulopathy 2.1% 2.9% 4.3% 2.6% 2.8% 4.1% 3.1% 3.5% 5.1% 
Depression 4.0% 4.4% 4.0% 4.7% 5.3% 5.0% 5.8% 6.4% 6.8% 
Diabetes 25.7% 28.6% 30.6% 26.4% 28.8% 29.7% 28.2% 31.8% 32.7% 
Diabetes with complications 3.3% 5.1% 8.2% 3.5% 6.0% 9.2% 4.3% 6.6% 11.0% 
Drug abuse 1.3% 1.7% 1.4% 1.7% 1.9% 1.9% 2.0% 2.1% 1.9% 
Hypertension 61.9% 65.5% 62.5% 64.6% 66.5% 64.5% 68.8% 71.1% 70.3% 
Hypothyroidism 6.5% 7.2% 7.9% 7.0% 7.9% 8.6% 8.3% 9.7% 11.1% 
Liver disease 0.6% 0.9% 1.0% 0.7% 0.8% 1.2% 0.9% 1.1% 1.6% 
Lymphomas 0.3% 0.5% 0.6% 0.4% 0.4% 0.5% 0.4% 0.4% 0.6% 
Fluid and electrolyte disturbances 7.6% 10.8% 17.5% 9.3% 13.2% 21.3% 11.8% 16.6% 25.3% 
Other neurological disorders 2.5% 2.9% 3.7% 2.7% 3.7% 4.5% 3.3% 4.4% 6.0% 
Obesity 8.7% 9.3% 7.8% 10.3% 10.3% 8.3% 12.9% 13.0% 12.4% 
Paralysis 0.7% 0.9% 1.4% 0.8% 1.0% 1.6% 1.0% 1.4% 2.3% 
Psychoses 1.1% 1.2% 1.4% 1.1% 1.2% 1.7% 1.5% 1.6% 2.3% 
Pulmonary circulation disorder 0.01% 0.02% 0.05% 0.03% 0.00% 0.04% 0.05% 0.09% 0.1% 
Renal failure (chronic) 4.0% 6.8% 13.2% 7.4% 11.9% 20.9% 11.2% 17.4% 28.2% 
Peptic ulcer disease 0.06% 0.15% 0.1% 0.04% 0.07% 0.05% 0.02% 0.07% 0.07% 
Weight loss 0.4% 0.5% 1.0% 0.6% 0.7% 1.6% 0.9% 1.1% 2.5% 
Solid tumor without mets 0.9% 1.0% 1.4% 0.8% 1.1% 1.7% 0.9% 1.4% 1.6% 
Metastatic cancer 0.3% 0.4% 0.5% 0.3% 0.4% 0.6% 0.4% 0.4% 0.7% 
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Dementia 1.4% 2.0% 2.4% 1.5% 2.3% 3.2% 1.9% 2.5% 3.8% 
Charlson Comorbidity Index          
0 45.0% 35.6% 23.3% 43.9% 34.4% 22.9% 41.1% 31.1% 20.9% 
1 33.7% 35.1% 33.8% 33.8% 34.9% 33.0% 33.8% 34.5% 32.1% 
2 14.9% 19.3% 26.4% 15.5% 19.8% 26.8% 16.5% 21.1% 26.6% 
≥3 6.4% 10.0% 16.5% 6.8% 10.9% 17.3% 8.6% 13.3% 20.4% 
Hospital bed size          
Small 8.6% 5.7% 6.0% 5.6% 5.8% 5.9% 6.3% 6.0% 6.0% 
Medium 17.1% 20.0% 19.6% 21.6% 22.8% 23.3% 20.7% 21.3% 21.9% 
Large 74.3% 74.3% 74.3% 72.9% 71.4% 70.8% 73.0% 72.7% 72.1% 
Hospital Region          
Northeast 28.6% 23.0% 28.6% 25.3% 24.1% 27.8% 22.8% 20.8% 24.6% 
Midwest 17.5% 17.5% 15.3% 17.3% 15.9% 12.7% 17.7% 17.3% 16.1% 
South 41.5% 46.6% 44.4% 42.9% 47.6% 47.9% 44.1% 47.3% 47.0% 
West 12.4% 12.9% 11.7% 14.5% 12.4% 12.0% 15.4% 14.7% 12.3% 
Location/ Teaching status          
Rural 6.0% 6.4% 5.1% 5.0% 6.5% 5.1% 6.5% 7.6% 7.2% 
Urban-non teaching 35.5% 41.8% 41.5% 39.4% 42.2% 40.3% 39.3% 43.8% 43.4% 
Urban- teaching 58.5% 51.8% 53.4% 55.6% 51.3% 54.6% 54.2% 48.5% 49.4% 
Length of stay, Median (IQR) 3 (2-5) 4 (3-6) 6 (5-10) 3 (2-5) 4 (3-6) 7 (5-10) 4 (2-5) 4 (3-6) 6 (5-10) 































Table 5.2 continued. 
Year  2009-2010 2011-2012 2013-2014 
Timing of invasive strategy Early  Interm. Late Early Interm. Late Early Interm. Late 




































Men % 63.5% 58.5% 44.7% 64.0% 58.6% 55.0% 64.0% 59.4% 57.5% 
Ethnicity          
White 68.4% 66.6% 64.0% 71.8% 69.3% 67.7% 72.0% 70.3% 68.2% 
Black 9.3% 11.7% 14.0% 10.0% 13.2% 14.9% 9.9% 12.2% 13.8% 
Hispanic 6.3% 7.5% 8.0% 6.8% 7.7% 8.3% 7.3% 8.8% 9.0% 
Asian/Pacific Islander 1.7% 1.5% 2.2% 1.8% 1.9% 2.1% 2.0% 2.1% 2.4% 
Native American 0.6% 0.6% 0.6% 0.5% 0.5% 0.4% 0.4% 0.4% 0.4% 
Other 2.7% 2.8% 2.9% 3.4% 3.3% 3.2% 3.0% 2.7% 2.9% 
Missing Race 11.0% 9.3% 8.1% 5.8% 4.1% 3.3% 5.4% 3.6% 3.4% 
Weekend admission 19.8% 53.4% 24.4% 20.0% 53.7% 26.0% 20.8% 53.3% 24.3% 
Primary expected payer, %          
Medicare 48.4% 56.7% 64.9% 50.8% 60.1% 67.9% 51.3% 60.1% 67.6% 
Medicaid 6.5% 6.7% 7.5% 6.8% 7.0% 7.2% 7.8% 8.0% 8.4% 
Private Insurance 34.3% 26.6% 19.4% 31.1% 23.6% 16.9% 30.6% 23.5% 17.0% 
Self-pay 7.1% 6.6% 5.2% 7.2% 6.2% 4.9% 6.5% 5.3% 4.4% 
No charge 0.6% 0.6% 0.4% 0.8% 0.5% 0.5% 0.7% 0.7% 0.4% 
other 3.1% 2.8% 2.6% 3.2% 2.7% 2.4% 3.0% 2.4% 2.1% 
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Median Household Income (percentile)          
0-25
th
 28.9% 31.0% 31.9% 29.6% 31.3% 32.9% 29.5% 31.3% 32.6% 
26-50
th
 27.5% 28.3% 27.6% 26.3% 26.1% 25.0% 28.3% 28.8% 28.3% 
51-75
th
 24.0% 23.1% 22.7% 24.6% 24.0% 23.6% 23.4% 23.0% 22.1% 
76-100
th
 19.3% 17.6% 18.1% 19.5% 18.6% 18.5% 18.8% 16.8% 17.0% 
Comorbidities, %          
Dyslipidaemia 60.8% 56.1% 45.9% 63.4% 59.5% 51.2% 64.0% 60.1% 53.1% 
Smoking 41.0% 35.6% 30.4% 43.7% 39.3% 34.9% 47.1% 42.8% 39.6% 
Previous AMI 9.4% 9.9% 9.6% 10.4% 11.7% 10.8% 11.0% 12.4% 11.1% 
History of IHD 84.7% 80.6% 74.9% 84.1% 81.1% 76.0% 82.7% 79.3% 74.9% 
Previous PCI 12.0% 12.0% 10.2% 13.9% 15.4% 12.7% 15.0% 15.8% 14.0% 
Previous CABG 5.1% 6.6% 7.2% 5.7% 7.3% 7.7% 5.9% 7.5% 8.1% 
Previous CVA 3.7% 4.6% 5.2% 4.5% 5.6% 6.3% 5.0% 6.3% 6.7% 
Family history of CAD 10.1% 6.7% 4.4% 10.2% 7.8% 5.0% 10.9% 8.4% 5.9% 
Valvular heart disease 0.1% 0.2% 0.3% 0.1% 0.2% 0.3% 0.07% 0.1% 0.2% 
Peripheral vascular disease 10.8% 13.5% 16.5% 11.4% 14.7% 18.1% 11.5% 14.0% 18.5% 
Multivessel PCI  9.7% 7.2% 6.5% 10.8% 8.6% 8.3% 11.3% 9.0% 8.9% 
Use of assist devise or IABP 4.6% 2.5% 2.8% 4.6% 2.4% 3.5% 4.2% 2.5% 3.2% 
Shock 2.8% 1.7% 2.7% 3.1% 1.8% 3.3% 3.1% 2.0% 3.7% 
AIDS 0.15% 0.11% 0.22% 0.14% 0.13% 0.16% 0.13% 0.16% 0.21% 
Alcohol abuse 2.9% 3.1% 3.4% 3.1% 3.3% 3.8% 3.3% 3.4% 3.9% 
Deficiency anaemias 11.4% 16.5% 25.2% 12.3% 18.7% 28.7% 11.9% 17.8% 28.5% 
Chronic Blood loss anaemia 0.6% 0.8% 1.8% 0.5% 0.8% 1.5% 0.5% 0.5% 1.2% 




Congestive heart failure 0.4% 0.5% 1.3% 0.3% 0.4% 1.0% 0.2% 0.4% 0.9% 
Chronic pulmonary disease 17.9% 22.2% 27.4% 18.9% 23.5% 29.8% 19.4% 24.3% 30.2% 
Coagulopathy 3.9% 4.1% 6.2% 4.4% 5.1% 7.5% 4.7% 5.3% 7.5% 
Depression 6.7% 7.4% 7.6% 7.6% 8.5% 9.6% 8.3% 9.4% 9.6% 
Diabetes 29.4% 32.2% 33.3% 31.5% 34.8% 36.0% 32.1% 34.7% 37.3% 
Diabetes with complications 4.5% 6.9% 11.3% 5.4% 8.6% 13.3% 6.0% 8.7% 14.4% 
Drug abuse 2.1% 2.1% 2.3% 2.4% 2.5% 2.7% 2.7% 2.8% 2.8% 
Hypertension 71.3% 73.4% 72.5% 74.3% 77.6% 77.0% 76.1% 79.4% 78.0% 
Hypothyroidism 9.0% 10.8% 11.0% 10.1% 12.3% 13.0% 10.8% 11.8% 13.5% 
Liver disease 1.0% 1.2% 1.8% 1.2% 1.5% 2.1% 1.4% 1.9% 2.6% 
Lymphomas 0.3% 0.6% 0.7% 0.4% 0.5% 0.6% 0.4% 0.6% 0.7% 
Fluid and electrolyte disturbances 13.4% 17.3% 28.5% 15.2% 20.8% 32.0% 16.4% 22.4% 34.2% 
Other neurological disorders 3.5% 4.7% 6.2% 3.9% 5.4% 6.8% 4.3% 5.7% 6.8% 
Obesity 14.8% 14.7% 14.2% 17.2% 18.1% 18.0% 19.1% 19.9% 21.0% 
Paralysis 1.0% 1.3% 2.2% 1.1% 1.3% 2.2% 1.0% 1.5% 2.3% 
Psychoses 1.8% 2.3% 2.6% 2.0% 2.5% 3.3% 2.2% 2.8% 3.4% 
Pulmonary circulation disorder 0.07% 0.1% 0.2% 0.05% 0.1% 0.1% 0.04% 0.08% 0.1% 
Renal failure (chronic) 12.5% 19.5% 31.0% 14.0% 22.9% 34.0% 14.7% 22.5% 35.3% 
Peptic ulcer disease 0.02% 0.02% 0.04% 0.03% 0.05% 0.05% 0.02% 0.02% 0.04% 
Weight loss 1.4% 1.5% 3.0% 1.5% 2.3% 4.3% 1.6% 2.2% 4.3% 
Solid tumor without mets 1.0% 1.2% 1.6% 1.0% 1.1% 1.8% 1.0% 1.3% 1.8% 
Metastatic cancer 0.4% 0.5% 0.7% 0.4% 0.5% 0.8% 0.4% 0.5% 0.7% 
Dementia 2.3% 3.2% 4.6% 2.5% 3.6% 5.6% 2.4% 3.6% 5.2% 
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Charlson Comorbidity Index          
0 38.8% 29.9% 18.7% 36.2% 25.8% 15.8% 34.8% 25.1% 14.4% 
1 33.3% 32.8% 30.3% 33.0% 31.1% 27.7% 32.5% 30.8% 26.6% 
2 17.6% 21.9% 26.1% 18.3% 23.6% 26.9% 19.1% 23.5% 27.8% 
≥3 10.2% 15.4% 24.9% 12.4% 19.5% 29.6% 13.6% 20.5% 21.1% 
Hospital bed size          
Small 7.3% 6.6% 6.6% 7.6% 7.5% 7.5% 10.3% 9.8% 9.6% 
Medium 19.4% 20.7% 21.4% 23.8% 24.8% 23.3% 26.4% 27.1% 26.7% 
Large 73.3% 72.6% 72.0% 68.6% 67.7% 69.2% 63.2% 63.1% 63.7% 
Hospital Region          
Northeast 19.1% 19.2% 21.9% 17.6% 18.2% 20.9% 17.0% 18.3% 21.1% 
Midwest 21.9% 18.5% 17.6% 23.4% 20.9% 19.8% 24.9% 23.7% 22.6% 
South 41.8% 47.5% 47.1% 41.6% 45.6% 46.7% 40.7% 43.6% 43.7% 
West 17.2% 14.7% 13.4% 17.4% 15.3% 12.6% 17.4% 14.4% 12.6% 
Location/ Teaching status          
Rural 7.3% 6.7% 5.9% 6.2% 5.6% 5.3% 6.4% 6.3% 5.2% 
Urban-non teaching 41.4% 44.4% 42.4% 40.4% 42.3% 41.3% 33.0% 33.3% 33.2% 
Urban- teaching 51.3% 48.9% 51.7% 53.4% 52.0% 53.4% 60.6% 60.4% 61.6% 
Length of stay, Median (IQR) 3 (2-5) 4 (3-6) 6 (5-10) 2 (2-4) 3 (3-6) 6 (4-10) 2 (2-4) 3 (3-6) 6 (4-10) 



























AMI= acute myocardial infarction, IHD, ischemic heart disease, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft, CVA= 
cerebrovascular accident, CAD= coronary artery disease, IABP= intra-aortic balloon pump, AIDS= acquired immunodeficiency syndromes, RA= Rheumatoid 
arthritis, IQR= interquartile range.
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5.4.2 Temporal trends 
The use of an invasive strategy in the early group increased from 65.6% to 72.6% and 
late invasive strategy declined commensurately from 19.6% to 13.5% from 2004 to 
2014 (Figure 5.2). There were significant disparities in the secular trends of an invasive 
strategy in patients stratified according to gender, comorbidity burden, admission day, 
age and ethnicity. Temporal trends in the timing of an invasive strategy stratified 
according to gender reveal that early invasive strategy was comparatively higher in men 
(68.6% to 74.2%) during the study period, although there was a greater proportional 
increase in the use of early invasive strategy from 60.9% to 70.0% in women (Figure 
5.3). There were significant disparities in the timing of invasive strategy use in patients 
with different comorbidity burden as defined by the Charlson comorbidity index (Figure 
5.4). During the 11-year study period, the use of early invasive strategy increased from 
75.0% to 82.1% in patients with no comorbidity (CCI=0) compared to 47.2% to 58.3% 
in the CCI≥3 category. For weekend admissions (Figure 5.5), the use of early invasive 
strategy has increased from 47.4% to 58.5% in patients admitted on a weekend, the 
intermediate invasive strategy group remained relatively unchanged (31.4% to 29.0%). 
Similar inequalities in use of early versus late invasive strategy were noted in patients 
from different ethnic backgrounds and age groups. Young patients aged <65 years were 
more likely to be managed with early invasive strategy (76.1%) compared to older 
patients aged >75 (63.1%) (Figure 5.6). Similarly, overall, higher proportions of African 
American received late invasive strategy compared to early invasive strategy (12.7% vs 




Figure 5.2: Temporal trends in time to invasive strategy stratified according to the early, 
intermediate and late groups. 
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Figure 5.4: Temporal trends in time to invasive strategy and comorbidity burden as 




































































































































































































































































































Figure 5.5: Trends in timing of invasive strategy stratified according to weekday versus 
weekend admission  




























































































































































































































































































b: Weekend admissions 
 











































































































































































Figure 5.7: Trends in the timing of an invasive strategy stratified according to Ethnicity 
a) white ethnicity  
 
b) African American ethnicity  
 
5.4.3 Independent predictors  
Independent clinical and institutional predictors of early invasive strategy as shown in 
Table 5.3. The presence of haemodynamic compromises such as cardiogenic shock (OR 
1.45, 95%CI 1.37-1.54) and use of intra-aortic balloon pump (OR 2.09, 95%CI 2.00-
2.19) was associated with early use of invasive strategy. Conversely, Female sex (OR 





































































































































































































































































































American (OR 0.77, 95%CI 0.74-0.81), complicated diabetes (OR 0.64, 95%CI 0.62-
0.66) and chronic renal failure (OR 0.61, 95%CI 0.60-0.63) were strong negative 
predictors of early invasive strategy. 
Table 5.3: Independent predictors of an early invasive strategy  
Variable  Odds Ratio 95% confidence 
interval  
Age 0.98 0.98 0.98 
Weekend admission 0.35 0.34 0.36 
Female 0.92 0.91 0.94 
African American (Ref White) 0.77 0.74 0.81 
Alcohol abuse 0.81 0.77 0.85 
Chronic deficiency anaemia 0.74 0.72 0.76 
Chronic blood loss 0.61 0.56 0.66 
Congestive heart failure 0.81 0.72 0.92 
Depression 0.92 0.89 0.95 
Diabetes mellitus  0.86 0.84 0.87 
Diabetes mellitus with complications 0.64 0.62 0.66 
Liver disease 0.76 0.71 0.81 
Lymphoma 0.79 0.71 0.88 
Metastatic cancer 0.82 0.73 0.91 
Obesity  0.94 0.91 0.96 
Paralysis 0.78 0.73 0.84 
Peripheral vascular disease 0.90 0.88 0.92 
Renal failure 0.61 0.60 0.63 
Cancer 0.78 0.73 0.83 
Weight loss 0.82 0.77 0.88 
Smoking 1.15 1.12 1.17 
Dyslipidemia 1.21 1.19 1.24 
Ischemic heart disease 1.32 1.29 1.36 
Family history of coronary artery disease 1.28 1.23 1.34 
Previous myocardial infarction  0.92 0.90 0.95 
Previous Cerebrovascular accident 0.92 0.88 0.96 
Previous coronary artery bypass graft 0.84 0.81 0.87 
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Cardiogenic Shock 1.45 1.37 1.54 
Intra-aortic balloon pump 2.09 2.00 2.19 
Dementia 0.84 0.80 0.87 
 
5.4.4 Clinical outcomes 
Crude outcomes stratified according to the three different timings of an invasive 
strategy are shown in Figure 5.8. In-hospital mortality in the early, intermediate and late 
were 1.8%, 1.5% and 2.3%, (p<0.0001) respectively. Lower rates for crude MACCE 
and bleeding was observed in the early and intermediate category compared to late 
invasive strategy category as depicted in Figure 5.8. Multivariable logistic regression 
analysis after adjusting for all the potential confounders revealed that early invasive 
strategy was associated with reduced in-hospital mortality (OR 0.39 95%CI 0.37-0.41), 
in-hospital stroke (OR 0.86 95%CI 0.80-0.92) and MACCE (OR 0.80 95%CI 0.77-
0.83); however, the lowest risk was observed in the intermediate category (Table 5.4). 
The comparison group in this analysis was patients receiving conservative management. 
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129 
 























































5.5 Discussion  
In this large, contemporary cohort of patients admitted with a diagnosis of an NSTEMI 
in the US, there are several important observations. First, there is an increasing trend in 
the use of early invasive strategy compared to intermediate and late invasive strategy 
over an 11-year period. Second, there were significant changes in clinical characteristics 
and baseline risk profile of patients treated with early invasive strategy compared to 
intermediate and late invasive strategy, so that use of an early invasive strategy remains 
attenuated in elderly, complex and multi-morbid patients despite an overall increase in 
adoption of an early invasive strategy in NSTEMI. Third, there remain significant 
disparities in use of early invasive strategy across different groups of patients 
particularly women, high comorbidity burden, weekend admission and African 
Americans, who were less likely to receive early invasive strategy compared to men, 
lower comorbidity burden, weekday admission and Caucasians. Fourth, the presence of 
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non-cardiac comorbidities such as liver disease, peripheral vascular disease, chronic 
renal failure, dementia and history of alcohol disease was inversely associated with 
receipt of an early invasive strategy. Finally, the use of invasive strategy on day 2 from 
admission appears to be safe and feasible in the majority of the patients admitted 
following NSTEMI. 
 This study demonstrates that women, African Americans and those without 
private insurance were less likely to undergo early invasive strategy. Women admitted 
with NSTEMI are older, burdened with more comorbidities and are known to have a 
higher risk of peri-procedural bleeding when compared to men
38
. However, women also 
have a higher risk of ischemic complications following NSTEMI admission such as re-
infarction and repeat admissions and therefore are more likely to benefit from an early 
invasive approach
153-155
. This is in keeping with the current AHA/ACC NSTEMI 
guidelines recommending an early invasive approach be adopted particularly in those 
with high-risk features to improve outcomes
3
. Lower utilization of invasive cardiac 
procedures has been reported in patients without private health insurance
156
. Consistent 
with the literature, patients with private insurance were more likely to have an early 
invasive strategy (33.5%) than late invasive strategy (16.7%), while patients on 
Medicare were more likely to have a late invasive strategy (66.4%) than early invasive 
strategy (49.5%). More than half of all patients treated conservatively (54.2%) were on 
Medicare, while only 30.8% had private insurance. Socioeconomic status, varying 
practices amongst treating physician and hospitals, lack of access to appropriate health 
care resources, and regional factors may be responsible for these biases in management 
in different patient groups when partitioned into payer categories
139,157-160
. This study 
shows that there remain significant disparities in early aggressive treatment of these 
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undertreated subgroups of patients and the need for the development of uniform 
pathways to improve the outcomes in this underserved population.  
 Another important finding is the significantly lower adoption of an early 
invasive strategy in patients admitted on the weekend. Previous studies reporting on 
“weekend effect” in acute myocardial infarction setting have mainly studied the 
association of clinical outcomes with a weekend admission
161
. In this large 
contemporary analysis over the past decade, the results illustrate that almost 30% of the 
patients admitted on weekends receive invasive strategy after 2 days compared to only 
8.6% on a weekday. More importantly, this trend has remained stable over the study 
period with very little change in the use of an invasive strategy in patients admitted on 
the weekend. The most likely explanation for this findings is that patients admitted on a 
weekend are less likely to be reviewed by a cardiologist and may wait till the weekday 
to receive a specialist input where the decision is taken around further invasive 
management.  
 It also appears that there exists a treatment paradox where younger and less 
comorbid patients selectively receive early invasive strategy in contrast to older, 
multimorbid patients who may have more to gain from the early invasive strategy. The 
presence of non-cardiac comorbidities such as liver disease, chronic kidney disease, 
previous CVA, dementia, and peripheral vascular disease were strong negative 
predictors of early invasive strategy. Current guidelines recommend the use of early 
invasive strategy in patients presenting with high-risk features including ischemic 
electrocardiographic changes, elevated troponin levels, new CHF symptoms, left 
ventricular dysfunction, or haemodynamic instability
3,4
. Presence of cardiogenic shock 
or use of intra-aortic balloon pump, cardiovascular risk factors such as smoking, 
dyslipidaemia was strongly associated with early use of invasive strategy in our study.  
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 Finally, there was an overall decreasing trend in in-hospital mortality, MACCE 
and in-hospital stroke in patients managed invasively compared to a conservative 
approach consistent with the findings in chapter 4. Interestingly, there appears to be a U 
shaped relationship were patients in the intermediate category receiving an invasive 
strategy on day 2 appear to have the lowest in-hospital mortality and MACCE, both in 
the unadjusted and adjusted analysis. Although it is widely believed that an invasive 
strategy improves outcomes by reducing ischemic complications following NSTEMI, 
the studies have shown inconsistent results regarding the timing of an invasive 
strategy
58,60,105,150
. It is important to note that the majority of these studies are conducted 
in the pre-P2Y12 inhibitor era with far less aggressive pharmacotherapy compared to 
current practices. The main benefit of early invasive approach in NSTEMI in driven by 
the reduction in ischemic complications such as re-infarction and future 
events
16,18,162,163
. It is plausible that with newer potent antiplatelet and anticoagulant use, 
risk of ischemic complications has reduced and an early invasive strategy can be 
deferred safely. Lindholm et al used data from SWEADHEART registry to study the 
optimal timing of invasive strategy in NSTEMI patients demonstrating a 16% relative 
risk reduction (HR 0.86(95%CI 0.77-0.97) in patients undergoing an invasive treatment 
on day 2 or day 3 whereas no difference in death or MI was found on day 1
164
. National 
guidelines advocate a risk based approach in offering early invasive approach using 
validated risk scores such as Global Registry of Acute Coronary Events (GRACE) ACS 
score
3,4
. It is important to highlight that NIS data doesn’t capture information around 
haemodynamic status, ECG findings, cardiac biomarker, the severity of coronary 
disease and GRACE ACS score, therefore a true casual inference between optimal 
timing of invasive strategy and in-hospital outcomes cannot be inferred from this study. 
The patient in the early invasive angiography had increased comorbidity burden and 
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likely to have other high-risk features such as ongoing pain, ECG changes, 
haemodynamic instability for each they undergo early invasive strategy. As such NIS 
lacks this information and therefore, the favourable outcomes in patients in the 
intermediate group may just reflect residual confounding.  
5.6 Study strengths and limitations 
These findings must be interpreted in the context of certain limitations. First, the time 
from admission to an invasive strategy is calculated from admission to procedure day 
which may be confounded by inter-hospital transfers and unavailability of onsite 
coronary angiography facilities. The NIS doesn’t collect information around the 
haemodynamic status, ECG changes and biomarker positivity, hence risk stratification 
scores such as the GRACE score cannot be calculated or adjusted. This may be 
particularly relevant in the early invasive group, where high-risk features such as 
dynamic ECG changes, biomarker positivity, on-going symptoms or adverse 
haemodynamic profiles may be over-represented in the early invasive group and are 
unable to adjust for these features. Consequently, this may have confounded the 
influence of earlier angiography on mortality in these patients. Previous work has 
suggested that the benefit of an early invasive approach was seen predominantly in 
those patients with a high GRACE risk score (GRACE >140)
145
, hence it was not 
possible to further study the timing of invasive strategy as well as clinical outcomes 
stratified by the GRACE score. Furthermore, the NIS does not capture the severity of 
coronary artery disease or antiplatelet therapy that are important determinants of clinical 
outcomes. Finally, it is important to note that NIS is an administrative database which is 
subject to coding errors in both diagnoses and procedure codes. 
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5.7 Conclusion  
In this large contemporary national analysis of patients admitted with NSTEMI in the 
US, there was an increasing trend in the use of early invasive strategy associated with 
significant changes in baseline characteristics and risk profile of these patients 
compared to those receiving late invasive strategy. Although younger, healthier patients 
are more likely to receive early invasive strategy there remains important gender, ethnic, 
admission day and payment status inequalities in receipt of early invasive strategy. 
Women, African American, weekend admission and lack of private insurance were less 
likely to receive early invasive strategy. There was a U shape relationship in the time to 
invasive strategy and in-hospital clinical outcomes where patients receiving invasive 
strategy at day 2 had better outcomes compared to those receiving early or late invasive 
strategy. Future efforts should be focused around implementing a uniform risk guided 
approach in clinical practice and development of pathways to improve access to the 





Chapter 6  
 
 
Guidelines recommended risk stratification and receipt of an invasive strategy in the 
management of the NSTEMI 
136 
 
6.1 Introduction  
In line with the second part of the thesis, this chapter was aimed to investigate the 
utilisation of an invasive strategy based on the risk criteria recommended by two major 
international guidelines namely ESC and AHA/ACC. The manuscript from this chapter 
is currently under review in peer review cardiology journal.  
An invasive strategy followed by revascularisation where appropriate compared 
to conservative medical management is associated with reduced ischemic complications 
and improved survival in patients presenting with an NSTEMI and is recommended by 
international guidelines
3,4,52,57,58,104,165
. However, the results from individual studies 
evaluating the optimal timing of an invasive strategy in patients with different baseline 
risk profiles are inconsistent
60,105,150,164
. For instance, in the most comprehensive and up 
to date individual patient level meta-analysis of eight randomised control trial including 
5324 patients, early intervention was not associated with mortality benefit at 180 days 
(HR 0.81, 95%CI 0.64-1.03, p=0.08). However, in pre-specified analyses of high-risk 
groups such as elevated cardiac biomarkers (HR 0.76 95%CI 0.58-0.99), high GRACE 
risk score more than 140 (HR 0.67 95%CI 0.45-0.99), early intervention was associated 
with lower mortality. As the debate around the optimal timing of an invasive strategy in 
NSTEMI continues, international guidelines have adopted a time sensitive approach that 
is risk profile dependent. Consequently, guidelines recommend that the timing of 
interventional management should be determined by baseline risk 
3,4
, with both the 
European Society of Cardiology (ESC) and American Heart Association / American 
College of Cardiology (AHA/ACC) guidelines advising early intervention (<24 hours) 
in patients meeting the high-risk criteria, whereas a period of medical management 
followed by an invasive strategy within 72 hours is advised in patients with an 
intermediate-risk profile. Finally, a selective invasive strategy is recommended in low-
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risk patients who do not have any of the features present in the intermediate or high-risk 
criteria. The ESC and AHA/ACC risk criteria are presented in Table 6.1 & 6.2 below. 
Table 6.1: ESC risk criteria for the use of an invasive strategy  
Very- high-risk criteria (within 2 hours) 
Haemodynamic instability or cardiogenic shock  
Recurrent or ongoing chest pain refractory to medical management 
Life-threatening arrhythmias or cardiac arrest 
Mechanical complications of myocardial infarction  
Acute heart failure 
Recurrent dynamic ST-T wave changes, particularly with intermittent ST-elevation  
High-risk criteria (within 24 hours) 
Rise of fall in cardiac troponin compatible with myocardial infarction  
Dynamic ST or T-wave changes (symptomatic or silent) 
GRACE risk score >140 
Intermediate risk-criteria (within 72 hours) 
Diabetes mellitus 
Renal insufficiency (eGFR<60mL/min/1.73m2) 
Left ventricular ejection fraction <40% or congestive cardiac failure 
Early post-infarction angina 
Prior percutaneous coronary intervention  
Prior coronary artery bypass graft surgery 
GRACE risk score >109 and <140 
Low-risk criteria 
Any characteristics not mentioned above  
Adopted from Roffi M et al 2015 ESC Guidelines for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation: 
Task Force for the Management of Acute Coronary Syndromes in Patients Presenting 
without Persistent ST-Segment Elevation of the European Society of Cardiology 





Table 6.2: AHA/ACC risk criteria for the use of invasive strategy  
Very- high-risk criteria (within 2 hours) 
Haemodynamic instability  
Recurrent angina 
Sustained ventricular tachycardia or fibrillation  
Acute heart failure 
Recurrent angina or ischemia at rest or with low level activities despite intensive medical 
therapy  
High-risk criteria (within 24 hours) 
Temporal changes in troponin   
New or presumable ST depression 
GRACE risk score >140 
Intermediate risk-criteria (within 72 hours) 
Diabetes mellitus 
Renal insufficiency (eGFR<60mL/min/1.73m2) 
Left ventricular ejection fraction <40% or congestive cardiac failure 
Early post-infarction angina 
Prior percutaneous coronary intervention within 6 months 
Prior coronary artery bypass graft surgery 
GRACE risk score >109 and <140 
Low-risk criteria 
Any characteristics not mentioned above  
Low-risk troponin negative female patients 
Patient or clinician preference in the absence of high-risk features.  
Adopted from Amsterdam EA et al 2014 AHA/ACC Guideline for the Management of 
Patients with Non–ST-Elevation Acute Coronary Syndromes 
Despite these guidelines, provision of an invasive strategy in real world clinical 
practice is variable and often discrepant due to a variety of potential barriers such as 
treating physician's bias, local network guidelines and financial restraints
44-46
. In this 
thesis, chapters 4 & 5 results demonstrate that there is significant heterogeneity in the 
use of an invasive strategy and its timing in patients admitted with NSTEMI. The 
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patients who are most likely to benefit from an invasive strategy were least likely to 
receive it. 
Sex differences in clinical outcomes of patients presenting with ACS are widely 
reported in the literature
26-31
. The unfavourable outcomes in women have often been 
attributed to the delayed or atypical presentation, older age, less aggressive management 
and higher comorbidity burden 
9,32-35
. However, more contemporary data suggest that 
differences in clinical characteristics and presentation only partially contribute towards 
the higher mortality amongst women
36,37
. A recent analysis of the MINAP registry 
showed that women in England and Wales were less likely to receive guidelines 
indicated care and had significantly higher mortality than men following ACS
25
. These 
data highlight the need for greater understanding of factors driving these differences in 
outcomes and optimising the therapeutic strategies in women to improve survival 
38
.  
 Given this variable practice and the perception that use of invasive strategy in clinical 
practice is often discrepant with guidelines, it is important to understand the relationship 
between baseline risk and timing of access to the invasive strategy in contemporary 
practice. Therefore, this chapter aimed to meet the following objectives. 
6.2 Objectives 
I. To study the relationship between baseline risk as defined by two major 
international guidelines and timing of access to the invasive strategy in a large 
national population admitted with a diagnosis of NSTEMI in England and 
Wales. 
II. To examine whether the timing of an invasive strategy is related to this baseline 
risk and how this varies in different components of each risk criteria. 
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III. To examine any inequalities in the utilization of guidelines based on an invasive 
strategy in women compared to men. 
IV. To study the independent predictors of receiving an invasive strategy within the 
recommended time across all three risk groups.  
V. Finally, to study whether the utility of an invasive strategy varies across 
healthcare regions in England and Wales. 
6.3 Methods 
6.3.1 Study design  
Data for this study were obtained from MINAP, a comprehensive, national registry of 
patients hospitalised with a diagnosis of ACS in England and Wales. The design, data 
variables, strengths and limitations of MINAP registry have been described in full 
details in chapter 3 of this thesis. Briefly, there are over 120 data fields in MINAP, 
encompassing baseline characteristics, comorbidities, the timing of presentation and 
invasive intervention, peri-admission pharmacology, in-hospital outcome, diagnosis on 
discharge and receipt of secondary prevention treatment
21,101,166
. Data collection is 
mandated by the Department of Health across 235 acute hospitals in the National Health 
Service (NHS) and its management have previously been described in chapter 3. 
Secondary use of anonymised MINAP dataset for research purposes is authorised under 
NHS research governance arrangements and further supported under section 251 of the 
NHS act 2006 (NIGB: ECC1-06(d)/2011), which allows researchers to use patient 
information collected within the dataset for medical research without patient consent. 
Therefore, formal ethical approval was not sought for this study, however, the data 
application was reviewed by the MINAP and HQIP data monitoring and research 
committee (appendix 10.3).  
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6.3.2 Study population  
Consecutive patients admitted with a diagnosis of an NSTEMI in one of the 235 
hospitals between 1
st
 January 2010 to 31
st
 December 2015 were included in this study. 
The discharge diagnosis of NSTEMI in the MINAP registry is determined by local 
clinicians according to the presenting history, clinical examination, and the results of 
inpatient investigations in keeping with the consensus document of the Joint European 
Society of Cardiology and American College of Cardiology
167
. Patients with missing 
information on age, gender, in-hospital mortality, the timing of invasive strategy and 
those managed conservatively were excluded from the analysis to allow a complete case 
analysis (Figure 6.1). This constituted a final cohort of 137,265 patients, which were 









MINAP variables which were mapped against each guideline risk stratification criterion 
are shown in Table 6.3. 
Table 6.3 Risk criteria mandating an invasive strategy in NSTEMI according to ESC, 
AHA/ACC guidelines and variables used from MINAP registry for risk-stratification  
2015 ESC guidelines for the 
management of NSTEMI  
2014 AHA/ACC guidelines for 
the management of NSTEMI 
Defined as or surrogate 
from MINAP dataset 
High-risk Criteria (Invasive 
strategy <24hrs) 
  
Haemodynamic instability or 
cardiogenic shock 
Haemodynamic instability  Killip class 4 
Life threatening arrhythmias or 
cardiac arrest 
Sustained VT/ VF Any cardiac arrest out of 
hospital or in-hospital 
Acute heart failure Signs or symptoms of HF  Killip class 3 
Dynamic ST or T-wave changes 
( symptomatic or Silent) 
New or presumably new ST 
depression 
ST changes recorded on 
ECG  
Rise or fall in cardiac troponin 
compatible with MI  
Temporal change in troponin  Elevated troponin with at 




GRACE risk score >140 GRACE risk score >140 GRACE risk score >140 
Intermediate risk criteria 
(Invasive strategy (24-72hrs) 
  






History of CRF 
LVEF <40% or CCF LVEF <40% or CCF History of CCF or 
LVEF<40% 
Prior PCI PCI within 6 month  Previous PCI  
Prior CABG Prior CABG Previous CABG 
GRACE risk score >109 and 
<140 
GRACE score >109 and <140 GRACE risk score >109 
and <140 
Low-risk criteria (Invasive 
strategy >72hrs) 
  
Any characteristics not 
mentioned above  
Any characteristics not 
mentioned above 
All other patients 
HF= heart failure, VT/VF= ventricular tachycardia/ventricular fibrillation, GRACE= Global Registry of 
Acute Coronary Events, CRF= chronic renal failure, PCI= percutaneous coronary intervention, CABG= 
coronary artery bypass graft, CCF= congestive cardiac failure, LVEF= left ventricular ejection fraction 
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6.3.3 Study outcomes 
Time to the invasive strategy was calculated from the time of admission to the hospital 
and time of coronary angiography or PCI, which was then categorised into early (within 
24 hours), intermediate (within 72 hours) and late (>72 hours) groups. As the timing is 
not always captured in hours within the MINAP dataset, hence it was not possible to 
accurately ascertain the timing of an invasive strategy for up to two hours. Therefore, 
the very high-risk category was merged into the high-risk category as patients meeting 
any of these criteria would still be required to undergo an invasive strategy within 24 
hours of admission and this approach was felt to be the most pragmatic after discussions 
with the supervisory team.  
6.3.4 Study covariates  
In addition to the patient’s risk factors, information on co-existing comorbidities, 
cardiac biomarkers, in-hospital and discharge medications, in-hospital outcomes 
including all-cause mortality, cardiac mortality, re-infarction, major bleeding, receipt of 
PCI and receipt of CABG was also collected. MINAP doesn’t collect the actual 
calculated GRACE risk score as such, however, information available from variables 
within the dataset was used to calculate GRACE risk score which has been previously 
described and validated for use in this registry
2,168
. 
6.3.5 Statistical analysis  
Baseline characteristics of all three groups were reported using numbers and 
percentages for categorical variables, or median and interquartile ranges for continuous 
variables across the three groups. Chi
-
square and Wilcoxon's rank sum were used to 
make the comparisons across three groups, whereas proportion tests were used to test 
statistical differences in proportions with the alpha level of significance of p<0.05. The 
data completion for mandatory fields and most of the variables included in the study 
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was more than 80% in most of the data fields. The missing information about each 
variable is provided in Appendix Table 5. An imputation framework based on chained 
equations to account for missing data for each group characteristic variables. Age, 
gender, hospital catheter laboratory status, ethnicity, timing of invasive strategy and in-
hospital all-cause and cardiac mortality were registered as regular variables in the 
imputations model whereas all other variables including body mass index (BMI), 
GRACE risk-score >140, troponin elevation, acute heart failure, cardiogenic shock, 
seen by cardiologists, left ventricular (LV) systolic function or congestive cardiac 
failure, ECG changes defined as ST depression or transient ST elevation, prior history 
of PCI, coronary artery bypass graft (CABG), heart failure, hypercholesterolemia, 
angina, cerebrovascular disease, peripheral vascular disease, chronic renal failure, 
diabetes, hypertension, smoking status, asthma/COPD, family history of coronary 
disease, use of warfarin, loop diuretics, aspirin, P2Y12 inhibitors, statin, ACE inhibitor, 
beta-blocker were imputed. For the intermediate-risk group, high-risk group 
characteristics such as troponin elevation, acute heart failure, ECG changes, cardiogenic 
shock and GRACE risk score >140 were excluded from the imputation model. 
Similarly, intermediate-risk characteristics were excluded from the low-risk imputation 
model. Using these models, 10 imputed datasets were generated for each of the risk 
groups which were then used to perform all the analyses for multivariable logistic 
regression. Multivariable logistic regression models were used to study the independent 
predictors of the receipt of an invasive strategy within guideline recommended 
timeframes. The variables selected in the models included all the variables used in the 
imputations. Finally, for geographical variation analysis, patient geographical residence 
information was located according to clinical commissioning groups (CCGs) recorded 
in the MINAP dataset and stratified according to gender. Each patient’s data was then 
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mapped to geographic information system CCGs layers accessed from NHS England to 
create choropleth maps of patients receiving an invasive strategy according to 
guidelines recommended time frames using spmap function in Stata. 
6.4 Results  
6.4.1 Patient and hospital characteristics 
From a total of 137,265 patients that received an invasive management following 
admission with an NSTEMI, 3608 (2.6%) were categorised as low-risk, whereas 5,037 
(3.7%) and 128,621 (93.7%) were categorised as intermediate and high-risk 
respectively, according to both ESC and AHA/ACC guidelines. Typically, patients in 
the low-risk category were younger (61.4years vs 68years, p<0.001), more likely to be 
women (31.5% vs 29.8%, p<0.001) and were less comorbid with lower prevalence of 
previous cerebrovascular disease (3.9% vs7.3%, p<0.001), peripheral vascular disease 
(2.6% vs 5.3%, p<0.001), hypertension (46.5% vs 55.9%, p<0.001), and asthma or 
COPD (12.5% vs 15.3%, p<0.001) compared to the high-risk group (Table 6.4). In the 
high-risk group the vast majority of patients had troponin elevation (n=125,070, 98.0%) 
whereas the prevalence of cardiogenic shock (n=463, 0.4%) and cardiac arrest on 
admission (n=3,092, 2.5%) was low. Within the intermediate-risk group, patients had 
higher prevalences of diabetes (42.2% vs 25.0%, p<0.001), previous coronary artery 
bypass surgery (16.0% vs 8.9%, p<0.001) and previous PCI (49.0% vs 16.8%, p<0.001) 
compared to the high-risk group. Finally, unadjusted all-cause mortality (1.0% vs 0.1%, 
p<0.001), cardiac mortality (1.0% vs 0.1%, p<0.001) and reinfarction (0.8% vs 0.4%, 





Table 6.4: Baseline Characteristics of patient stratified into low, intermediate and high-
risk groups according to ESC and AHA/ACC guidelines 








Age ( Years) 61.4[52.4-70] 66[57-74] 68[58-77] <0.001 
Women (%) 1,137 (31.5%) 1,383 (27.5%) 38,291 (29.8%) <0.001 
Caucasians (%) 2,805 (77.7%) 3,592 (71.3%) 103,644 (80.6%) <0.001 
BMI median [IQR] 27.7 [24.9-31.0] 28.4 [25.4-3.6] 27.5 [24.5-31.1] <0.001 
High-risk 
Characteristics 
    
Cardiogenic shock - - 463 (0.4%)  
ECG ST changes - - 34,288 (26.9%)  
Cardiac arrest - - 3,092 (2.5%)  
Acute heart failure - - 9,203 (7.2%)  
GRACE score >140 - - 35,298 (44.2%)  
Troponin positive - - 125,070 (98.0%)  
Intermediate risk 
characteristics  
    
Intermediate risk 
109-140 
- 1,423 (49.3%) 25,388 (31.9%) <0.001 
Chronic renal failure - 215 (4.4%) 7,148 (5.8%) 0.01 
Percutaneous 
coronary intervention 
- 2,426 (49.0%) 20,713 (16.8%) <0.001 
Coronary artery 
bypass graft 
- 789 (16.0%) 11,015 (8.9%) <0.001 
Diabetes - 2,106 (42.2%) 31,729 (25.0%) 0.001 
LVEF<40% or CCF - 837 (34.5%) 24,548 (35.7%) <0.001 
Other clinical 
characteristics  
    
Hypercholesterolemia 1,306 (43.5%) 2,904 (59.6%) 50,757 (41.7%) 0.10 
Angina 764 (26.5%) 2,609 (54.0%) 34,840 (28.4%) <0.001 
Cerebrovascular 
disease 
119 (3.9%) 351 (7.2%) 9,019 (7.3%) <0.01 
Peripheral vascular 
disease 
77 (2.6%) 219 (4.6%) 6,501 (5.3%) <0.001 
Hypertension 1,423 (46.5%) 3,224 (65.2%) 69,088 (55.9%) <0.001 
Smoking status     
Previous smoker 1,026 (33.0%) 2,064 (42.4%) 46,156 (37.1%) <0.001 
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Current smoker 842 (27.1%) 846 (17.4%) 32,305 (26.0%) <0.001 
Asthma / COPD 378 (12.5%) 779 (15.9%) 18,776 (15.3%) <0.001 
Seen by cardiologist 3,367 (98.56%) 4,912 (98.8%) 126,664 (99.1%) 0.03 
Heart rate, bpm, 
median (IQR) 




140 [125-155] 138 [122-155] 140 [124-159] <0.001 
Family history of 
CHD 
1,191 (44.8%) 1,686 (39.2%) 38,970 (35.6%) 0.001 
Hospital catheter lab 
status 
    
No onsite laboratory  292 (8.1%) 319 (6.3%) 8,999 (7.0%) 0.01 
Onsite diagnostic 
laboratory  
354 (9.8%) 457 (9.1%) 16,262 (12.6%)  
Onsite PCI laboratory  2,962 (82.1%) 4,261 (84.6%) 103,360 (80.4%)  
In-hospital 
Pharmacology 
    
Low molecular 
weight heparin 
1,208 (41.5%) 2,129 (46.8%) 57,214 (50.8%) <0.001 
Warfarin 61 (2.2%) 245 (4.1%) 5,713 (5.2%) 0.001 
Loop Diuretic 196 (7.0%) 708 (15.9%) 22,529 (20.7%) <0.001 
Glycoprotein use 117 (4.1%) 188 (4.1%) 6,869 (6.2%) <0.001 
Discharge 
Medications 
    
Aspirin 2,920 (96.9%) 4,440 (96.9%) 110,412 (97.0%) 0.79 
P2Y12 inhibitors 3,098(94..1%) 4,673 (95.4%) 122,474 (96.9%) 0.001 
Statins 2,869 (96.5%) 4,396 (96.0%) 108,940 (96.6%) 0.04 
ACE inhibitors 1,619 (85.3%) 2,805 (89.3%) 69,293 (89.5%) <0.001 
Beta-Blockers 2,395 (83.7%) 3,785 (85.3%) 97,628 (87.2%) <0.001 
Crude outcomes     
Death 3 (0.1%) 6 (0.1%) 1,354 (1.0%) 0.001 
Cardiac mortality 1 (0.1%) 3 (0.1%) 1,125 (0.9%) 0.001 
Reinfarction 12 (0.4%) 33 (0.7%) 1,028 (0.8%) 0.01 
Major bleeding 48 (1.4%) 97 (2.0%) 2,032 (1.6%) 0.06 
GRACE= Global Registry of Acute Coronary Events, CRF= chronic renal failure, PCI= percutaneous 
coronary intervention, CABG= coronary artery bypass graft, CCF= congestive cardiac failure, LVEF= 
left ventricular ejection fraction, COPD= chronic obstructive airway disease. 
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Table 6.5 compares the differences in the baseline characteristics, in-hospital and 
discharge pharmacology and outcomes amongst men and women across the three risk 
groups. In the low-risk group, there were 2,471 (68.5%) men and 1,137 (31.5%) 
women. Compared to low-risk men, low-risk women had a higher prevalence of 
hypertension (44.9% vs 38.1%, p<0.001), history of asthma or chronic obstructive 
airway disease (16.2% vs 10.2%, p<0.001). Within the intermediate-risk group, men 
had a higher incidence of the previous PCI (51.8% vs 41.7%, p<0.001) and CABG 
(18.6% vs 8.9%, p<0.001) respectively. Finally, high-risk women were significantly 
older (72year vs 66 year, p<0.001) and were likely to have more adverse features on 
presentation in the form of higher prevalence of acute heart failure (9.3% vs 6.2%, 
p<0.001), GRACE risk score > 140 (48.0% vs 42.6%, p<0.001), chronic renal failure 
(6.1% vs 5.7%, p<0.001) and history of diabetes (26.1% vs 24.5%, p<0.001) compared 
to high-risk men. Notably, higher risk women were also less likely to receive secondary 
prevention medications on discharge in the form of aspirin (96.2% vs 97.4%, p<0.001), 
statins (95.5% vs 97.1%, p<0.001), ACE inhibitors (86.8% vs 89.5%, p<0.001) and 
beta-blockers (85.3% vs 88.1%, p<0.001). 
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Table 6.5 Baseline characteristics of the Men and Women stratified into low, intermediate and high-risk according to ESC and AHA/ACC 
guidelines 
Variables Low risk  
3,608 (2.6%) 
P value Intermediate risk 
5,037 (3.7%) 
P value High Risk  
128,620 (93.7%) 
P value  
 Men (2,471) Women 
(1,137) 












893 (78.5%) 0.26 2,594 
(71.0%) 











         
Cardiogenic 
shock 
- - - - - - 330 (0.4%) 133 (0.4%) 0.62 
ECG ST 
changes 







- - - - - - 2,338 (2.7%) 754 (2.0%) <0.001 
Acute heart 
failure 
- - - - - - 5,632 (6.2%) 3,580 (9.3%) <0.001 
High risk 
>140 





















- - - 1,032 
(48.6%) 











- - - 1,858 
(51.8%) 








- - - 668 (18.6%) 121 (8.9%) <0.001 9,070 
(10.5%) 
1,945 (5.3%) <0.001 
Diabetes - - - 1,472 
(407%) 
















         
Hypercholest
erolemia 
903 (44.0%) 403(42.6%) 0.47 2,099 
(59.3%) 





Angina 496 (25.2%) 268 (29.2%) 0.02 1,906 
(54.2%) 





























         
Previous 
smoker 
749 (35.3%) 277 (28.1%) <0.001 1,653 
(46.7%) 



























































806 (44.5%) 385 (45.4%) 0.67 1,211 
(38.8%) 








         
No onsite 
laboratory  
196 (7.9%) 96 (8.4%) 0.17 228 (6.2%) 91 (6.6%) 0.81 6,400 (7.1%) 2,599 (6.8%)  0.01 



























817 (41.1%) 391 (42.3%) 0.54 1,528 
(46.1%) 





Warfarin 38 (2.0%) 23 (3.6%) 0.31 183 (5.6%) 62 (5.1%) 0.51 3,987 (5.2%) 1,726 (5.3%) 0.48 
Loop 
Diuretic 







82 (4.2%) 35 (3.8%) 0.63 145 (4.4%) 43 (3.4%) 0.16 5,120 (6.5%) 1,749 (5.3%) <0.001 
Discharge 
Medications 
         
Aspirin 2,013 
(97.2%) 































































Death 3 (0.1%) 0 (0.0%) 0.24 2 (0.1%) 4 (0.3%) 0.03 902 (1.0%) 452 (1.2%) 0.003 
Cardiac 
mortality 
1 (0.1%) 0 (0.0%) 0.49 1 (0.1%) 2 (0.1%) 0.12 751 (0.8%) 374 (1.0%) 0.01 
Reinfarction 8 (0.4%) 4 (0.4%) 0.89 25 (0.7%) 8 (0.6%) 0.71 717 (0.8%) 311 (0.9%) 0.72 
Major 
bleeding 
28 (1.2%) 20 (1.9%) 0.12 69 (2.0%) 28 (2.1%) 0.75 1,301 (1.5%) 731 (2.0%) <0.001 
GRACE= Global Registry of Acute Coronary Events, CRF= chronic renal failure, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft, CCF= 
congestive cardiac failure, LVEF= left ventricular ejection fraction, COPD= chronic obstructive airway disease. 
155 
 
6.4.2 Temporal trends & regional variations 
Analysis of temporal trends showed an increase in uptake of invasive strategy in all 
groups, but with a greater proportional in low-risk women (22.9% to 41.9%, p<0.001), 
whereas high-risk women had the least increase from 11% to 19.3%, p<0.001 during the 
study period (Figure 6.4). 
Figure 6.2 Temporal trends in proportions of men and women receiving an invasive 
strategy within guidelines recommended time frame according to their risk. 
A) Men  
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Regional variations in the attainment of targets recommended in the guidelines across 
different CCGs and healthcare board areas in England and Wales are illustrated in 
Figure 6.3. In the high-risk group, almost equal proportions of women (38%) and men 
(39%) received treatment in the Northeast of England whereas greater differences were 
observed in Wales (57%) and Southwest (59%) of England, where higher proportions of 
high-risk men received guidelines indicated invasive strategy. In the low-risk group, 
greater proportions of men in the Northeast (78%) and Southwest (75%) received timely 
treatment whereas lower proportions of women in the Midlands (20%) were treated in 
the recommended time frames. 
Figure 6.3 Proportion of Men and Women stratified according to their risk receiving an 
invasive strategy within guidelines recommended time frame across the clinical 
commissioning group in England and Wales 
 





B) Intermediate risk 
 





6.4.3 Independent predictors of receipt of invasive strategy within the recommended 
time 
Independent predictors of attainment of an invasive strategy within the recommended 
timeframe for high, intermediate and low-risk are reported in Table 6.6. In the high-risk 
group, the presence of cardiogenic shock (OR 0.35 95%CI 0.27-0.44), ST-segment 
ECG changes (OR 0.60 95%CI 0.57-0.63) and cardiac arrest (OR 0.43 95%CI 0.38-
0.47) were associated with reduced odds of receiving an invasive strategy with 24hours. 
In contrast, troponin elevation was associated with more than two-fold increase in odds 
of receiving an invasive strategy within 24 hours (OR 2.35 95%CI 2.08-2.66. The 
presence of onsite PCI facilities was a strong positive predictor of receiving an invasive 
strategy within recommended time in the high-risk group (OR 2.49 95%CI 2.43-2.63) 
whereas they were less likely to receive an invasive strategy (OR 0.75 95%CI 0.68-




Table 6.6: Independent Predictors of receiving invasive coronary strategy within guidelines 
recommended time frames in high, intermediate and low-risk groups. 
Variables High-risk group Intermediate 
risk group 
Low-risk group 
High-risk characteristics Odd ratio (95%CI) 
Cardiogenic shock 2.78 (2.28-3.39) - - 
ECG ST changes 1.67 (1.61-1.73) - - 
Cardiac arrest 2.44 (2.24-2.64) - - 
Acute heart failure 0.65 (0.61-0.70) - - 
Troponin positive 0.39 (0.36-0.43) - - 
Intermediate risk 
characteristics  
  - 
Chronic Renal Failure 0.74 (0.68-0.80) 0.88 (0.63-1.23) - 
Previous Percutaneous 
coronary intervention 
1.08 (1.02-1.13) 0.94 (0.79-1.11) - 
Previous CABG 0.87 (0.82-0.93) 1.37 (1.11-1.67) - 
Diabetes 0.81 (0.78-0.84) 1.05 (0.91-1.22) - 
LVEF <40% or CCF 1.26 (1.21-1.32) 0.61 (0.48-0.76) - 
Other predictors   - 
Female gender 0.91 (0.88-0.94) 1.09 (0.93-1.27) 1.06 (0.89-1.25) 
Age 0.98 (0.986-0.988) 1.00 (1.00-1.01) 1.00 (0.99-1.00) 
Black Ethnicity 1.22 (1.06-1.39) 1.35 (0.77-2.33) 1.45 (0.74-2.83) 
Hypercholesterolemia  1.25 (1.21-1.30) 0.75 (0.64-0.87) 0.63 (0.52-0.76) 
Angina 0.95 (0.92-0.99) 1.05 (0.91-1.21) 1.40 (1.15-1.70) 
Cerebrovascular disease 0.89 (0.83-0.93) 1.12 (0.85-1.47) 0.79 (0.53-1.19) 
Peripheral vascular disease 1.10 (1.02-1.18) 0.79 (0.57-1.08) 0.91 (0.51-1.53) 
Hypertension  1.02 (0.98-1.06) 0.95 (0.81-1.12) 0.97 (0.82-1.15) 
Asthma/ COPD 0.84 (0.84-0.88) 0.95 (0.79-1.14) 1.09 (0.84-1.42) 
Seen by cardiologist  0.88 (0.79-1.04) 1.03 (0.53-2.00) 1.51 (0.76-2.96) 
Family history of heart disease 1.13 (1.09-1.17) 1.14 (0.98-1.32) 1.12 (0.93-1.36) 
Hospital catheter lab status 
(Ref no laboratory centres) 
   
Diagnostic centre 0.75 (0.68-0.83) 1.37 (0.94-2.00) 2.00 (1.42-2.81) 
PCI centres 2.49 (2.43-2.63) 0.74 (0.56-0.98) 2.16 (1.67-2.79) 
CCF= congestive cardiac failure, LVEF= left ventricular ejection fraction, COPD= chronic obstructive 
airway disease, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft, 
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6.4.4 Level of compliance with the guidelines 
Overall, more than two thirds (83.6%) of patients in the high-risk group did not receive an 
invasive strategy within the recommended target time (<24 hrs), whilst it was provided 
within the recommended time targets (within 72 hours) in 35.3% of the intermediate and 
37.5% of the low-risk cohorts category respectively (Figure 6.4). 
Figure 6.4 Overall proportion of patients receiving an invasive strategy within 
guidelines recommended time frame according to their risk 
 
Both men and women in the low-risk category were almost twice as likely to receive 
early an invasive strategy (within 24 hours) compared to high-risk men (28.9% vs 17%, 
p<0.001) and women (26.9% vs 15%, p<0.001) (Figure 6.5). Women were also 
consistently less likely to receive an invasive strategy within the recommended time 
points across all groups; low-risk (35.6% vs 38.3%, p=0.02) intermediate-risk (33.0% 
vs 36.2%, p=0.03) and high-risk group (15.0% vs 17.0%, p<0.001) compared to men. 
Paradoxically, Women in the high-risk group also experienced greater delays: 51.2% of 
















Low Risk Intermediate risk High risk
Invasive strategy within recommended time Invasive strategy outside the recommended time
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Figure 6.5 Proportion of Men and Women receiving an invasive strategy within 
guidelines recommended time frame according to their risk
 
Major differences were observed in the timing of invasive strategy amongst 
patients with high-risk features as defined by ESC or AHA/ACC guidelines. Early 
invasive strategy within the recommended time was most commonly used in patients 
presenting with cardiac arrest (49.8%) or cardiogenic shock (22.1%) but lesser 
proportion of patients with a GRACE score >140 (14.0%) or presenting with acute heart 
failure (11.8%) received an invasive strategy within the recommended target time 
(Figure 6.6). Furthermore, women in very high or high-risk categories (cardiogenic 
shock, cardiac arrest, acute heart failure, ST depression on the ECG, elevated troponin 
and GRACE risk score >140) were consistently less likely to receive an appropriately 
early invasive strategy compared to men (Figure 6.8). In addition, subgroup analysis 
demonstrated important differences in access to the invasive strategy in intermediate-
risk patients (Figure 6.7). For example, women with history of diabetes (29.3% vs 
35.0%, p=0.007) and congestive cardiac failure (23.2% vs 29.4%, p<0.001) were less 
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receipt of an invasive strategy within recommended time frames were similar in women 
with history of chronic renal disease (29.6% vs 26.4%, p=0.2) and intermediate GRACE 
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Figure 6.7: Men, women and overall proportions in the intermediate-risk group receiving an invasive strategy within guidelines 
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6.5 Discussion  
In this analysis of nearly 140,000 NSTEMI patients from a national AMI registry, there 
was a significant disconnect between targets for the timing of invasive strategy based 
upon baseline risk according to the guidelines. In this study population, over 90% of 
NSTEMI patients admitted within the United Kingdom are deemed to be high-risk 
according to ESC or AHA/ACC guidelines, and in this cohort, the recommendation is 
for an early invasive strategy (within 24 hours). In reality, only one in ten such high-risk 
NSTEMI patients actually received an invasive strategy within this target time. 
Paradoxically, patients in the lowest risk category were twice as likely to receive an 
early invasive strategy compared to high-risk patients. Finally, access to an invasive 
strategy within guideline recommended time targets was significantly lower in women 
than men. Specifically, high-risk women were more likely to present with adverse 
baseline clinical characteristics and were less likely to receive an invasive strategy 
within the recommended time points compared to men. These gender differences in 
attainment of guideline recommendations for an invasive strategy were apparent across 
different CCGs and healthcare boards in England and Wales. In fact, the findings from 
this study show a wide variation in adherence to guidelines, particularly amongst high-
risk women.  
Current ESC guidelines around the management of NSTEMI recommend an early 
invasive strategy within 24 hours in patients with high-risk features, with an aim to offer 
it no later than 72 hours in patients with intermediate-risk. The AHA/ACC risk 
stratification criteria and time points for offering an invasive strategy are similar to the 
ESC guidelines
3
. Almost 93% of the NSTEMI cohort in this study were deemed high-
risk, in the majority of whom this was based upon them having at least one troponin 
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level above the 99
th
 percentile. Both ESC and AHA/ACC guidelines recommend that at 
least one elevated troponin level above the 99
th
 percentile cut off is required to make a 
diagnosis of NSTEMI. However, offering an early invasive strategy within 24 hours to 
patients meeting these criteria will have major resource implications and is likely to 
require a restructuring of national ACS services. Firstly, condensed data from RCTs 
shows that only high-risk patients with GRACE risk score >140 benefits from an early 
invasive strategy and have better clinical outcomes whereas the optimal timing of 
invasive strategy in patients with other high-risk features such as troponin positive or 
ECG changes is less clear 
60,150
. Secondly, utilisation of increasingly highly sensitive 
troponin assays has resulted in increased detection of low-risk NSTEMI patients and 
concurrent fall in the diagnosis of Unstable angina
169-171
. Furthermore, the advent of 
highly sensitive troponin assays has resulted in the misinterpretation of apparently 
raised assay results to indicate Type 1 MI, when in fact the result may reflect Type 2 MI 
or myocardial injury
172
. Although, rise or fall in cardiac troponin is important from a 
diagnostic point of, optimal timing of intervention in this cohort requires further 
research. Therefore, mandating an invasive strategy within 24 hours to such large 
proportions of patients would require a major expansion in service structure and 
delivery in an already stretched healthcare system. The other second largest proportions 
(48%) of patients in the high-risk group were those with a GRACE risk score >140, yet 
both men and women with GRACE risk score >140 experienced greater delays in 
receiving an invasive strategy within 24 hours. Further research is required to elucidate 
an optimal time of intervention in patients with different high-risk features as currently 
prescribed by guidelines. 
The results from this national heart attack registry analysis show a clear 
disassociation between the recommendations for target times for invasive strategy 
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access on one hand and what is actually offered to patients on the other. There was a 
consistently lower real life use of an invasive strategy in all risk groups. Remarkably, 
over 80% of patients in the high-risk group did not receive an invasive strategy within 
the recommended time frame of 24hours. More importantly, there was a significant 
risk-treatment paradox in that low and intermediate-risk patients were far more likely to 
get an early invasive strategy than those estimated to be at high-risk. This discrepancy 
may be explained by several factors such as treating physician bias, patient-related 
factors such as age, comorbidities and organisational factors such availability of onsite 
catheter lab facilities
173
. The results of chapter 4 of this thesis demonstrate that patients 
with increased comorbid burden, old age were less likely to receive angiography 
compared to their younger and less comorbid counterparts. In the current analysis, we 
found that low-risk patients were almost three times more likely to receive an invasive 
strategy when admitted to hospitals with onsite cardiac catheter laboratory facilities. 
Further efforts are required to develop a multifaceted approach in dissemination of 
guidelines, as well as to improve adherence and clinical care
46
. The association between 
the presence of onsite cardiac catheter facilities and the use of an invasive strategy will 
be explored in the next chapter (chapter 7.0) of this thesis. 
The most striking observation in this analysis was around inequalities in the receipt of 
appropriate, guidelines based invasive strategy amongst women and men. It appears that 
women presenting with high-risk features were not only less likely to receive an 
invasive strategy within recommended time points but experienced greater delays 
compared to men. Furthermore, there was also significant heterogeneity in the 
application of guidelines based invasive approach in women with an intermediate-risk 
profile. Disparities in cardiovascular care and outcomes amongst men and women are 
widely reported in the literature 
27,32,34,93
. The lower survival in women presenting with 
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ACS is not entirely explained by the differences in their presentation, symptomology 
and comorbidities
37
. Whilst previous studies have reported significant discrepancies in 
the use of an invasive strategy amongst women
93,174
, this study is the first one to 
highlight heterogeneity between the use of an invasive strategy and guideline prescribed 
risk criteria. These findings indicate that women are only more likely to experience 
biases in receipt of guidelines-based invasive strategy compared to men but this gender 
gap appears to be greater with increasing baseline risk amongst women which may 
explain the poor outcomes in women admitted with NSTEMI. 
There was also a significant disconnect between the clinical practice and guidelines-
base delivery of an invasive strategy amongst women across different CCGs and 
healthcare boards in England and Wales. These disparities may partly be related to 
differences in institutional practices and the availability of services such as cardiac 
catheter laboratory facilities
43,175,176
. However, differences within the institute reflect 
that treating physician bias and may be a barrier to the delivery of guideline-based care 
in this cohort
177,178
. In addition, current NICE guidelines in the UK adopt a more 
conservative approach of undertaking an invasive strategy within 96 hours if the 
patient’s predicted mortality is above 3.0% apart from high ischemic risk or 
haemodynamically unstable patients
8
. The guidance around risk stratification is less 
clear in NICE recommendations and may explain such wide variation in practice in the 
UK as risk stratification is left at physician discretion. It is also important to note that 
NICE guidelines on early management of NSTEMI and unstable angina were originally 
developed in 2010 and last updated in 2013. There has been a significant development 
in the management of NSTEMI. Development of quality improvement programmes and 






6.6 Study strengths and limitations 
To best of my knowledge, this is the first study to provide a comprehensive illustration 
of the real-world practice of guidelines recommended invasive strategy amongst men 
and women in a single national healthcare system. However, certain limitations should 
be considered whilst interpreting these observations. A majority of these patients were 
in a high-risk group due to a significant number of patients having positive cardiac 
biomarkers. MINAP dataset doesn’t collect information about dynamic changes in the 
cardiac troponin, therefore the guideline recommended criteria of the rise in cardiac 
troponin with at least one value above the 99
th
 percentile was used to define these 
patients. Secondly, the patients with very high-risk features such as cardiogenic shock, 
cardiac arrest, acute heart failure and dynamic ECG changes were included into a high-
risk category because information around the timing of CA was not available in hours 
for all patients in the MINAP dataset. Current ESC and AHA/ACC guidelines actually 
recommend an immediate invasive strategy within 2 hours in these patients, therefore 
after discussion with the supervisory team, it was felt that the logical approach would be 
to combine the very high-risk criteria with high-risk criteria as they would be requiring 
CA within 24 hours anyway.  
6.7 Conclusion  
In this NSTEMI cohort, there was a significant disconnect between guidelines 
recommended risk and the use of an invasive strategy in clinical practice. Specifically, 
over two thirds of high-risk NSTEMI patients did not receive an invasive strategy 
within guidelines recommended time points. There also appear to be significant sex-
based inequalities in that women were not only more likely to experience higher delays 
in receipt of invasive strategy, women presenting with high-risk characteristics were 
significantly less likely to be treated invasively in the recommended time points 
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compared to men. Future efforts need to focus on the development of quality 
improvement programmes and educational interventions to promote uniform delivery of 
guidelines-based care in this cohort. 
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Chapter 7  
 
 
Association between onsite cardiac catheter laboratory facilities and use of an invasive 
strategy in the management of NSTEMI 
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7.1 Introduction  
The previous chapter of this thesis described the use of an invasive strategy in the 
management of patients admitted with a diagnosis of NSTEMI based on the risk criteria 
of international guidelines namely European Society of Cardiology (ESC) and 
American Heart Association / American College of Cardiology (AHA/ACC). The 
current chapter aims to study the association between the presence of cardiac catheter 
laboratory facilities at the first admitting hospital and use of an invasive strategy in 
patients admitted with the diagnosis of NSTEMI in England and Wales. The analysis 
from this chapter is also currently under review for consideration of a publication in a 
peer reviewed cardiology journal. 
Invasive CA is the gold standard diagnostic modality for the assessment of coronary 
artery disease in patients admitted with ACS. Patients who present with STEMI are 
urgently transferred for primary PCI even when they initially present to hospitals 
without onsite cardiac catheter laboratory facilities based on current guideline 
recommendations
3,4
. Consequently, patients presenting to hospitals without onsite 
catheter laboratory are transferred to the nearest hospital with PCI facilities within a 
target time of 90 minutes from first medical contact. In contrast, the decision to 
undertake an invasive strategy in the form of CA in patients admitted with NSTEMI is 
based on initial presentation, ECG changes, risk factors, presence of haemodynamic 
instability and co-existing comorbidities
3,4,146
. Organisational factors, such as the 
availability of cardiac catheter laboratory facilities at the presenting hospital, are 




A proportion of patients with NSTEMI are admitted to hospitals without PCI 





Previous studies have reported a positive association between the presence of an on-site 
catheter laboratory and receipt of an invasive strategy in patients with ACS
24,42,43,184-186
 
but the association between catheter laboratory facilities at the admitting hospital with 
clinical outcomes were inconsistent 
42,43,184-188
. In an analysis of the GRACE registry, 
Van de Werf et al reported that the presence of on-site cardiac catheter laboratory was 
associated with the increased use of PCI but no differences in in-hospital mortality 
compared to the hospitals without an on-site cardiac catheter laboratory in patients 
admitted with ACS. In contrast, a study of 718,028 beneficiaries admitted with a 
diagnosis of ACS found that admission to a hospital with on-site cardiac catheter 
laboratory facilities was associated with lower 30-day mortality compared with 
admission without on-site cardiac catheter laboratory
189
. The interpretation of these data 
is challenging because the majority of previous studies are based on mixed cohorts of 
ACS patients including STEMI as well as NSTEMI patients and the availability of 
diagnostic only and PCI capable interventional facilities, in particular, is not considered 
separately. Furthermore, as described in chapter 6, current guidelines recommend an 
early invasive strategy within 24 hours in patients presenting with high-risk features, 
however, such time target times are unlikely to be met without the presence of onsite 
cardiac catheter laboratory facilities
3,4
. More importantly, there is a paucity of data 
around the use of an invasive strategy and clinical outcomes stratified according to 
admitting hospital catheter laboratory facilities in high-risk NSTEMI patients such as 
those with GRACE risk score >140. As such, it remains unclear how the types of 
cardiac catheter laboratory facilities at the first admitting hospital might influence the 




The main aim of the present study was to describe associations between use of 
an invasive strategy and outcomes in patients with NSTEMI and how these associations 
are influenced by the catheter laboratory and interventional (PCI) facilities of admitting 
hospitals. In order to further delineate the association between baseline NSTEMI risk 
and clinical outcomes, a pre-specified subgroup analysis of high-risk patients with a 
GRACE score >140 was also undertaken.  
7.2 Objectives 
The main objectives of this chapter were,  
I. To describe the difference in the baseline characteristics stratified according to 
the types of cardiac catheter laboratory facilities at the first admitting hospital in 
patients admitted with a diagnosis of NSTEMI in England and Wales.  
II. To study the association between the presence of different types of cardiac 
catheter laboratory facilities at the first admitting hospital and the use of an 
invasive strategy. 
III. To study whether there is an association between different types of cardiac 
catheter laboratory facilities and in-hospital clinical outcomes.  
IV. To study the association between different types of cardiac catheter laboratory 
facilities and in-hospital clinical outcomes in high-risk patients with GRACE 
risk score >140. 
V. To study the independent predictors of receipt of CA and PCI according to 




7.3.1 Study design  
The design of this study was similar to previous chapters in this thesis in the form of an 
observational, retrospective cohort study comprising of all adults admitted with a 
diagnosis of NSTEMI in England and Wales. MINAP dataset was used to define this 
cohort, details of which have been provided in chapter 3. Briefly, MINAP is a national 
audit which prospectively collects information around the management of ACS in 
England and Wales to meet the audit requirements of the National Service Framework 
(NSF) for coronary heart disease
23,190,191
. MINAP amasses almost 85,000 hospital 
admissions per year with a diagnosis of ACS admitted to acute National Health Service 
(NHS) hospitals in England and Wales
80
. Each entry in the MINAP dataset provides 
comprehensive information about patient’s journey encompassing patient 
demographics, coexisting comorbidities, admission method/route, clinical 
characteristics and investigations, in-hospital drug treatments, primary reperfusion 
treatment, interventional treatments, in-hospital outcome, diagnosis on discharge and 
discharge (secondary prevention) treatment
21,101,166
.  
7.3.2 Study population  
The analytical cohort for this study included all patients over the age of 18 years, 
admitted with a diagnosis of NSTEMI in one of the 235 hospitals in the England and 
Wales from 1
st
 Jan 2007 and 31
st
 Dec 2015. Only the first admission of each patient in 
the dataset was included in the analysis which was then matched to the first admitting 
hospital catheter laboratory facilities. All patients were then stratified into three groups; 
according to the catheter laboratory facilities of the admitting hospital as follows: `no 
lab` hospitals – hospital without catheter laboratory; `diagnostic` hospitals – hospitals 
with diagnostic catheter laboratory only; PCI hospitals – hospital with interventional 
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(PCI) laboratory facilities Patients with missing age, gender, in-hospital mortality 
information or those admitted to hospitals in Northern Ireland were excluded from the 
analysis (Figure 7.1). The Northern Ireland hospitals were excluded because 
participation in the MINAP registry is not mandated in Northern Ireland and hence the 
data collection is not complete for those hospitals in the registry. In order to examine 
the association between different types of cardiac catheter laboratory facilities and 
clinical outcomes in patients admitted with high-risk NSTEMI, a subgroup analysis of 
patients with GRACE risk score > 140 was undertaken. For this analysis, all other 
patients were removed from the analysis except patients with GRACE risk score >140. 
They were then stratified into three groups according to the admitting hospital cardiac 
catheter laboratory facilities as described above. The patients admitted to ‘no lab’ 
hospitals will be either medically managed or referred to nearest ‘PCI hospital’ for an 
invasive strategy, whereas patients admitted to ‘diagnostic hospitals’ may follow 
different treatment pathways in the form of either medical management alone, onsite 
CA only, onsite CA and referral to nearest ‘PCI hospital’ for PCI or direct referral to 
‘PCI hospitals’ for CA+/- PCI. Therefore, in order to further delineate the differences in 
treatment practices of high-risk NSTEMI patients admitted first in the diagnostic 
hospitals, a sensitivity analysis of patients receiving an invasive strategy onsite at the 
diagnostic hospitals compared to those transferred out directly to PCI hospitals from the 
diagnostic hospitals for an invasive strategy was performed. In this analysis, high-risk 
NSTEMI patients with GRACE risk score > 140 admitted to ‘diagnostic hospital’ and 
received an invasive strategy were divided into two groups based on whether they 
received an invasive strategy at the ‘diagnostic hospital’ or referred to ‘PCI hospital’ 


















7.3.3 Study outcomes 
The outcomes of interest were in-hospital all-cause mortality, cardiac mortality, and 
major bleeding which are collected within the MINAP dataset. 
7.3.4 Study covariates  
 Further information on the patient’s baseline characteristics, details of the presentation, 
comorbidities, in-hospital and discharge pharmacology, receipt of invasive strategies in 
the form of CA, PCI or CABG during admission and GRACE risk score was also 
collected. GRACE 2.0 score was calculated as previously described
2
 and patients were 




Missing information on 
gender = 1070 & age= 
792, mortality=12,397, 
Ireland hospitals= 5,534 
 
   Final admissions with NSTEMI diagnosis 
                              n=452,216 
Admissions in 
`diagnostic` 
hospitals   n= 
134,381 
Total number of admissions with diagnosis of 
NSTEMI from 2007-2015 













The MINAP database is collected and used for research purposes without informed 
patient consent by the NICOR under section 251 of the National Health Service Act 
2006. Therefore, ethical approval was not required for this study under current 
arrangements by the NHS research governance.  
7.3.5 Statistical analysis  
The baseline characteristics across the three groups were described using the number 
and percentages for categorical variables and median and interquartile ranges for 
continuous variables. In order to limit the influence of biases related to missing data, 
multiple imputation techniques with chained equations were used to account for the 
missing data. Full details of the percentage of missing data of each variable included in 
the study are provided in Appendix Table 6. Age, gender, hospital catheter laboratory 
status, ethnicity and in-hospital all-cause and cardiac mortality were registered as 
regular variables in the imputations model whereas all other variables including body 
mass index (BMI), GRACE risk score, seen by cardiologists, left ventricular (LV) 
systolic function, ECG changes defined as ST depression or transient ST elevation or T 
wave inversion, prior history of PCI, coronary artery bypass graft (CABG), heart 
failure, hypercholesterolemia, angina, cerebrovascular disease, peripheral vascular 
disease, chronic renal failure, diabetes, hypertension, smoking status, asthma/COPD, 
family history of coronary disease, in-hospital use of low molecular weight heparin, 
warfarin, loop diuretics, glycoprotein 2b3a inhibitors, discharge medications including 
aspirin, P2Y12 inhibitors, statin, ACE inhibitor, beta-blocker, in-hospital major 
bleeding, receipt of CA and receipt of PCI were imputed. Using these models, 10 
imputed datasets were generated which were used to perform all the analyses. 
Multivariable logistic regression models were used to study the independent predictors 
of the receipt of an invasive strategy in the form of CA or PCI. In order to account for 
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variations at the hospital level, multilevel logistic regression models were fitted as 
patients were clustered by the hospitals in these analyses. The multilevel logistic 
regression model captures any unobserved hospital components factors that were 
omitted but may influence the outcomes. All models included the same aforementioned 
variables used in the multiple imputation models as well as the year of admission. Full 
details of statistical modelling have been discussed in chapter 3 of this thesis. Estimates 
in the form of odds ratios and 95% confidence intervals were reported. 
7.4 Results  
7.4.1 Patient and hospital characteristics 
The analytical cohort of this study consisted of 452,216 patients admitted with a final 
diagnosis of NSTEMI across 235 acute hospitals in England and Wales during the study 
period. Of these patients, 97,777 (21.6%) were admitted to hospitals with ‘no lab’ 
hospitals, whereas 134,381 (29.7%) and 220,058 (48.7%) were admitted to ‘diagnostic’ 
and ‘PCI hospitals’ respectively. Table 7.1 shows the differences in the baseline 
characteristics of the patients stratified according to the type of cardiac catheter 
laboratory facilities at the first admitting hospital. Typically, patients admitted to ‘PCI 
hospitals’ were younger [median age 72 interquartile range (60.8-81)], had worst 
baseline cardiovascular profiles with increased prevalence of hypercholesterolemia 
(39.9%), peripheral vascular disease (5.8%), current smoking (22.4%) and family 
history of coronary heart disease (32.1%) compared to those patients admitted to `no 
lab` and `diagnostic` hospitals. In contrast, patients admitted to ‘no lab’ hospitals were 
more likely to be high risk with GRACE risk score >140 (59.6%) and had increased 
prevalence of out hospital cardiac arrest (1.2%), acute ECG changes (79.6%), poor LV 
systolic function (13.6%) compared to ‘PCI hospitals’. Patients admitted to `no lab` 
hospitals were less likely to be seen by a cardiologist compared with those admitted to 
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‘PCI hospitals’ (87.6% vs 95.6%). Rates of CA were higher in ‘PCI hospitals’ (77.3%) 
compared with `diagnostic` and `no lab` (63.2% and 61.4%) hospitals respectively. 
Likewise, patients in ‘PCI hospitals’ were almost twice as likely to receive PCI (45.9%) 
compared to `no lab` (28.3%) and `diagnostic` hospitals (22.4%). Finally, patient 
admitted to ‘no lab’ hospitals were less likely to receive guidelines recommended 
medications on discharge in the form of aspirin (89.9%), P2Y12 inhibitors (86.3%), 
statins (91.8%), ACE inhibitors (80.8%) and beta-blockers (77.7%) compared to the 
other two groups.   
Table 7.1: Baseline characteristics of the patients stratified according to `no lab`, 
`diagnostic` and PCI hospitals.  












Age 74 [63-83] 74 [63-83] 72 [60.8-81] <0.001 
Male (%) 60,422(61.8%) 82,210 (61.2%) 144,096 
(65.5%) 
<0.001 














    
Heart rate, bpm, median 
(IQR) 
80 [67-94] 80 [67-94] 77 [65-91] <0.001 
Systolic blood pressure, 
median (IQR) 
140 [121-158] 139 [121-158] 140 [121-158] 0.001 














Out of hospital cardiac 
arrest 
1,105 (1.2%) 1,175 (0.9%) 2,285 (1.1%) <0.001 











Left ventricular systolic 
function 
   <0.001 
Good 21,533 
(58.2%) 
29,450 (59.3%) 56,750 (60.4%)  
Moderate 10,438 
(28.2%) 
13,975(28.2%) 26,380(28.1%)  
Poor 5,002 (13.6%) 6,202 (12.5%) 10,836 (11.5%)  
GRACE risk score    <0.001 
Low <109 6,120(17.2%) 7,178 (17.3%) 20,742 (20.1%)  
Intermediate 109-140 8,251 (23.2%) 9,863 (23.8%) 27,351 (26.5%)  
High >140 21,226 
(59.6%) 
24,448 (58.9%) 55,224 (53.4%)  
Previous medical 
history 
    
Percutaneous coronary 
intervention 
11,527(12.4%) 14,559(11.8%) 35,519 (16.6%) <0.001 
Coronary artery bypass 
graft 
8,149 (8.7%) 11,352 (9.2%) 21,248 (10.2%) <0.001 
Heart failure 8,711 (9.3%) 10,930 (8.8%) 14,659 (7.1%) 0.001 
Hypercholesterolemia 30,475 
(33.2%) 
44,900(36.4%) 82,128 (39.9%) <0.001 
Angina 34,059 
(36.5%) 
48,243(38.9%) 69,637 (33.5%) 0.001 
Cerebrovascular disease 10,594 
(11.1%) 
13,771 (11.1%) 20,469 (9.8%) <0.001 
Peripheral vascular 
disease 
4,980 (5.4%) 6,714 (5.5%) 11,758 (5.8%) <0.001 
Chronic renal failure 8,013 (8.6%) 10,100 (8.2%) 17,375 (8.4%) 0.04 
Diabetes 24,212 
(25.3%) 
32,395 (24.6%) 56,291 (26.1%) 0.001 
Hypertension 51,125 
(54.6%) 
67,945 (54.3%) 119,921 
(57.0%) 
0.001 
Smoking status    <0.001 
Previous smoker 36,946 
(39.6%) 
48,324 (38.3%) 78,747 (38.0%)  
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Current smoker 18,941 
(20.9%) 
26,136 (20.8%) 46,456 (22.4%)  
Asthma / COPD 16,738 
(18.0%) 
23,049 (18.8%) 33,638 (16.3%) 0.001 
Family history of CHD 20,315 
(27.4%) 
27,909 (27.6%) 57,252 (32.1%) <0.001 
In-hospital 
Pharmacology 
    
Low molecular weight 
heparin 
58,058(64.3%) 77,468 (64.4%) 109,781 
(57.2%) 
<0.001 
Warfarin 6,105 (6.9%) 8,649 (7.3%) 11,215 (6.1%) <0.001 
Loop Diuretic 28,666 
(32.0%) 
38,048 (32.1%) 52,755 (28.7%) <0.001 
Glycoprotein use 2,098 (2.3%) 2,554 (2.2%) 11,067 (5.9%) <0.001 
Coronary angiography 49,755 
(61.4%) 
72,277 (63.2%) 153,668 
(77.3%) 
<0.001 
Discharge Medications     
Aspirin 61,470 
(89.9%) 
83,883 (89.0%) 181,828 
(94.7%) 
<0.001 









85,890 (91.8%) 178,985 
(94.4%) 
<0.001 
ACE inhibitors 52,967 
(80.8%) 





72,641 (77.6%) 156,595 
(83.5%) 
<0.001 
BMI= body mass index, bmp= beats per minute, GRACE= global registry of acute coronary events, 
COPD= chronic obstructive airway disease, ACE= angiotensin converting enzyme  
The differences in the characteristics of patients receiving an invasive strategy 
according to admitting hospital cardiac catheter laboratory facilities compared to 
medically managed patients are elucidated in Table 7.2 and Table 7.3. Among patients 
receiving an invasive strategy, patients admitted to ‘PCI hospitals’ were more likely to 
be older, male and have electrographic changes on admission. There were no 
differences in baseline GRACE scores across the three groups (Table 7.2). Patients with 
high-risk features such as those with high GRACE risk score >140, out of hospital 
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cardiac arrest or electrographic changes on admission were more likely to be medically 
managed in `no lab` hospitals compared to `diagnostic` and PCI capable hospitals 
(Table 7.3). These patients were also less likely to receive in-patient cardiology input in 
the form of a consultant cardiologist review in the `no lab` hospitals compared to the 
other two groups.  
Table 7.2: Baseline characteristics of the patients receiving coronary angiography 
stratified according to `no lab`, `diagnostic` and PCI hospitals.  










Age 67 [57-76] 67 [57-76] 67.9 [58-76] <0.001 
Male (%) 34,533(69.0%) 49,379 (68.6%) 105,971 (70.0%) <0.001 
Caucasians (%) 41,412 (82.7) 62,523 (86.9%) 121,342 (80.2%) <0.001 
BMI median [IQR] 27.7 [24.7-31.3] 27.7 [24.8-31.2] 27.4 [24.6-31.0] 0.0001 
Presenting Characteristics     
Heart rate, bpm, median (IQR) 76 [65-90] 76 [65-90] 75 [65-88] <0.001 
Systolic blood pressure, median 
(IQR) 
142 [125-160] 141 [125-160] 140 [124-159] 0.001 
ECG changes 37,412 (76.3%) 54,059 (76.6%) 114,547 (77.1%) 0.001 
Trop positive 45,540 (93.4%) 66,325 (94.8%) 135,539 (91.9%) 0.001 
Out of hospital cardiac arrest 368 (0.7%) 501 (0.7%) 1,495 (1.0%) <0.001 
Creatinine, median (IQR) 88 [74-105] 88 [74-105] 87 [73-105] <0.001 
Seen by cardiologist 44,709 (94.9%) 65,819 (97.9%) 145,423 (98.9%) <0.001 
LV systolic function    <0.001 
Good 14,239 (65.8%) 20,400 (66.9%) 45,195 (64.5%)  
Moderate 5,452 (25.2%) 7,683 (25.2%) 18,529(26.3%)  
Poor 1,937 (9.0%) 2,397 (7.9%) 6,378 (9.1%)  
GRACE risk score    0.66 
Low <109 5,184 (24.6%) 6,239 (24.7%) 18,207 (24.8%)  
Intermediate 109-140 6,544 (31.0%) 7,947 (31.5%) 22,929 (31.2%)  
High >140 9,368 (44.4%) 11,031 (43.7%) 32,396 (44.1%)  
Previous medical history     
Percutaneous coronary intervention 6,931 (14.5%) 9,035 (13.6%) 25,420 (17.7%) <0.001 
Coronary artery bypass graft 3,842 (8.0%) 5,326 (8.0%) 13,580 (9.5%) <0.001 
Heart failure 2,122 (4.4%) 2,711 (4.1%) 6,193 (4.4%) 0.003 
Hypercholesterolemia 17,897 (37.9%) 25,717 (38.6%) 61,041 (43.1%) <0.001 
184 
 
Angina 14,790 (30.8%) 21,612 (32.4%) 43,931 (30.7%) 0.001 
Cerebrovascular disease 3,419 (6.9%) 4,532 (6.8%) 10,651 (7.4%) <0.001 
Peripheral vascular disease 2,147 (4.5%) 2,742 (4.2%) 7,299 (5.2%) <0.001 
Chronic renal failure 2,313 (4.8%) 2,965 (4.4%) 8,200 (5.8%) 0.001 
Diabetes 11,342 (23.1%) 15,747 (22.2%) 37,091 (25.0%) 0.001 
Hypertension 25,494 (52.9%) 35,022 (52.1%) 81,626 (56.5%) 0.001 
Smoking status    <0.001 
Previous smoker 18,259 (38.0%) 25,398 (36.7%) 54,605 (37.5%)  
Current smoker 12,806 (26.7%) 18,460 (26.7%) 37,262 (25.7%)  
Asthma / COPD 7,296 (15.4%) 10,453 (15.9%) 20,916 (14.8%) 0.001 
Family history of CHD 14,335 (35.1%) 20,295 (35.3%) 46,695 (37.0%) <0.001 
In-hospital Pharmacology     
Low molecular weight heparin 28,746 (62.3%) 40,955 (64.3%) 75,174 (56.6%) <0.001 
Warfarin 2,138 (4.7%) 2,940 (4.7%) 6,450 (5.1%) <0.001 
Loop Diuretic 8,645 (18.9%) 11,639 (18.5%) 26,913 (21.4%) <0.001 
Glycoprotein use 1,655 (3.6%) 2,069 (3.3%) 10,024 (7.7%) <0.001 
Discharge Medications     
Aspirin 29,844 (95.6%) 41,888 (94.5%) 133,715 (97.0%) <0.001 
P2Y12 inhibitors 45,513 (93.1%) 63,945 (90.9%) 137,751 (93.4%) <0.001 
Statins 29,949 (96.4%) 42,492 (96.0%) 132,337 (96.5%) <0.001 
ACE inhibitors 26,785 (88.7%) 36,940 (85.7%) 116,704 (87.9%) <0.001 
Beta-Blockers 26,046 (84.5%) 36,958 (84.1%) 116,074 (86.2%) <0.001 
Outcomes     
Death 229 (0.5%) 277 (0.4%) 1,512 (1.0%) <0.001 
Cardiac mortality 188 (0.4%) 233 (0.3%) 1,203 (0.8%) <0.001 
Major bleeding 399 (0.8%) 355 (0.5%) 2,491 (1.7%) <0.001 
BMI= body mass index, bmp= beats per minute, GRACE= global registry of acute coronary events, 
COPD= chronic obstructive airway disease, ACE= angiotensin converting enzyme  
 
Table 7.3: Baseline characteristics of medically managed patients stratified according to 
`no lab`, diagnostic` and PCI hospitals.  












Age 81 [72-87] 81 [73-87] 81 [72-87] <0.001 
Male (%) 17,523 (54.0%) 22,012 (52.3%) 24,302(54.1%) <0.001 
Caucasians (%) 28,289 (87.2) 37,366 (88.7%) 37,517 (83.6%) <0.001 
BMI median [IQR] 25.6 [22.3-29.4] 25.7 [22.5-29.4] 25.8 [22.6-29.4] 0.03 
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Presenting Characteristics     
Heart rate, bpm, median (IQR) 83 [70-100] 84 [70-100] 82 [70-99] <0.001 
Systolic blood pressure, median 
(IQR) 
136 [118-156] 136 [117-156] 136 [118-156] 0.76 
ECG changes 27,136 (85.8%) 35,213 (85.9%) 36,986 (84.8%) 0.001 
Trop positive 29,220 (92.3%) 37,789 (93.1%) 39,781 (91.2%) 0.001 
Out of hospital cardiac arrest 464 (1.5%) 350 (0.9%) 433 (1.1%) <0.001 
Creatinine, median (IQR) 104 [82-137] 104 [83-138] 103 [81-140] 0.003 
Seen by cardiologist 23,200 (79.5%) 30,321 (81.2%) 36,070 (87.4%) <0.001 
Left ventricular  systolic function    <0.001 
Good 4,898(48.6%) 6,006 (48.2%) 6,179 (45.1%)  
Moderate 3,249 (32.3%) 4,116(33.1%) 4,709(34.3%)  
Poor 1,922 (19.1%) 2,329 (18.7%) 2,822 (20.6%)  
GRACE risk score    <0.001 
Low <109 332 (4.9%) 375 (4.9%) 848 (5.5%)  
Intermediate 109-140 714 (10.5%) 862 (11.3%) 1,863 (12.2%)  
High >140 5,746 (84.6%) 6,380 (83.8%) 12,627 (82.3%)  
Previous medical history     
Percutaneous coronary intervention 2,842(9.4%) 3,513 (9.0%) 5,947 (14.1%) <0.001 
Coronary artery bypass graft 2,891 (9.5%) 4,047 (10.3%) 5,152 (12.2%) <0.001 
Heart failure 4,497 (14.7%) 5,320 (13.6%) 5,659 (13.5%) 0.001 
Hypercholesterolemia 8,720 (28.9%) 13,391(34.4%) 13,681 (32.9%) <0.001 
Angina 13,295 (43.3%) 18,415(46.9%) 17,549 (41.3%) 0.001 
Cerebrovascular disease 4,882 (15.8%) 6,138 (15.6%) 6,609 (15.7%) <0.001 
Peripheral vascular disease 1,940 (6.4%) 2,586 (6.8%) 2,900 (7.1%) <0.001 
Chronic renal failure 3,683 (11.9%) 4,481 (11.5%) 6,150 (14.7%) 0.04 
Diabetes 8,262 (27.2%) 11,098 (27.0%) 12,725 (29.1%) 0.001 
Hypertension 17,435 (56.7%) 22,268 (56.3%) 25,312 (59.0%) 0.001 
Smoking status    <0.001 
Previous smoker 12,271 (42.1%) 15,410 (40.4%) 15,987 (39.3%)  
Current smoker 4,283 (14.7%) 5,167 (13.5%) 5,782 (14.2%)  
Asthma / COPD 6,375 (20.9%) 8,436 (21.7%) 8,293 (19.9%) 0.001 
Family history of CHD 4,196 (18.5%) 5,454 (18.2%) 6,994 (20.1%) <0.001 
In-hospital Pharmacology     
Low molecular weight heparin 21,114 (70.2%) 26,352 (67.8%) 23,860 (61.2%) <0.001 
Warfarin 2,777 (9.4%) 2,884 (10.2%) 3,278 (8.7%) <0.001 
Loop Diuretic 13,701 (45.6%) 18,222 (47.7%) 17,807 (47.1%) <0.001 
Glycoprotein use 284 (1.0%) 295 (0.8%) 532 (1.4%) <0.001 
Discharge Medications     
186 
 
Aspirin 22,545 (85.2%) 29,370 (84.2%) 32,274 (88.2%) <0.001 
P2Y12 inhibitors 25,500 (78.9%) 32,900 (78.3%) 36,056 (81.1%) <0.001 
Statins 22,557 (88.2%) 30,344 (87.7%) 31,778 (88.3%) 0.04 
ACE inhibitors 18,751 (73.9%) 24,145 (70.7%) 25,068 (72.2%) <0.001 
Beta-Blockers 18,030 (69.7%) 24,514 (70.6%) 26,628 (74.7%) <0.001 
Outcomes     
Death 4,100 (12.6%) 5,048 (12.0%) 4,716 (10.5%) <0.001 
Cardiac mortality 3,077 (9.5%) 3,960 (9.4%) 3,737 (8.3%) <0.001 
Major bleeding 957 (3.0%) 612 (1.5%) 8,47 (2.0%) <0.001 
BMI= body mass index, bmp= beats per minute, GRACE= global registry of acute coronary events, 
COPD= chronic obstructive airway disease, ACE= angiotensin converting enzyme  
In the subgroup analysis looking at the utilisation of an invasive strategy and clinical 
outcomes in 100,898 high-risk NSTEMI patients (defined as GRACE score >140) 
21,226 (21.0%) were admitted to `no lab` hospitals, whereas 24,448 (24.3%) and 55,224 
(54.7%) to `diagnostic` and ‘PCI hospitals’ respectively. Out of the 24,448 admitted to 
`diagnostic` hospitals, 5,184 (21.2%) were transferred out to the nearest PCI hospital for 
an invasive strategy, whereas 19,264 (78.8%) were managed onsite at the first admitted 
diagnostic hospital. Patients transferred out to a ‘PCI hospital’ displayed a significantly 
worse baseline cardiovascular profile with increased prevalence of out of hospital 
cardiac arrest, electrographic changes, history of previous PCI or CABG, hypertension 
and current smoking status compared to those that remained and were managed in the 
diagnostic hospital. The patients who were treated onsite in `diagnostic` hospitals had a 
higher prevalence of non-cardiac comorbidities such as chronic renal failure, asthma or 
COPD, previous cerebrovascular accident and peripheral vascular disease. (Appendix 
Table 7) 
7.4.2 Temporal trends 
In the whole NSTEMI cohort, overall rates of invasive strategy increased from 50.8% to 
86.0% during the study period (Figure 7.2). While the number of ‘PCI hospitals’ 
increased from 87 to 99, the ‘diagnostic hospital’ declined from 70 to 56 whereas the 
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‘no lab hospitals’ almost remained constant from 74 to 78 from 2007 to 2015 (Figures 
7.3).  
Figure 7.2: Trends in utilisation of invasive strategy in England and Wales between 
2007-2015.  
 
Figure 7.3: Growth in Catheter lab facilities in England and Wales hospitals between 
2007-2015 
 
The utilisation of an invasive strategy in the form of CA or PCI increased across all the 
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86.0% and 85. 6%) (Figure 7.4). However, although receipt of PCI alone also increased 
across all hospitals during the study period it remained consistently lower in 
`diagnostic` hospitals compared to PCI hospitals and by 2015, was also lower compared 
to `no lab` hospitals (Figure 7.5). A similar pattern was seen for receipt of any 
revascularisation (composite of PCI or CABG) procedures in the patients admitted to 
`diagnostic` hospitals (Figure 7.6).  
Figure 7.4: Receipt of coronary angiography stratified according to hospital cardiac 





Figure 7.5: Receipt of percutaneous coronary intervention stratified according to 
hospital cardiac catheter laboratory facilities between 2007-2015. 
 
Figure 7.6: Receipt of percutaneous coronary intervention or coronary artery bypass 





7.4.3 Independent predictors  
Independent predictors of receipt of an invasive strategy in the form of CA and PCI are 
reported in Table 7.4. High-risk NSTEMI patients defined by GRACE score >140 were 
less likely to receive CA (OR 0.89 95%CI 0.83-0.95) or PCI (OR 0.84 95%CI 0.84-
0.94). Female sex and was also associated with reduced odds of receiving CA (OR 0.73 
95%CI 0.71-0.74) and PCI (OR 0.76 95%CI 0.75-0.77). Patients with prior history of 
PCI were more likely to receive CA (OR 1.28 95%CI 1.24-1.32) and PCI (OR 1.36 
95%CI 1.32-1.40). Receipt of cardiology care in the form of consultant cardiologist 
review as an in-patient was the strongest independent predictor of receipt of CA (OR 
6.09 95%CI 5.79-6.41) and PCI (OR 4.27 95%CI 4.01-4.55). Finally, compared to 
patients treated in `no lab` hospitals, the odds of receiving CA were greater for those 
treated at `diagnostic` (OR 1.14 95%CI 1.11-1.16) and PCI hospitals (OR 1.64 95%CI 
1.60-1.68). Conversely, the odds of receiving PCI were lower in `diagnostic` hospitals 
(OR 0.88 95%CI 0.86-0.90) but higher in PCI hospitals (OR 1.69 95%CI 1.66-1.73) 
compared to `no lab` hospitals.  
Table 7.4: Independent predictors of receipt of coronary angiography and percutaneous 
coronary intervention 
 Predictors of Receipt of 
CA 
Predictors of Receipt of 
PCI 
Variables OR (95% CI) OR (95% CI) 
GRACE risk Score (low-risk baseline)   
Intermediate (109-140) 1.17 (1.12-1.23) 1.09 (1.06-1.13) 
High (>140) 0.89 (0.83-0.95) 0.89 (0.84-0.94) 
Female Gender 0.73 (0.71-0.74) 0.76 (0.75-0.77) 
Age  0.94 (0.944-0.946) 0.97 (0.978-0.981) 
Previous acute myocardial infarction 0.65 (0.63-0.66) 0.70 (0.69-0.72) 
Previous coronary artery bypass grafting 0.92 (0.89-0.95) 0.99 (0.96-1.02) 
Previous percutaneous coronary 
intervention 
1.28 (1.24-1.32) 1.36 (1.32-1.40) 
History of angina 0.86 (0.84-0.88) 0.86 (0.84-0.88) 
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Hypertension  1.07 (1.05-1.08) 0.99 (0.97-1.07) 
Hypercholesterolemia  1.24 (1.22-1.26) 1.26 (1.23-1.28) 
Peripheral vascular disease 0.96 (0.92-0.96) 1.03 (0.99-1.07) 
Asthma/ COPD 0.94 (0.92-0.96) 0.99 (0.97-1.01) 
Chronic renal failure 0.73 (0.70-0.76) 0.88 (0.85-0.91) 
Heart failure 0.70 (0.68-0.73) 0.82 (0.79-0.85) 
Cerebrovascular accident 0.67 (0.65-0.68) 0.75 (0.73-0.77) 
Diabetes 0.84 (0.83-0.86) 0.86 (0.84-0.88) 
Left ventricular dysfunction    
Moderate  0.86 (0.83-0.89) 0.94 (0.92-0.96) 
Severe  0.67 (0.64 -0.70) 0.71 (0.68-0.74) 
Family history of coronary heart disease 1.33 (1.30-1.36) 1.23 (1.21-1.25) 
Seen by cardiologist  6.09 (5.79-6.41) 4.27 (4.01-4.55) 
Catheter laboratory facilities (ref=no lab)   
Diagnostic hospitals 1.14 (1.11-1.16) 0.88 (0.86-0.90) 
PCI hospitals 1.64 (1.60-1.68) 1.69 (1.66-1.73) 
 CA= coronary angiography, PCI= percutaneous coronary intervention, GRACE= global registry of acute   
 coronary events, COPD= chronic obstructive airway disease,  
 
7.4.4 Clinical outcomes 
Figure 7.7 illustrates unadjusted in-hospital outcomes stratified according to admission 
to the three different types of hospital. In-hospital mortality was lowest (10.5%) in PCI 
hospitals compared with `diagnostic` (12.0%) and `no lab` (12.6%) hospitals. After 
adjustment for differences in baseline clinical characteristics, no differences in-hospital 
mortality (OR 1.09 95%CI 0.96-1.24), cardiac mortality (OR 1.03 95%CI 0.90-1.18) or 
bleeding complications (OR 0.95 95%CI 0.73-1.23) were observed in ‘PCI hospital’ 
and ‘diagnostic hospital’ (in-hospital all-cause mortality (OR 0.93 95%CI 0.83-1.04), 
cardiac mortality (OR 0.95 95%CI 0.84-1.07) and bleeding (OR 0.99 95%CI 0.77-1.26) 
(Table 7.5). In the subgroup analysis of the high-risk NSTEMI patients with a GRACE 
score > 140, the odds of in-hospital mortality (OR 1.36 95% 1.06-1.75) and cardiac 
mortality (OR 1.28 95%CI 0.99-1.65) were higher but no difference in bleeding (OR 
0.96 95%CI 0.65-1.43) in `diagnostic` hospitals compared to `no lab` and PCI hospitals. 
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(Table 7.5). However, the sensitivity analysis of high-risk NSTEMI cohort showed that 
patients from ‘diagnostic hospitals’ receiving an invasive strategy onsite at the 
admitting hospital had significant increase in in-hospital mortality (OR 1.45 95%CI 
1.13-1.87) and cardiac mortality (1.35 95%CI 1.05-1.75) compared to those transferred 
to nearest PCI hospital, `no lab` and PCI hospitals. (Table 7.6) 
Figure 7.7: Unadjusted in-hospital outcomes stratified according to hospital cardiac 
catheter laboratory facilities 
 
Table 7.5: Association between different types of cardiac catheter laboratory facilities 




Ref ( no lab centres) 
Diagnostic hospitals 
Ref ( no lab centres) 
In hospital death 1.09 (0.96-1.24)p=0.17 0.93 (0.83-1.04)p=0.22 
Cardiac mortality  1.03 (0.90-1.18)p=0.61 0.95 (0.84-1.07)p=0.43 
Bleeding  0.95 (0.73-1.23), p=0.70 0.99 (0.77-1.26),p=0.95 
Clinical outcomes in patients with GRACE score >140 
In hospital death 1.10 (0.87-1.39)p=0.38 1.36 (1.06-1.75)p=0.01 
Cardiac mortality  0.94 (0.75-1.18)p=0.62 1.28 (0.99-1.65)p=0.05 




Table 7.6: Clinical outcomes in patients with high GRACE risk score > 140 receiving 
an invasive strategy onsite compared to those transferred to a PCI centre 
 
 
7.5 Discussion  
In this national analysis of patients admitted with a diagnosis of NSTEMI in England 
and Wales, patients admitted to hospitals with onsite cardiac catheter laboratory 
facilities have similar outcomes compared to those admitted at hospitals without such 
facilities. In high-risk NSTEMI patients (with GRACE score >140), admission to a 
diagnostic hospital was associated with an increased risk of in-hospital all-cause and 
cardiac mortality particularly in those receiving CA locally compared to those 
transferred to the nearest PCI hospital. This also analysis suggests that the presence of 
onsite catheter laboratory facilities was associated with increased utilisation of an 
invasive strategy, although paradoxically patients admitted to diagnostic hospitals were 
less likely to receive PCI or CABG compared to hospitals without onsite catheter 
laboratory facilities or PCI hospitals. These findings have important implications in 
developing regional treatment pathways for NSTEMI care to allow effective access to 
an invasive strategy. 
Several studies have reported the influence of on-site catheter laboratory 
facilities on invasive strategy in ACS patients
43,175,186-189,192,193
. Unsurprisingly, the 
majority of these studies show increased use of an invasive strategy in patients admitted 
Clinical outcomes  








In-hospital mortality  0.35 (0.21-0.51) 1.45 (1.13-1.87) 1.06 (0.84-1.33) 
Cardiac Mortality  0.40 (0.24-0.65) 1.35 (1.05-1.75) 0.90 (0.72-1.14) 
Bleeding  0.24 (0.12-0.47) 0.72 (0.43-1.20) 0.96 (0.65-142) 
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to hospitals with onsite cardiac catheter laboratory facilities. There are no data studying 
the relationship between the type of catheter laboratory facilities of the admitting 
hospital and receipt of an invasive strategy in an exclusively NSTEMI national cohort. 
The referral patterns and utilisation of an invasive strategy are likely to be different in 
NSTEMI patients, compared to STEMI patients where referral pathways are focussed 
on transfer to a PCI capable hospital for primary PCI and early reperfusion. In the 
current study, a uniform uptake in the use of CA in patients admitted with a diagnosis of 
NSTEMI in England and Wales independent of catheter laboratory facilities of the 
admitting hospital was observed, however, patients admitted to diagnostic hospitals 
were less likely to receive an invasive strategy in the form of PCI or CABG. This is 
likely to be due to selection bias and variation in referral patterns of the admitting 
hospital, as patients admitted to hospitals without any laboratory facilities are likely to 
be referred to a nearest tertiary hospitals with onsite PCI facilities
194
. In contrast, 
patients admitted to diagnostic hospitals receive CA locally before a decision about 
further revascularisation is made by the treating physician, who may not necessarily be 
an interventional cardiologist. Consequently, such patients may be potentially denied 
early access to guideline-recommended invasive strategies
3,4
. The lower rates of PCI 
and CABG in patients admitted to diagnostic hospitals suggests that in clinical practice, 
physicians are likely to adopt a risk-averse strategy even after obtaining information 
from CA particularly in patients admitted first to diagnostic hospitals.   
In this prospective observational cohort study of over 450,000 patients, there 
were no differences in in-hospital all-cause and cardiac mortality or bleeding 
complications and type of catheter laboratory facilities at the first admitting hospital. 
The effect of onsite site versus off site cardiac catheter laboratory facilities in ACS 
patients was compared in the GRACE registry showing that patients admitted to 
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hospital with onsite cardiac catheter laboratory facilities had similar outcomes as 
compared to those admitted to hospital without such facilities
188
. Similar findings were 
reported by the European Network of Acute Coronary Treatment (ENACT) and 
National Registry of Myocardial Infarction investigators showing no benefit of onsite 
cardiac catheter laboratory facilities on clinical outcomes in ACS
195,196
. To the best of 
my knowledge, this is the first study comparing association with different levels of 
hospital cardiac catheter laboratory facilities and clinical outcomes in an exclusive 
NSTEMI cohort. These findings also highlight important differences in institutional 
practices and treatment gaps, particularly in high-risk NSTEMI patients. In the high-risk 
NSTEMI cohort, patients admitted to diagnostic hospitals first were at increased risk of 
in-hospital all-cause and cardiac mortality, which may be related to a significantly lower 
use of invasive strategies in the form of PCI or CABG in these hospitals. We observed a 
similar mortality hazard in high-risk NSTEMI patients receiving CA onsite in 
diagnostic hospitals compared to those referred for CA to PCI hospitals from the 
diagnostic hospitals. Previous studies from international registries have shown that the 
use of invasive strategies is independently associated with improved survival in 
NSTEMI patients
21,197
. Ideally, hospitals treating these patients should be able to offer 
effective care and uniform access to CA and revascularisation as per guidelines 
recommendations. Therefore, regionalisation of care for NSTEMI patients whereby 
merging the diagnostic hospitals with PCI hospitals and direct referral of patients to PCI 
hospitals after appropriate risk stratification may translate into early, uniform access to 
an invasive strategy, better resource allocation and improved patient care
175,189
. 
Current guidelines emphasise an early invasive approach followed by revascularisation 
either in the form of PCI or CABG in patients with GRACE score ≥140 or other high-
risk features
3,4
. The results from this analysis indicate that patients presenting with high-
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risk features such as those with LV dysfunction, heart failure, history of diabetes and 
high GRACE score ≥140 were least likely to receive CA or PCI independent of the type 
of admitting hospitals. This finding is consistent with well-known treatment-risk 
paradox whereby patient who most likely to benefit from an intervention are least likely 
to receive it
198
. A recent individual patients’ level meta-analysis of eight RCTs 
including 5,324 patients found significantly lower mortality in high-risk patients such 
those with history of diabetes, age above 75 years and GRACE score ≥ 140 when 
treated with early invasive strategy
150
. Appropriate risk stratification, recognition of this 
paradox and development of quality improvement programmes are required to offer 
guidelines recommended treatment to patients presenting with high-risk features.  
7.6 Study strengths and limitations 
This analysis is subject to certain limitations that should be borne in mind whilst 
interpreting these findings. The follow-up data beyond hospital discharge was not 
available so only in-hospital outcomes were evaluated. However, previous studies have 
reported similar comparable outcomes at shorter and longer-term follow up in patients 
who were admitted to hospitals with or without cardiac catheter laboratory facilities in 
all ACS patients
43,186
. Although completion of mandatory data fields has improved 
considerably in MINAP over time, there was a significant amount of missing data in 
important variables such as LVEF and GRACE risk score that could have biased the 
estimates. However, in order to limit the influence of bias from missing data we 
implemented an imputation strategy as previously described and validated for use in this 
registry
88
. Finally, the observational nature of the study is susceptible to unmeasured 
confounding and only associations rather than causal relationships can be inferred.  
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7.7 Conclusion  
In this large, contemporary analysis from a national healthcare system, there were 
significant disparities in utilisation of an invasive strategy, which is influenced by the 
type of cardiac catheter laboratory facilities of the admitting hospital. This study serves 
to highlight important differences in institutional practices and treatment gaps whereby 
high-risk NSTEMI patients admitted to diagnostic hospitals were less likely to receive 
an invasive strategy in the form of PCI or CABG and were at increased risk of in-
hospital mortality. These differences in the care of NSTEMI may be improved by 
developing a stronger network of a regional system of care with transfer algorithms and 






Chapter 8  
 
 
Appropriate radial access site selection and clinical outcomes in the use of invasive 
strategy in ACS 
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8.1 Introduction  
The previous chapters in this thesis systematically studied the use of invasive strategy 
amongst different groups of patients admitted with a diagnosis of NSTEMI, the timing 
of an invasive strategy, the independent predictors of invasive strategy and hospital 
factors such as the presence of cardiac catheter laboratory facilities. Given the central 
role of an invasive strategy in the management of NSTEMI patients, it is important to 
understand if there are any procedural aspects of an invasive strategy that may influence 
the clinical outcomes of patients, and in particular access site choice. Therefore, this 
chapter focuses on access site selection and clinical outcomes in patients that underwent 
PCI in the UK. The findings from this chapter were published in the Journal of 
American College of Cardiology (JACC): Cardiovascular Interventions
199
. Furthermore, 
the manuscript was selected as Continued Medical Education (CME) choice by the 
editor and was awarded CME points by the editorial board for the accompanying CME 
questions (appended in chapter 10). There was also an editorial to highlight the 
importance of this work (Appendix 10.3) 
The radial artery is now the most common vascular access site utilised for percutaneous 
coronary interventions (PCI) across many European
4
, Canadian and South Asian 
countries 
200,201
 and continues to gain popularity in the US 
202,203
. According to most 
recent audit figure published by British Cardiovascular Intervention Society (BCIS), the 
transradial access (TRA) is now being used in almost 90% of patients undergoing PCI 
procedures in the UK and similar surge in use of TRA has been noted in the USA where 
use of TRA has increased fourfold to almost 40% in the last 5 years
204,205
. The main 
advantages of transradial access (TRA) over transfemoral access (TFA) include a lower 
incidence of vascular complications, significant reductions in major bleeding, a lower 
rate of MACE and, in some settings, death 
72,73,206
 as well as earlier ambulation, shorter 
200 
 
hospital stay and greater patient satisfaction 
207,208
. The most recent guidelines from the 
European Society of Cardiology also emphasis on the use of TRA with class 1A 
indication
15
. Most radial operators use the right radial access (RRA) as their initial 
access site due to the ease of working on the right hand side of the patients and catheter 
lab setup 
63
. However, radial operators may need to switch to the left side in the event of 
radial artery spasm 
74
, radial artery occlusion 
75
, the presence of arteriovenous shunt in 
the right arm, or presence of extreme tortuosity in the right forearm or right subclavian 
artery 
209,210
. Left radial access (LRA) also offers much more favourable vascular 
anatomy compared to RRA particularly in short stature patients or those with previous 
coronary artery bypass grafts resulting in lesser catheter manipulation, shorter procedure 
time and a theoretically smaller risk of procedure related stroke
79,211-213
. However, lack 
of training dedicated cardiac catheter lab equipment and increase operator discomfort 
particularly in the early stages is a significant limitation in the use of LRA and has 
limited the use of LRA to selected cases in clinical practice. This has also meant that 
many operators will switch to a default femoral approach when right radial access is not 
possible, with inherently worse outcomes such as the increased risk of major bleeding 
and vascular access site complications.  
Data from published studies comparing the RRA versus LRA have only compared the 
procedural efficacy such as procedure time, contrast use, fluoroscopy time and 
crossover to femoral access reporting conflicting results
212,214
. The TALENT study 
investigators randomised 1,540 patients in two hospitals to RRA or LRA for either 
diagnostic coronary angiography or PCI. The primary endpoint was fluoroscopy time 
for diagnostic coronary angiography and for PCI measured independently for each 
group. In the diagnostic group, LRA was associated with lower fluoroscopy time and 
lower dose area product (a surrogate of radiation exposure to the patient); however, 
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there were no differences in either of these primary endpoints in patients undergoing 
PCI
215
. Another study comparing RRA versus LRA for primary endpoints of radiation 
exposure and operator discomfort reported decreased radiation exposure to the operators 
in the LRA group albeit at the expense of increase operator discomfort 
79
. The majority 
of these studies were limited to single centres and small sample sizes, therefore, one 
cannot determine whether there are any clinically relevant differences between either 
access site. Very importantly, there is no data comparing clinical outcomes such as in-
hospital, 30-day mortality and procedural related complications such as access site 
complications or peri-procedural stroke in LRA versus RRA.  
As the population requiring PCI grows and ages, it is likely that LRA will become 
commonplace for performing CA or PCI. There are few data that describe the 
differences in patient and clinical characteristics relating to the use of LRA compared to 
RRA, whether this practice is changing over time nationally, how multiple successive 
procedures influence the use of LRA or importantly whether the use of LRA is 
associated with different risks to patients. This study used a large national registry of all 
PCI procedures to answer these questions.  
8.2 Objectives 
The main objectives of this chapter were as follows 
I. To compare the clinical and procedural characteristics of patients receiving LRA 
versus RRA. 
II. To study the temporal trends in the use of LRA and RRA 
III. To examine changes in access site practice in patients undergoing successive 
procedure after the first RRA procedure. 





8.3.1 Study design  
This observational study was a retrospective analysis of a prospectively collected data in 
the British Cardiovascular Intervention Society (BCIS) registry.  
8.3.2 Study population  
The data from the British Cardiovascular Intervention Society (BCIS) registry was used 
to define the patient cohort and study variables. Full details of BCIS registry, strengths 
and limitations are provided in chapter 3. Briefly, the BCIS registry is a national 
registry that prospectively collects data around the clinical, procedural and outcome of 
almost all PCI undertaken in the United Kingdom and is managed by the National 
Institute of Cardiovascular Research Outcome (NICOR)
68,82,216
. All cause-mortality 
outcomes are robustly tracked via a linkage to the Office of National Statistics (ONS) 
using the unique national health system (NHS) number of all patients in England and 
Wales only. All data collected in the BCIS registry are a part of a national audit 
initiative by NICOR and are anonymised with no patient identifiable information 
provided to the researcher in the dataset; therefore, ethical approval was not required for 
this study. The initial cohort selection was made by including all patients undergoing an 
invasive strategy in the form of at least one PCI via either RRA or LRA in the United 
Kingdom, however, as the out of hospital mortality data is not available for patients in 
Scotland, therefore they were excluded from the outcome analyses. Patients with 
femoral, brachial, multiple, unknown or missing access site information were excluded. 
Further data restrictions were applied to patients with missing information around age 
and gender. For the outcomes analysis, the patients with missing information on 
mortality or in-hospital complications were also excluded from the analysis.  
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8.3.3 Study outcomes 
The primary endpoints were in-hospital and 30-day mortality, in-hospital major 
bleeding (defined as a composite of blood or platelet transfusion, intracerebral 
haemorrhage, retroperitoneal haemorrhage, bleed resulting in cardiac tamponade, or an 
arterial access site bleeding requiring surgery or intervention), in-hospital Major 
Adverse Cardiovascular Events (MACE defined a composite of in-hospital mortality, 
in-hospital myocardial infarction or re-infarction and revascularization in the form of 
emergency PCI or CABG) and In-hospital Stroke complications (defined as 
haemorrhagic, ischemic, embolic stroke or transient ischemic attack). All the in-hospital 
complications are operator reported and not adjudicated independently. 
8.3.4 Study covariates  
In addition to the information around clinical outcomes and complications, further data 
were collected on each patient’s baseline demographics such as age, gender, ethnicity, 
clinical and cardiovascular risk profile, indication for PCI, and all other aspects of 
interventional and pharmacological treatment administered. In order to explore the 
access site practice in patients undergoing repeat PCI in successive procedures in the 
dataset, a sub-group analysis of patients with RRA procedure as their first procedure 
was undertaken. The access site at each subsequent procedure was tracked to see how 
the access site selection changes in patients having first procedure via RRA. The RRA 
was selected as the first access site because it is most widely practised radial access.  
8.3.5 Statistical analysis  
First, the characteristics were compared between patients with RRA and LRA used in 
the first procedure. Analysis of variance (ANOVA) for continuous variables and 
Fisher’s exact tests for binary/categorical variables were used. The independent 
predictors of use of LRA were determined to use multivariable logistic regression 
204 
 
(MLR), model. This predictive analysis was undertaken using a backward stepwise 
approach by including all the variables and potential confounders in the MLR and then 
removing the variables with significance above the defined threshold of (p>0.011).  
In order to protect against the biases arising from informative missing data mechanisms, 
multiple imputations with chained equations framework were used to impute for all 
variables with missing information. The patients with missing information on mortality 
outcomes were excluded before the imputation since the inclusion of these cases in the 
imputation model makes no difference
89
. Complete variables registered in the 
imputation model were age, sex, access site and study outcome variables and imputed 
variables were indication for PCI, previous AMI, previous CABG, history of diabetes 
mellitus, peripheral vascular disease, previous PCI, hypercholesteraemia, hypertension, 
cerebrovascular accident, renal disease, body mass index, left ventricular systolic 
function, smoking status, mechanical ventilation, use of intra-aortic balloon pump, 
pharmacological inotropic support, use of GP2b3a inhibitor, Ticagrelor, Prasugrel, 
bivalirudin, PCI to left main stem, multi-vessel PCI, cardiogenic shock, stent use and 
operator status.  
The final analyses were run on the 10 datasets generated under the multiple imputation 
framework. The approach can deal with data missing completely at random (MCAR) or 
on missing at random (MAR), and not necessarily missing not at random (MNAR) 
scenarios, while levels of missingness are high for certain variables. However, it has 
been previously illustrated that multiple imputation frameworks are robust even with 
high levels of missingness and can offer some protection with MNAR data as discussed 
in detail in chapter 3
89
. MLR modelling was used for risk estimation of all outcomes 
across both groups, adjusting for age, sex and all the other variables included in the 
multiple imputations. To account for any systematic differences in the baseline 
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characteristics between the two groups, multiple imputations with propensity score 
matching were used to calculate the average treatment effects using the same variables 
as in our main MLR model. The coefficients were converted to odds ratio to aid 
interpretation under assumptions for right radial access risk presented in Table 8.1. 
Finally, although it is technically possible to undertake PCI procedure in patients with 
previous CABG via the RRA, it is common practice to use LRA in these patients as the 
left internal mammary artery (LIMA) graft can be easily cannulated with a catheter 
from the LRA. Therefore, in order to minimise selection bias in the LRA group, we 
performed a sensitivity analysis by excluding patients with a previous history of CABG 
(Appendix Table 7-10). In order to study the regional variations in the use of LRA 
across primary care trusts and healthcare boards in England, Scotland and Wales, 
proportions of LRA procedures per year were calculated for each area from the BCIS 
dataset. Each patient’s data was then mapped to geographic information system primary 
care trust layers accessed from NHS England, Scotland and healthcare board across 
NHS Wales to create choropleth maps of patients receiving LRA procedure using the 
spmap function in Stata. 
8.4 Results  
8.4.1 Patient and hospital characteristics 
There were 343,725 patients undergoing PCI using radial access during the study period 
from which 328,495 (96%) were undertaken through the RRA and 14,311(4%) via the 
LRA (Figure 8.1). The relationship between different demographic characteristics and 
LRA use are illustrated in Figures 8.2-8.6. It can be seen that LRA PCI was undertaken 
in Asians (27.9% n=1854) far more than in Caucasians (4.2% n=228,908) and other 
ethnic groups (Figure 8.2). Similarly, LRA access was used relatively common in 
patients with a previous history of CABG (23.4% vs 3%) (Figure 8.3). In contrast, LRA 
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access was used infrequently for patients requiring PCI for STEMI indication compared 
to elective PCI (1.8% vs 5.5%). Finally, there was a strong inverse relationship between 
height and the use of LRA access with 6.8% of procedures undertaken via the LRA in 
short stature patients (height <150cm) compared to only 3.4% in taller patients (height 
>190cm).  
  












Total PCI performed in United Kingdom from 
2007-2014 
                                  n= 669279 
                   Procedures via radial access 
                                 n=342806 
Missing information on 
gender = 529 & age= 390 
 
Procedures via left radial 
access   n= 14311 
Total procedure via radial access from 2007-
2014                      n= 343725 
Procedure via femoral, 
brachial, ulnar access = 
325554 
 
Procedures via right radial 
access   n= 328495 
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Figure 8.2: Left Radial access use by Ethnicity 
 
Figure 8.3: Left Radial access use by the history of CABG 
 
















































































Indication for PCI 
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Figure 8.5: Left Radial access use by the patient’s height. 
 
Table 8.1 shows the demographics, cardiovascular risk profile, procedural 
characteristics and crude outcomes differences across the two groups. Patients in the 
LRA group were older and had a higher risk baseline cardiovascular profile, with an 
increased incidence of diabetes (27.7% vs 18.2%, p<0.001), hypertension (64.8% vs 
52.7%, p<0.001), history of previous cerebrovascular event (CVA) (7.4% vs 4.0%, 
P<0.001), acute myocardial infarction (47.6% vs 24.4%, p<0.001), coronary artery 
bypass grafting (CABG) (33.2% vs 4.9%, p<0.001) and peripheral vascular disease 
(PVD) (12.8% vs 4.5%, p<0.001). Patients in the RRA access group received more 
aggressive pharmacotherapy with a higher use of Ticagrelor (7.7% vs 6.8%, p<0.001), 
Prasugrel (5.5% vs 3.6%, p<0.001), Glycoprotein 2b3a inhibitors (25.0% vs 16.7%, 
p<0.001) and bivalirudin (4.4% vs 1.9%, p<0.001). From the operator skill perspective, 
more trainees were likely to undertake LRA procedures compared to consultants (34.0% 
vs 31.2%, p<0.001). Missing data information about each variable is provided in 




































































Table 8.1 Baseline characteristics and procedural details of patients undergoing left and 
right radial percutaneous coronary intervention in the United Kingdom 







Age (y), mean (SD) 63.8±11.8 66.2±11.0 <0.001 
Male, n(%) 249,974 (76.1%) 10,572 (73.9%) <0.001 
BMI mean, (SD) 28.5±5.16 29.1±5.61 <0.001 
Hypercholesterolemia (%) 167,993 (54.3%) 8,995 (66%) <0.001 
Hypertension (%) 163,160 (52.7%) 8,840 (64.8%) <0.001 
Diabetes (%) 57,616 (18.2%) 3,848 (27.7%) <0.001 
Previous CABG (%) 11,169(4.9%) 3,413 (33.2%) <0.001 
Previous CVA (%) 12,463 (4.0%) 1,014 (7.4%) <0.001 
Peripheral vascular disease (%) 14,003 (4.5%) 1,747 (12.8%) <0.001 
Previous AMI (%) 75,204 (24.4%) 6,393 (47.6%) <0.001 
Previous PCI (%) 63,413 (19.9%) 5,413 (39%%) <0.001 
LVSD (%) 53,320 (30.1%) 3,058 (36.0%) <0.001 
Smoking (%)   <0.001 
Never smoked 107,671(35.9%) 4,480(34.2%)  
Current smoker 82,931(27.6%) 2,658(20.2%)  
Ex-smoker 109,457(36.4%) 5,961(45.5%)  
Renal Failure (%) 2,293 (0.74%) 215 (1.6%)  
Indication for PCI   <0.001 
Stable Angina (%) 112,998 (34%) 6,508(46.1%)  
STEMI (%) 82,872 (25.7%) 1,500 (10.6%)  
UA/NSTEMI 129,269 (39.6%) 6,100 (43.2%)  
Operator status   <0.001 
Consultant  200,251 (68.7%) 8,380 (65.9%)  
Trainee 91,083 (31.2%) 4,331 (34.0%)  
Multi vessel PCI (%) 43,685 (13.5%) 2,063 (14.6%) <0.001 
Cardiogenic Shock (%) 3,874 (1.84%) 165 (2.2%) 0.02 
Pharmacological Inotropes 1.246 (0.4%) 69 (0.5%) 0.05 
Intra-aortic balloon pump device 
(%) 
2,122 (0.6%) 80 (0.6%) 0.19 
Left main stem PCI (%) 9,216 (2.85%) 892 (6.3%) <0.001 
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Mechanical ventilation (%) 2,484 (0.9%) 179 (1.4%) <0.001 
PCI to Grafts 5,166 (1.6%) 2,216(15.7%) <0.001 
Chronic total occlusion PCI 17,553 (5.7%) 897 (6.7%) <0.001 
Stent Use    <0.001 
No Stents (%) 21,180 (6.7%) 1,495 (10.8%)  
BMS only (%) 63,479 (20%) 2,236 (16.2%)  
DES only (%) 222,017 (70.0%) 9,632 (70.0%)  
BMS & DES (%) 10,203 (3.2%) 385 (2.8%)  
Bivalirudin (%) 13,316 (4.4%) 249 (1.9%) <0.001 
GP2b3a use (%) 77,681 (25.0%) 2,248 (16.7%) <0.001 
Ticagrelor (%) 23,271 (7.7%) 900 (6.8%) <0.001 
Prasugrel (%) 16,647 (5.5%) 484 (3.6%) <0.001 
Warfarin (%) 3,418(1.1%) 375 (2.8%) <0.001 
Length of stay (days), median 
(IQR) 
1 (0-2) 1 (0-1) <0.001 
In hospital death (%) 2,206 (0.7%) 120 (0.9%) 0.01 
MACE (%) 4,234 (1.33%) 225 (1.62%) 0.004 
Major Bleeding (%) 1,305 (0.41%) 75 (0.54%) 0.02 
In hospital Stroke 363 (0.11%) 11 (0.08%) 0.230 
30-day mortality (%) 3,881 (1.47%) 211 (1.88%) <0.001 
MACE=major adverse cardiovascular events defined as composite of in-hospital mortality, in-hospital 
myocardial infarction or re-infarction and revascularization- emergency percutaneous coronary 
intervention or CABG, LVSD= left ventricular systolic dysfunction, CABG= coronary artery bypass 
grafting, AMI= acute myocardial infarction, PCI= percutaneous coronary intervention, GP2b3a= 
glycoprotein 2b3a. 
8.4.2 Temporal trends 
Use of LRA access increased modestly from 3.2% (n=527) in 2007 to 4.6% (n=3110) in 
2014 (Figure 8.6). Temporal changes and regional variation in LRA practices are 
depicted in Figures 8.7-8.8 showing a significant heterogeneity in the use of LRA 
access amongst different primary care trust areas across Scotland, England and Wales. 
During the study period, the highest proportions of LRA procedures were undertaken in 
England with some areas performing almost 20% of their radial procedures via the 
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LRA, whereas the use of LRA access was sporadically low in Scotland (10%) and 
Wales (7%). 
Figure 8.6: Use of left radial access from 2007 to 2014 in the United Kingdom 
 
Figure 8.7: Overall proportions of left radial access procedures across different primary 
care trusts in the United Kingdom. 




















































Figure 8.8: Proportions of left radial access procedures across different primary care 




8.4.3 Access site switch in successive procedures 
During the study period, 35,388 patients from the radial cohort had more than one 
successive PCI procedures. RRA was used in 33,956 patients at their index PCI whereas 
1,432 patients had their first PCI using LRA. In patients receiving their first PCI using 
RRA, subsequent successful RRA PCI was only possible in 72% of the patients. 
Notably, the majority of the switch from RRA was to femoral (23.5%) access instead of 
LRA (4.5%). However, LRA remained relatively stable between 4.5% to 6% at four or 
more procedures (Figure 8.9). The patterns of access site switch during successive 
procedures based on gender (male versus female) and age (age>75 vs age <75) was also 
studied. It appeared that females were less likely to undergo a subsequent procedure 
through the RRA approach compared to males (Figure 8.10-8.11). For example, almost 
30% of female had their access site changed to TFA compared to only 19% in males at 
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the ≥4 PCI procedure. Similar trends were observed in the elderly age≥75 who were 
again more likely to have their access site switched to femoral instead of LRA at each 
successive procedure compared to their younger counterparts, aged <75. (Figure 8.12-
8.13).  
Figure 8.9: Access site switch in patients undergoing repeat percutaneous coronary 
intervention after right radial access in the United Kingdom 
 
Figure 8.10: Access site switch in males undergoing repeat percutaneous coronary 
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Figure 8.11: Access site switch in females undergoing repeat percutaneous coronary 
intervention after right radial access in the United Kingdom 
 
Figure 8.12: Access site switch in patients age < 75-year undergoing repeat 




























Figure 8.13: Access site switch in patients age > 75-year undergoing repeat 
percutaneous coronary intervention after right radial access in the United Kingdom 
 
8.4.4 Independent predictors  
The independent predictors of LRA at any time are reported in Table 8.2. It was found 
that previous CABG (OR 9.32 95%CI 7.72-11.24 P<0.001), PCI to vein graft (OR 2.10 
95%CI 1.61-2.74 p<0.001), renal failure (OR 2.65 95%CI 1.63-4.30), mechanical 
ventilation (OR 2.61 95%CI 1.64-4.15 p<0.001), peripheral vascular disease (OR 1.81 
95%CI 1.48-2.22 p<0.001), previous AMI (OR 1.29 95%CI 1.11-1.51 p<0.001), female 
sex (OR1.27 95%CI 1.10-1.46 p<0.001) and repeat PCI (OR 1.09 95%CI 1.05-1.35 
p<0.006) were strong independent predictors of LRA access.  
Table 8.2: Predictors of Left radial access 
Predictors Odds ratio (95%CI) p-value 
Previous CABG 9.32 (7.72-11.24) <0.001 
Female  1.27 (1.10-1.46) <0.001 
Repeat Procedures 1.09(1.05-1.35) <0.006 
Previous AMI 1.29 (1.11-1.51) <0.001 















Mechanical ventilation  2.61 (1.64-4.15) <0.001 
PCI to vein graft 2.10 (1.61-2.74) <0.001 
Renal Failure 2.65(1.63-4.30) <0.001 
CABG= coronary artery bypass grafting, AMI= acute myocardial infarction, PCI= percutaneous coronary 
intervention 
8.4.5 Clinical outcomes 
Crude MACE (1.6% n=225 vs 1.3% n= 4234, p=0.004), in-hospital (0.9% n=120 vs 
0.7% n=2,206, p=0.01) and 30-day mortality (1.9% n=211 vs 1.5% n=3881, p<0.001) 
rates were significantly higher in the LRA group but there were no differences in stroke 
and bleeding complications (Table 8.1). In the MLR analysis after adjustments for all 
the baseline differences in clinical and procedural characteristics and other potential 
confounders (Table 8.3), there were no differences between use of either access site and 
clinical outcomes, in-hospital death (OR 1.19 95% CI 0.90-1.57, p= 0.20), 30-day 
mortality (OR 1.17 95%CI 0.93-1.74, p=0.16), MACE (OR 1.06 95%CI 0.86-1.32, 
p=0.56), in-hospital stroke complication (OR 0.45 95%CI 0.16-1.26, p=0.13) and major 
bleeding (OR 1.22 95%CI 0.87-1.77, p=0.24). Notably, in the propensity score 
matching analysis (Table 8.4), LRA was associated with a significant decrease in in-
hospital stroke risk (OR 0.52 95%CI 0.37-0.82, p=0.005) whereas all the other 
outcomes results were consistent with the MLR analysis.  
Table 8.3: Adjusted outcomes following Left radial versus right radial access 
Clinical outcome Odds ratio (95%CI) p-value 
In hospital death 1.19 (0.90-1.57) 0.20 
Major bleeding  1.22 (0.87-1.71) 0.24 
In hospital stroke 0.45 (0.16-1.26) 0.13 
MACE 1.06 (0.86-1.32)  0.56 
30- day mortality  1.17 (0.93-1.47)  0.16 
MACE=major adverse cardiovascular events defined as a composite of in-hospital mortality, in-hospital 
myocardial infarction or re-infarction and revascularization- emergency percutaneous coronary 




Table 8.4 Propensity score matching analysis on 10 imputed datasets, reporting average 
























152,956 -0.001045 -0.001858 -0.00232 0.52 (0.37-
0.82) 
0.005 





131,778 -0.009475 -0.003708 0.022658 1.33 (0.31-
2.37) 
0.15 
MACE=major adverse cardiovascular events defined as composite of in-hospital mortality, in-hospital 
myocardial infarction or re-infarction and revascularization- emergency PCI or CABG 
 
For sensitivity analysis, patients with the previous history of CABG were excluded 
from the dataset. The baseline characteristics and differences in procedural and in-
hospital pharmacology were compared in patients undergoing RRA and LRA 
respectively. Similar to the main analysis, the patients receiving LRA PCI procedure in 
this subgroup were older, had increased prevalence of cardiovascular risk factors such 
as hypertension, diabetes, previous CVA, previous AMI, previous PCI and peripheral 
vascular disease (Appendix tables 8). The adjusted outcomes in this subgroup are 
reported in Appendix Table 9, showing no differences in clinical outcomes in patients 
receiving LRA compared to RRA PCI procedures. Finally, the multivariable predictive 
analysis again showed that female sex (OR 1.01 95%CI 1.0.-1.01, p<0.001), repeat 
procedure (OR 1.30 95%CI 1.22-1.37, p<0.001), previous AMI (OR 1.77 95%CI 1.65-
1.90, p<0.001), peripheral vascular disease (OR 2.02 95%CI 1.84-2.21, p<0.001), 
mechanical ventilation (OR 2.09, 95%CI 1.71-2.56, p<0.001) and renal failure (OR 
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1.57, 95%CI 1.26-1.95, p<0.001) were strong independent predictors of LRA use 
(Appendix Table 10). 
8.5 Discussion  
To best of my knowledge, this is the first study describing the patterns of radial access 
use from a national perspective over a period where access site practice has transitioned 
to predominantly transradial in the United Kingdom. There are several important 
findings from this study. Firstly, these results show that use of LRA has modestly 
increased over time in UK practice and is used more often in females, the elderly, Asian 
ethnicity, patients with a previous history of CABG and short stature patients. 
Furthermore, the patients receiving LRA were multimorbid with a significantly higher 
prevalence of cardiovascular comorbidities and receiving less potent in-hospital 
pharmacology. Secondly, in patients undergoing repeat PCI, over one third of the 
patients (28%) had access site switched from RRA at each successive procedure to 
mainly femoral access with only a minority undergoing procedures through the 
contralateral arm (LRA). Finally, in the main MLR analyses, complications with LRA 
access were similar to those seen with RRA access with no difference in in-hospital or 
30-day mortality, in-hospital MACE or major bleeding complications, although there 
was a significantly decreased odds of in-hospital stroke following PCI using the LRA 
approach in the propensity matched cohort. 
In line with best available evidence from randomised trials, national bodies recommend 
the use of TRA instead of TFA access with the most recent guidelines placing a class 
1A indication on the use of TRA
15,217,218
. RRA access is more commonly practised by 
radial operators because of ergonomics of the cardiac catheter lab, previous training 
experience and increased operator discomfort due to the need of having to bend over to 
the left side in patients requiring an LRA procedure. On the other hand, a recent meta-
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analysis of 12 prospective randomised trials enrolling 6,450 patients confirmed that 
LRA access provides more favourable anatomy for catheter manipulation and coronary 
engagement translating into a small but statistically significant reduction in fluoroscopy 
time and contrast use
212
. Despite the advantages of offering similar anatomical 
considerations applicable to the TFA access even early in the training
215
, uptake of LRA 
access remains low, although there has been a marginal increase over time in the UK 
(3.2% to 4.6% during the period of this study). There was significant heterogeneity in 
LRA usage across different regions of England, Scotland and Wales. The proportions of 
radial procedures undertaken via the LRA varied from as low as 0.5% to 20% in 
England, from 2.3% to 6.9% in Wales and 0.3% to 10.2% in Scotland showing a wide 
variation in uptake of LRA in clinical practice. In addition to the difference in patient’s 
demographics, this variation in practice may be related to local culture, the operator’s 
previous training experience and personal preference to adapt to innovations in 
procedural skills. In this analysis, trainees were more likely to use LRA compared to 
consultants and this exposure to using the contralateral arm for PCI may persist beyond 
the training stages. Whilst investigating the independent predictors of LRA usage in the 
multivariate predictive analysis, it was found that a history of previous CABG and PCI 
to a vein graft were the strongest predictors of LRA use. The most likely explanation for 
this is that LRA offers better access to grafts in patients with previous CABG compared 
to RRA and in some cases to TFA. Similarly, factors that are associated with an 
increased risk of radial artery spasm and access site failure such as female gender, 
repeat procedure and history of peripheral vascular disease were significant predictors 
of LRA use. Previous studies have reported that the anatomical course of the radial 






The study also describes the access site practice in patients undergoing repeat PCI and 
found that when RRA is used at the first procedure, future use of the RRA for PCI drops 
by 28% overall, by 35% in females and 27% in patients aged >75 at a second procedure 
with a concomitant increase mainly in the use TFA access but with a slight increase in 
LRA usage. Although success rates and complication rates of repeat transradial access 
have been described in small case series from single centres 
219-221
, the utility of 
different radial access has not previously been reported at a national level. For example 
in an early series from Japan, Sakai et al described that the failure rate of repeat radial 
access was approximately 16% in male and 30% in women
221
. More recently published 
data from a high volume radial centre illustrated that TRA access can be safely 
attempted in about 60% of cases for up to 10 procedures 
219
. Progressive luminal 
narrowing and radial artery occlusion are known to occur following transradial access 
and may limit the use of ipsilateral radial access for a repeat procedure
75,222
. This study 
shows a higher switch rate of an RRA approach in elderly and female patients with a 
concomitant increase in the use of TFA and LRA access. It is possible that the higher 
switch from RRA to TFA was observed because the subsequent procedure was 
undertaken by a femoral operator instead of a radial operator. However, this analysis is 
from an era where more than 80% of the PCIs in the United Kingdom are undertaken 
via TRA and most femoral operators have switched their access site practice to from 
TFA to TRA, which may suggest that this is less likely 
68
. The key messages from these 
findings are that although repeat RRA access can safely be performed in the majority of 
cases, alternative access is used in a significant number of patients and currently, a 
transfemoral approach is undertaken more commonly than the contralateral radial 
artery, particularly in elderly and female patients. Given the established advantages of 
radial access in terms of reducing major bleeding and access site complications, there 
222 
 
may be benefits in using the LRA access site as the default in such circumstances. 
These observations also have important implications for training. Trainees should be 
exposed to LRA early in their training so that the potential benefits of TRA access can 
still be offered in the event of RRA failure.  
Finally, in the clinical outcome analysis, there were no statistically significant 
differences between the use of the LRA and RRA and in-hospital or 30-day mortality, 
in-hospital major bleeding and MACE. However, statistically non–significant decreased 
odds of in-hospital stroke (OR 0.45 95%CI 0.16-1.26, p=0.13) were observed in the 
main MLR analysis albeit with wide confidence intervals that may reflect the low event 
rate, with a similar significant risk reduction in our propensity score matched cohort that 
was statistically significant (OR 0.52 95%CI 0.37-0.82, p=0.005). A number of previous 
studies have reported on procedural outcomes of LRA versus RRA showing that LRA 
offers a small advantage over RRA in terms of lower fluoroscopy time, radiation dose 
and contrast use 
79,212,214,215,223
. There is very little information on the association of 
LRA or RRA with clinical outcomes
212,215
. There is a large body of evidence confirming 
the advantages of radial over femoral access in reducing major bleeding, vascular access 
site complications and MACE translating into mortality benefit as discussed before. 
With RRA access, the anatomical variations such as increased incidence of tortuosity 
and loops in the arm and subclavian artery may require extra catheter manipulation. 
Additionally, during RRA access the catheter needs to be passed from the innominate 
artery into the ascending aorta where the right carotid comes off resulting in a 
theoretically increased risk of embolization of plaque into the right carotid artery 
resulting in an embolic stroke. In contrast, LRA access offers very similar anatomy to 
the TFA approach as the left common carotid artery arises directly from the aortic arch. 
This analysis suggests that LRA access may be associated with a lower stroke risk than 
223 
 
the RRA and possible mechanisms behind this effect may relate to the anatomical 
reasons outlined above. Given that stroke is a relatively rare event
224,225
, whilst there 
was a signal observed, we estimate that an operator would need to undertake 1,818 PCI 
procedures through the LRA to avoid 1 stroke (in comparison to RRA use). Given low 
event rates, it is unlikely that a randomised controlled trial will ever be adequately 
powered to investigate this further. Hence, this study for the first time in literature 
provides mechanistic insight into minimising a devastating complication of PCI 
procedure.  
8.6 Study strengths and limitations 
This study offers several key messages albeit with some limitations. This study 
illustrates the patterns of left and right radial access over almost a decade in a national 
registry. In addition to studying the independent predictors of LRA usage, the 
association between the use of LRA or RRA with clinical outcomes was also 
investigated in the national population. One of the limitations of the BCIS dataset is that 
it does not collect information around procedure outcomes such as fluoroscopy time, 
procedure time, contrast use and operator or patient radiation dose, therefore differences 
between procedural outcomes could not be reported. However, as mentioned earlier, 
data from randomised control and subsequent meta-analysis shows that LRA is 
associated with better procedural outcomes compared to RRA. Secondly, data around 
access site attempt and failure and crossover to the contralateral radial artery is not 
captured which makes it difficult to ascertain if the access was used as the primary 
default access or because of failure to cannulate the contralateral artery for other 
reasons. Furthermore, the BCIS registry only started collecting operator level data from 
the last two years of this study period; hence it was not possible to study the impact of 
operator volume or personal experience on the use of LRA. Therefore, the analysis was 
224 
 
limited to patient level data. Consequently, changes in access site practice in patients 
undergoing repeat PCI may actually reflect differences in operator practice. Finally, 
these findings are observational in nature and a possibility of biases from unmeasured 
confounders may have contributed to the results 
8.7 Conclusion  
Using a large and unique national PCI registry, I have shown that LRA access provides 
a safe and effective alternative access site choice compared to the RRA. There is 
significant variation in the use of the LRA across different health care regions in the UK 
with higher proportions of LRA PCI being undertaken in England compared to Wales 
and Scotland regions. In patients undergoing repeat PCI, although TRA access was 
safely used in about two thirds of patients, a change to a predominantly TFA approach, 
particularly in females and elderly patients, was used in up to one third of patients 
despite established advantages of radial access in this high-risk group. Finally, an 
important signal was observed in that the LRA access may be associated with a reduced 
risk of stroke compared to the RRA. Future efforts need to focus on education and 










9.1 Introduction  
This PhD thesis investigated the use of an invasive strategy in the form of either 
coronary angiography or PCI in the management of patients admitted with a diagnosis 
of an NSTEMI. As all the results have been discussed in detail in the respective chapter 
of this thesis, the focus in this chapter is to provide a brief summary of the key findings 
of each research question and identify further areas of research. 
9.2 Main findings 
The cornerstone of this thesis has been to comprehensively investigate the patient, 
hospital and procedural aspects associated with the use of an invasive strategy and the 
role of risk stratification in guiding the invasive management of patients admitted with 
NSTEMI. Generally, the thesis (i) reports important differences in the invasive 
management of patients admitted following an NSTEMI (ii) identifies different 
subgroups of patients who are at a disadvantage to receive an early invasive strategy 
despite having the potential to gain more benefit from it (iii) illustrates the lack of 
sensitivity of current guidelines to differentiate risk and leading to significant biases in 
the use of an invasive strategy particularly in high-risk patients (iv) reports an 
association between the presence of a cardiac catheter laboratory at the first admitting 
hospital and the receipt of an invasive strategy and clinical outcomes (v) optimal access 
site selection and the role of alternative access in performing an invasive strategy (PCI). 
Figure 9.1 illustrates the relationship between chapters and the research question, and 





Figure 9.1 Pictorial illustration of how each chapter reports the different aspects 
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9.2.1 What are the patient level factors related to the use of an invasive strategy and 
variations in different subgroups?  
Chapter 4 & 5 of this thesis were designed to examine different patient level factors 
such as age, gender, ethnicity, cardiac and non-cardiac comorbidities and how they are 
associated with the use of an invasive strategy overall and the timing of an invasive 
strategy respectively. The key findings from chapter 4 showed that despite an increase 
in the utilisation of an invasive strategy over the past decade, there remain significant 
disparities across different subgroups of patients. For example, patients with increased 
comorbidity burden defined as CCI≥3 were almost 25% less likely to receive an 
invasive strategy compared to less comorbid patients defined as CCI=0. Similar 
underutilisation of the invasive strategy was noted in elderly patients age≥81 compared 
to those aged≤60 who were almost twice as likely to receive an invasive strategy. 
Subgroups such as gender (men vs women), ethnicity (Whites vs African American) 
also showed similar inequalities in the use of an invasive strategy in women and African 
American. This study also shows that patient features, which are known to be associated 
with an increased risk of adverse events in NSTEMI such as age, diabetes with 
complications, prior history of CABG, PCI or ACS actually have a strong inverse 
relationship with receipt of an invasive strategy. Importantly, certain non-cardiac 
comorbidities, which are associated with poor outcomes such as metastatic cancer, 
dementia, and chronic renal failure were also independently associated with lower odds 
of receipt of an invasive strategy.  
Chapter 5 demonstrates that there is significant heterogeneity in access to an early 
invasive strategy (within 24 hours of admission). Together with the work in chapter 4.0, 
the results from this study illustrate that despite the increasing use of an early invasive 




Specifically, temporal trends in the timing of an invasive strategy stratified according to 
gender reveal that early invasive strategy was comparatively higher in men (74.2% to 
68.6%) during the study period, although there was a greater proportional increase in 
the use of an early invasive strategy from 60.9% to 70.0% in women. Similar to the 
findings reported in chapter 4, only half of the patients with higher comorbidity burden 
defined as CCI≥3 were managed invasively within 24hours compared to patients 
without any comorbidity. Similar inequalities were noted in patients admitted on 
weekend compared to weekday admission and older patients (age >75) compared to 
their younger counterparts (age<65) were significantly less likely to receive an early 
invasive strategy. Temporal analysis of patient characteristics showed that there were 
significant changes in clinical characteristics and baseline risk profile of patients treated 
with an early invasive strategy compared to intermediate and late invasive strategy, so 
that the use of an early invasive strategy remains attenuated in elderly, complex and 
multi-morbid patients despite an overall increase in adoption of an early invasive 
strategy in NSTEMI. The presence of non-cardiac comorbidities such as liver disease, 
peripheral vascular disease, chronic renal failure, dementia and history of alcohol 
disease was inversely associated with receipt of an early invasive strategy. In the 
adjusted outcomes analysis, the use of an invasive strategy on day 2 from admission 
appears to be safe with the greatest reduction in odds of in-hospital mortality and major 
adverse cerebrovascular events.  
9.2.2 Risk stratification and adoption of guidelines in the use of an invasive strategy  
This study in chapter 6 was focused to evaluate the use of an invasive strategy in the 
management of NSTEMI according to risk criteria of international guidelines
3,4
. 
Adherence to guidelines recommended use of an invasive strategy was examined and 




diagnosis of NSTEMI in England and Wales were deemed to be high-risk based on the 
current guidelines recommended risk criteria. Although, the recommendation in this 
high-risk group is to undergo an invasive strategy within 24 hours, only one in ten 
patients actually received an invasive strategy within this time period. There was also a 
significant disconnect between the guidelines recommended timing of invasive strategy 
and baseline risk of all patients. For instance, patients in the low-risk group were twice 
as more likely to receive early invasive strategy within 24 hours compared to the high-
risk group despite the fact that the recommendations in the low-risk cohort is to receive 
an invasive strategy within 72 hours from admission. In the subgroup analysis based on 
gender, access to guidelines recommended invasive strategy was significantly lower in 
the women compared to men. Specifically, high-risk women were not only less likely to 
receive an invasive strategy within 24 hours but experienced the greatest delay 
compared to high-risk women.  
9.2.3 Association between the presence of cardiac catheter laboratory facilities and the 
use of an invasive strategy in the management of NSTEMI 
Chapter 7 of this thesis was conceptualised to study the association between an 
important hospital factor in the form of the presence of cardiac catheter laboratory 
facilities, the use of an invasive strategy and clinical outcomes. This study highlights 
important differences in both the utilisation of an invasive strategy and the subsequent 
management of NSTEMI patients according to admitting hospital cardiac catheter 
laboratory facilities. The utilisation of an invasive strategy in the form of coronary 
angiography was similar in patients admitted to hospitals without any cardiac catheter 
laboratory facilities (no lab hospital; 85.6%), hospitals with only diagnostic cardiac 
catheter laboratory facilities (diagnostic hospitals; 86.0%) and hospital with facilities to 




centres were at a significant disadvantage to receive PCI. Patients admitted to hospitals 
with onsite cardiac catheter laboratory facilities had similar outcomes compared to those 
admitted at hospitals without such facilities. In high-risk NSTEMI group (with GRACE 
score >140), admission to a diagnostic hospital was associated significantly lower 
receipt of PCI and with an increased risk of in-hospital all-cause and cardiac mortality 
particularly in those receiving invasive strategy locally compared to those transferred to 
the nearest PCI hospital. 
9.2.4 Appropriate radial access site selection for performing an invasive strategy 
The final part of this thesis reports on the safety and clinical efficacy of using left versus 
right radial access in performing an invasive strategy in the form of PCI procedure. 
Right radial access is the most commonly used access site (96%) compared to left radial 
access (4%). However, patients with Asian ethnicity (27.9%), previous CABG (23.4%) 
and short height <150cm (6.8%) were more likely to have left radial access used for PCI 
procedure. In patients undergoing repeat PCI, over one-third of the patients (28%) had 
access site switched from RRA at each successive procedure to mainly femoral access 
with only a minority (<5%) undergoing procedures through the left radial access. There 
were no differences between the use of access site and clinical outcomes, in-hospital 
death, 30-day mortality, MACE, in-hospital stroke complication and major bleeding. 
Notably, in the propensity score matching analysis, the left radial access was associated 
with a significant decrease in in-hospital stroke risk, whereas all the other outcomes 
results were consistent with the main analysis with no differences in in-hospital death, 
major bleeding, MACE and 30-day mortality. For the first time in literature, this study 
confirmed that left radial access offers a safe alternative access site and may help to 




9.3 Clinical implications 
The results from studies conducted in this thesis provide novel information about 
various aspects of invasive management of NSTEMI, which may have important 
clinical implications.  
Chapter 4 of this thesis presents important results, demonstrating that there are 
significant disparities in the adoption of an invasive strategy with particularly slower 
utilisation in different subgroups of patients. A similar pattern in inequalities in the 
timing of invasive strategy was observed in chapter 5, where slower utilisation of early 
invasive strategy within 24hours was noted in elderly, female and patients with higher 
comorbidity burden. These results could have important consequences for routine 
clinical practice, particularly because they not only highlight the need for developing 
pathways to improve overall invasive management of NSTEMI patients but provide 
important information for healthcare providers to develop strategies designed to ensure 
fair and appropriate access to the invasive strategy in different subgroups of patients. 
These findings are of major interest given NSTEMI is the most frequent manifestation 
of acute coronary syndromes and is likely to be encountered by many healthcare 
professionals such as those working accident and emergency, general internal medicine 
and cardiology. 
Chapter 6 describes the level of compliance with the utilisation of an invasive strategy 
based on the risk criteria as per current ESC, AHA/ACC guidelines recommendations in 
the management of a national population of patients admitted following a diagnosis of 
NSTEMI. This shows that there is significantly lower compliance with the adoption of 
guidelines, particularly in high-risk patients. The significant rise in the number of 
patients being classified into the high-risk category was due to guidelines 




elevated cardiac troponin levels. The increased sensitivity of newer generation troponin 
assays has translated into an increasing number of patients being detected with elevated 
cardiac troponins. As such offering an invasive strategy within 24 hours to every patient 
with positive troponin test would require a significant expansion in cardiac catheter 
laboratory services, workforce and financial resources. That aside, from the logistics 
and structure point of it will not be possible to offer an invasive strategy within 
recommended time frames in an under-resourced healthcare system. An alternative 
approach would be to develop regional pathways for the invasive management of 
NSTEMI patients as discussed in the next section. Future research also needs to focus 
on investigating whether patients with elevated cardiac troponin would benefit from an 
invasive strategy and determine the optimal timing of procedure in this cohort.  
Chapter 7 of this thesis focuses on the institutional aspect of the invasive management 
of NSTEMI patients. It shows that the use of an invasive strategy varies according to 
the availability of cardiac catheterisation facilities at the first admitting hospital. The 
lower rates of invasive coronary strategy in patients admitted to diagnostic hospitals 
suggests that in clinical practice, physicians are likely to adopt a risk-averse strategy 
particularly in high-risk NSTEMI patients. In clinical practice, the physician performing 
a diagnostic procedure may not necessarily be an interventional cardiologist and may 
not be best placed to assess the risk & benefits of further revascularisation in the form 
of PCI or CABG. This may in return influence the decision to treat patients such as 
those with high-risk features conservatively. There is also a possibility that delays in 
treatment such as timely use of an invasive strategy may be culminating in a longer 
length of hospital stays and costs. Future efforts may need to be focused on 




a regional pathway for uniform and early access to an invasive strategy, especially in 
high-risk NSTEMI patients. 
Finally, chapter 8 investigated the procedural aspects of an invasive strategy. LRA was 
associated with a reduced risk of PCI-related in-hospital stroke complications due to 
favourable anatomy of the aortic arch on the left side, the lesser requirement for catheter 
manipulation and instrumentation in the aorta. Therefore, LRA offers a safe alternative 
access site and may help to reduce PCI-related stroke complications. Furthermore, a 
greater understanding for the reasons of higher access site switch from radial to femoral 
rather than the contralateral arm is needed with educational program development to 
improve familiarity amongst operators for the LRA approach at an early stage in their 
career and improve overall invasive management of NSTEMI patients.  
9.4 Future area for research 
There are several important findings presented in this thesis which can be extended to 
further research. As discussed earlier, the present analyses were derived from three 
different datasets to investigate various aspects of invasive management of patients 
admitted with an NSTEMI. Ideally, a dataset containing information around patient 
baseline profile, comorbidities, risk score, pharmacology, coronary anatomy and 
procedure details would serve well to conduct this type of research, however, the 
logistics and feasibility of such dataset on a national scale would very challenging and 
time consuming. An alternative approach would be to create a longitudinal cohort by 
linking electronic healthcare records to allow not only a comprehensive assessment of 
the patient’s journey during hospital admission but also investigate long term outcomes. 
This will also be more feasible in a shorter time span by using existing datasets. As 
discussed earlier, an important limitation of current work is not being able to investigate 




Prospective large randomised control studies or better data collection with accurate 
timing of procedures with adequate power based on patient baseline risk are required to 
answer this question.  
Current guidelines on risk stratification and timing of invasive strategy particularly on 
the high-risk group are mainly based on expert consensus or studies conducted pre-
potent antiplatelet era. Also as discussed in chapter 6, the advent of high sensitive 
troponin assay has resulted in a significant increase in the detection of type 2 
myocardial injury instead of true plaque rupture causing an NSTEMI. As such inclusion 
of cardiac biomarkers in the high-risk criteria certainly needs revisiting and future 
research needs to consider the role of cardiac biomarkers in risk stratification and the 
use of an invasive strategy. Additionally, there have been significant advancements in 
pharmacological treatments in the contemporary era such as more potent antiplatelet 
agents in the form of ticagrelor, prasugrel, cangrelor, which are associated with reduced 
ischemic complications of NSTEMI such as reinfarction. It is plausible that a proportion 
of patients being classified as high-risk in current risk criteria may benefit from an 
extended intense medical therapy rather than an early invasive strategy in contemporary 
practice. Therefore, future research needs to be focused to develop risk models in 
predicting risk along with the alignment of guideline’s risk criteria to contemporary 
practice.  
9.5 Overall strengths  
The work presented in this thesis provides a comprehensive overview of all aspects of 
invasive management of patients admitted with a diagnosis of NSTEMI. This work 
focused on examining the differences in baseline demographics of patients receiving an 
invasive strategy in the form of coronary angiography or PCI, associations between 




factors and procedural aspects with receipt of an invasive strategy and clinical 
outcomes. This thesis illustrates the value of using the large national database in 
examining the temporal changes in the risk profile and disparities in receipt of an 
invasive strategy amongst different subgroups of patients admitted with NSTEMI.  
The results from the thesis extend the knowledge about changes in population 
demographics, risk profile and subsequent invasive management in patients admitted 
with a diagnosis of an NSTEMI in the most recent past. Furthermore, novel results such 
as disparities in utilisation and timing of an invasive strategy in different subgroups of 
patients, associations between baseline risk and receipt of an invasive strategy and 
institutional differences in invasive management of high-risk NSTEMI patients are not 
only hypothesis generating but provide important information to healthcare 
policymakers.  
Another important overall strength of this thesis stems from the utilisation of large 
national datasets in cohort derivation. The size and national reach of these databases 
was a key strength and enabled a real-world analysis of different subgroups of patients, 
which are usually excluded from the randomised clinical trials. The national data 
allowed to study temporal trends, changes in characteristics of patients in all-comers, 
real-world setting compared to a highly selected randomised control trials undertaken in 
a much smaller number of patients from selected larger hospitals only. The granularity 
of data around the comorbidities, timing of the procedure, baseline risk profile and 
information about GRACE risk score formed the basis for studying the influence of 
comorbidity burden on the decision making process and compliance of guidelines 




9.6 Overall limitations  
In addition to the individual limitations of each study discussed in each relevant chapter, 
there are some important overall limitations, which need to be considered whilst 
interpreting the findings presented in this thesis as discussed below.  
First and foremost, the research question in the thesis was a comprehensive evaluation 
of invasive management of patients admitted with the diagnosis of NSTEMI and their 
clinical outcomes. As discussed in chapter 1, there are several key aspects of managing 
these patients and to draw robust and clinically meaningful results. We set to study all 
factors such as patient-level factors, hospital-level factors and procedural factors in this 
thesis. Although this approach seems logical and comprehensive, it resulted in using 
three different datasets to study the respective research questions. The strengths and 
limitations of each dataset are discussed at length in chapter 4. Ideally, a comprehensive 
dataset encompassing information around patient comorbidities, risk profile, 
pharmacological treatment and procedural detail would be able to conduct this type of 
research. However, the logistics of creating such dataset at the national scale will be not 
conducive and will need a long time to create a dataset over a decade. Therefore, 
creating a linked electronic healthcare record may be an alternative approach, as 
discussed already in this chapter.  
Another important limitation of this thesis is the fact that the research conducted 
was observational in the form of retrospective cohort studies. Such design allowed to 
study several hospital-level factors such as, the presence of cardiac catheter laboratory 
facilities at the first admitting hospital and their associations with receipt of an invasive 
strategy, temporal trends in changes in baseline risk profile and regional variations in 
the invasive management of NSTEMI which is only possible in an observational setting. 




clinical outcomes of these patients, therefore a causal relationship between the use of an 
invasive strategy, the timing of an invasive strategy and clinical outcomes cannot be 
established. These findings are hypothesis generating and will form the basis of future 
prospective studies.  
It is also important to mention that the diagnostic thresholds for diagnosing NSTEMI 
with the aid of cardiac troponin assays have evolved significantly over the past few 
years as mentioned earlier. Consequently, there has been a significant increase in 
detecting various types of myocardial injury, which may not necessarily reflect a true 
plaque rupture event. It was not possible to examine this in the current thesis due to the 
unavailability of information on types of cardiac troponin assays used.  
The clinical outcomes in this thesis were limited to in-hospital mortality and 
complications in the majority of the studies. It is possible that long term outcomes of 
patients receiving invasive strategy may be different compared to those receiving 
medical management only. Furthermore, the in-hospital complications in most instances 
were self-reported without independent adjudication of events, which may have resulted 
in an underestimation of event rates. Finally, the details about patient characteristics, 
risk factors, pharmacological and invasive treatments in this thesis were based on the 
assumption of acute capture of these details in each respective dataset. This approach 
may be prone to errors as the information collected as part of a national audit compared 
to those collected under restrict research conditions. Furthermore, none of these datasets 
was collected with a specific focus on invasive management of patients admitted with 
NSTEMI. Therefore, the possibility of unmeasured confounder cannot be ruled out. Not 
only that, the accurate information about blood tests, medications, patient’s risk profile 
may also influence the indication of an invasive strategy and inform the decision 





In conclusion, this thesis investigated the invasive management of one of the 
commonest phenotype of ACS. The results show that there are significant disparities in 
the use and timing of invasive strategy in different subgroups of patients. More 
importantly, patients who are most likely to benefit from an overall invasive strategy or 
an early invasive approach are least likely to receive it. There is also a significant 
disconnect between guidelines recommended risk stratification and the use of an 
invasive strategy and this gap appears to be widening with increasing risk. At the 
hospital level, high-risk NSTEMI patients admitted to hospitals with diagnostic cardiac 
catheter laboratory only may be denied early access to an invasive strategy and have 
poor outcomes. Finally, from the procedure point of left radial access offers a very safe 
alternative approach for performing an invasive strategy with the potential added benefit 
of reduced risk of procedure-related stroke complication. These findings not only have 
important implications for risk assessment, developing interventions to allow uniform 
access to an invasive strategy and improve quality of care for patients presenting with 
NSTEMI but also offer promising areas for further research.  
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10.1 Appendix I: Acronyms  
 
Acronym Full Text 
ACE Angiotensin-converting enzyme  
ACEI Angiotensin-converting enzyme inhibitor  
ACS Acute coronary syndrome  
AHA American Heart Association  
AIDS Acquired immune deficiency syndromes 
ATE Average treatment effects 
AHRQ Agency for Healthcare Research and Quality 
ACC American College of Cardiology  
AMI Acute myocardial infarction  
BCIS British Cardiovascular Intervention Society  
BMI  Body mass index 
BP  Blood pressure 
CABG  Coronary artery bypass graft  
CA Coronary angiography  
CCAD Central Cardiac Audit Database  
CHD Coronary heart disease  
CCI Charlson Comorbidity Index 
CI Confidence interval  
CVA Cerebrovascular accident  
CCF Congestive cardiac failure  
CCS Clinical Classification of Software 
ECG Electrocardiogram  
ESC European Society of Cardiology  
GRACE Global Registry of Acute Coronary Events 
HCUP Healthcare Cost and Utilization Project 
ICD- 9 International of the Classification of Diseases, Version 9  
IABP Intra-aortic balloon pump  
IHD  Ischemic heart disease  
IQR  Inter-quartile range  
LVF Left ventricular failure 
LRA Left radial access 
MI Myocardial infarction  
MINAP Myocardial Ischemia National Audit Project  




NICOR National Institute for Cardiovascular Research Outcomes 
NICE National Institute of Health and Clinical Excellence. 
NHS National Health System  
NIS National Inpatient Sample 
ONS Office of National Statistics 
PVD Peripheral vascular disease 
PCI Percutaneous coronary intervention  
PPCI Primary percutaneous coronary intervention  
RCT Randomised control trials 
RRA Right radial access 
RA Rheumatoid arthritis 
SD  Standard deviation  
STEMI  ST-elevation myocardial infarction  
TIA Transient ischaemic attack  
UA Unstable angina  
TIMI Thrombolysis In Myocardial Infarction 
TRA Transradial access 
 
10.2 Appendix II: supplementary tables  
 
Appendix Table 1: List of the international classification of disease, Ninth Edition, clinical modification 
(ICD-9-CM) and clinical classification software codes used for identifying additional comorbidities 
Comorbidities Source Codes 




Family history of 
IHD 
ICD-9-CM V17.3 




Previous CABG ICD-9-CM V45.81x 
Previous PCI ICD-9-CM V45.82x 
Cardiogenic shock ICD-9-CM 785.51 
Use of inotropic 
agents 
ICD-9-CM 00.17 
Use of inotropic 
assist device 
ICD-9-CM 376, 97.44 
Smoking ICD-9-CM V15.82, 305.1 
Dementia ICD-9-CM 290.xx,294.1x,294.2x,294.8,331.0,331.12,331.82,797 
IHD= ischemic heart disease, CABG= coronary artery bypass graft, PCI= percutaneous coronary intervention 
 




 ICD-9 codes Condition Charlson score 
412 Previous myocardial infarction 1 
428 – 428.9 Congestive heart failure 1 
433.9, 441 – 441.9, 785.4 V43.4 Peripheral vascular disease 1 
V12.54, 438.x Previous cerebrovascular disease 1 
290 – 290.9 Dementia 1 
490 – 496, 500 –505, 506.4 Chronic pulmonary disease 1 
710.0, 710.1, 710.4, 714 – 714.2, 
714.81, 725 
Rheumatologic disease 1 
531 – 534.9 Peptic ulcer 1 
571.2, 571.5, 571.6, 571.4 –571.49 Mild liver disease 1 
250 – 250.3, 250.7 Diabetes 1 
250.4 – 250.6 Diabetes with chronic complications 2 
344.1, 342 – 342.9 Hemiplegia or paraplegia 2 
582 – 582.9, 583 – 583.7, 585, 586, 588 
– 588.9 
Renal Disease 2 
140 – 172.9, 174 –195.8, 200 – 208.9 Any malignancy including leukaemia and 
lymphoma 
2 
572.2 – 572.8  Moderate or severe liver disease 3 
196 – 199.1 Metastatic solid tumour 6 




Appendix Table 3: ICD-9-CM codes for in-hospital outcomes 
Post-procedural Complication ICD-9-CM or CCS codes 
Bleeding complication  
Gastrointestinal CCS 153 
Unspecified haemorrhage 459.0 
Retroperitoneal haemorrhage 568.81, 998.1 
Intracranial haemorrhage 430-432x 
Post-op haemorrhage requiring transfusion 99.0 (procedure) 
Blood transfusion V58.2 
Vascular complications  
Vascular injury 900-904, 998.2, 447, 868.04, 999.7 (diagnosis) 
39.31, 39.41, 39.49, 39.52, 39.53, 39.56 - 39.59 39.79 
(procedure) 




Iatrogenic cardiac complication  997.1 
Pericardial complication 423.0, 423.3 (diagnosis) 47.0 (procedure) 
Requiring CABG surgery 36.1x, 36.2, 36.31, 36.32, 36.9x 
Coronary artery dissection complication 414.12 
CABG= coronary artery bypass graft surgery 
Appendix Table 4: Missing information about each variable included in the study 
Variables Number (%) 
Age ( Years) 0 (0%) 
Women (%) 0 (0%) 
Caucasians (%) 0 (0%) 
BMI median [IQR] 61,835 (45%) 
Cardiogenic shock 0 (0%) 
ECG ST changes 1,381 (1.0%) 
Cardiac arrest 5,192 (3.8%) 
Acute heart failure 0 (0%) 
GRACE score High risk >140 53,477 (39.0%) 
Troponin positive 3,097 (2.3%) 
GRACE score Intermediate risk 109-140 53,477 (39.0%) 
Chronic renal failure 6,560 (4.8%) 
Percutaneous coronary intervention 6,072 (4.4%) 
Coronary artery bypass graft 5,961 (4.3%) 
Diabetes 2,233 (1.6%) 
LVEF<40% or CCF 64,896 (47.3%) 
Hypercholesterolemia 7,606 (5.5%) 
Angina 6,941 (5.1%) 
Cerebrovascular disease 6,391 (4.6%) 
Peripheral vascular disease 7,070 (5.1%) 
Hypertension 5,573 (4.1%) 
Smoking status 4,938 (3.6%) 
Asthma / COPD 6,458 (4.7%) 
Seen by cardiologist 0 (0%) 
Heart rate, bpm, median (IQR) 17,555 (12.8%) 
Systolic blood pressure, median (IQR) 18,545 (13.5%) 
Family history of CHD 20,905 (15.2%) 
Hospital catheter lab status 0 (0%) 
Low molecular weight heparin 17,137 (12.5%) 
Warfarin 21,183 (15.4%) 




Glycoprotein use 18,440 (13.4%) 
Aspirin 15,892 (11.6%) 
P2Y12 inhibitors 2,687 (2.0%) 
Statins 16,980 (12.4%) 
ACE inhibitors 19,825 (14.4%) 
Beta-Blockers 18,066 (13.2%) 
Death 0 (0%) 
Cardiac mortality 0 (0%) 
Reinfarction 7,254 (5.3%) 
Major bleeding 3,195 (2.3%) 
BMI= body mass index, CHD, coronary heart disease, CCF= congestive cardiac failure 
Appendix Table 5: Missing information on each variable used in the analysis  
Variables Number Percentage  
Age 0 0% 
Male (%) 0 0% 
Caucasians (%) 0 0% 
Body mass index median [IQR] 273,226 60% 
Heart rate, bpm, median (IQR) 54,046 11.9% 
Systolic blood pressure, median (IQR) 54,375 12.0% 
ECG changes 10,812 2.4% 
Troponin positive 12,840 2.8% 
Out of hospital cardiac arrest 22,697 5.0% 
Creatinine, median (IQR) 50,345 11.1% 
Seen by cardiologist 26,891 6.0% 
Left ventricular systolic function 271,650 60.1% 
GRACE risk score 271,813 60.1% 
Percutaneous coronary intervention 27,614 6.1% 
Coronary artery bypass graft 26,656 5.9% 
Heart failure 29,545 6.5% 
Hypercholesterolemia 31,296 6.9% 
Angina 26,891 6.0% 
Cerebrovascular disease 28,454 6.3% 
Peripheral vascular disease 34,518 7.6% 
Chronic renal failure 29,335 6.5% 
Diabetes 9,063 2.0% 
Hypertension 23,115 5.1% 




Asthma / COPD 30,705 6.8% 
Family history of CHD 98,104 21.7% 
Low molecular weight heparin 49,885 11.0% 
Warfarin 62,116 13.7% 
Loop Diuretic 60,766 13.4% 
Glycoprotein use 56,663 12.5% 
Coronary angiography 59,381 13.1% 
Receipt of PCI 94,256 20.8% 
Aspirin 97,573 21.6% 
P2Y12 inhibitors 110,989 24.5% 
Statins 9,656 2.1% 
ACE inhibitors 111,209 24.6% 
Beta-Blockers 11,828 2.6% 
In-hospital mortality 0 0% 
Cardiac mortality 0 0% 
Bleeding 10,395 2.3% 
  
Appendix Table 6: Baseline characteristics of patients with GRACE risk score >140 stratified into 
different levels of hospital catheter laboratory facilities.  











Age 80 [74-86] 76 [70.1-81] 82 [75-87] 73[73-85] <0.001 
Male (%) 12,136 (57.8%) 3,767 (64.8%) 10,012 (53.7%) 33,318 (56.3%) <0.001 
Caucasians (%) 18,287 (86.2%) 5,240 (90.1%) 16,647 (89.3%) 46,015 (83.3%) <0.001 
BMI median [IQR] 26.1 [23.1-30.1] 27.5 [24.4-30.8] 25.8 [22.6-29.5] 26.5 [23.5-30.1] 0.0001 
Presenting Characteristics      
Heart rate, bpm, median 
(IQR) 
82 [69-98] 79 [67-95] 83 [70-98] 80 [68-96] <0.001 
Systolic blood pressure, 
median (IQR) 
137 [118-158] 140 [121-160] 136 [118-156] 137 [118-157] 0.001 
ECG changes 17,432 (82.1%) 4,926 (84.7%) 15,303 [82.1%) 46,223 (83.7%) 0.001 
Troponin positive 20,598 (97.0%) 5,737 (98.7%) 18,156 (97.4%) 53,532 (96.9%) 0.001 
Out of hospital cardiac arrest 311 (1.5%) 76 (1.3%) 210 (1.1%) 1,003 (1.8%) <0.001 
Creatinine, median (IQR) 102 [84-133] 97 [83-120] 103 [84-136] 101 [83-133] <0.001 
Seen by cardiologist 18,448 (88.6%) 5,651 (98.4%) 1,791 (90.2%) 51,727 (94.6%) <0.001 
Left ventricular systolic 
function 




Good 5,087 (49.5%) 1,550 (58.2%) 4,783 (50.4%) 15,199 (51.5%)  
Moderate 3,375 (32.9%) 789 (29.6%) 3,015 (31.8%) 9,658 (32.7%)  
Poor 1,812 (17.6%) 322 (12.1%) 1,696 (17.8%) 4,658 (15.8%)  
Previous medical history      
Percutaneous coronary 
intervention 
2,551 (12.3%) 862 (15.4%) 1,715 (9.8%) 8,798 (16.4%) <0.001 
Coronary artery bypass graft 2,142 (10.2%) 682 (12.2%) 1,820 (10.4%) 6,709 (12.5%) <0.001 
Heart failure 2,665 (12.8%) 368 (6.6%) 2,358 (13.5%) 6,211 (11.5%) 0.001 
Hypercholesterolemia 6,459 (31.4%) 2,291 (14.3%) 5,917 (34.1%) 20,539 (38.8%) <0.001 
Angina 8,210 (39.4%) 2,292(41.0%) 7,438 (42.5%) 20,042 (37.3%) 0.001 
Cerebrovascular disease 3,107 (14.9%) 533 (9.5%) 2,755 (15.7%) 7,384 (13.7%) <0.001 
Peripheral vascular disease 1,395 (6.7%) 328 (5.9%) 1,213 (7.0%) 4,156 (7.8%) <0.001 
Chronic renal failure  2,953 (14.2%) 503 (9.0%) 2,406 (13.8%) 7,957 (14.8%) 0.04 
Diabetes 6,394 (30.4%) 1,741 (30.2%) 5,389 (29.2%) 17,111 (31.3%) 0.001 
Hypertension 13,336 (63.8%) 3,658 (65.2%) 11,058 (62.9%) 35,278 (65.4%) 0.001 
Smoking status     <0.001 
Previous smoker 8,624 (43.5%) 2,477 (43.8%) 7,256 (40.9%) 22,465 (43.0%)  
Current smoker 2,357 (11.9%) 851 (15.0%) 1,941 (10.9%) 6,354 (12.2%)  
Asthma / COPD 4,270 (20.5%) 1,029 (18.4%) 3,832 (21.9%) 10,301 (19.1%) 0.001 
Family history of CHD  2,678 (17.3%) 1,140 (25.5%) 2,081 (15.8%) 9,523 (20.7%) <0.001 
In-hospital Pharmacology      
Low molecular weight 
heparin 
10,687 (53.8%) 2,444 (44.8%) 9,211 (52.8%) 25,957 (51.0%) <0.001 
Warfarin 1,799 (9.2%) 350 (6.5%) 1,885 (10.9%) 4,465 (8.9%) <0.001 
Loop Diuretic 8,199 (41.5%) 1,600 (29.6%) 7,781 (44.8%) 20,776 (41.2%) <0.001 
Glycoprotein use 367 (1.9%) 166 (3.1%) 125 (0.7%) 1,860 (3.6%) <0.001 
Coronary angiography use 9,368 (62.0%) 5,814 (100%) 5,217 (45.0%) 32,396 (72.0%) <0.001 
Receipt of PCI 3,440 (25.6%) 1,446 (49.9%) 1,175 (9.3%) 18,653 (38.9%) <0.001 
Discharge Medications      
Aspirin 13,077 (87.5%) 2,233 (96.2%) 12,709 (85.0%) 44,909 (92.7%) <0.001 
P2Y12 inhibitors 11,853 (83.0%) 2,106 (91.5%) 11,538 (79.8%) 41,334 (87.6%) <0.001 
Statins 13,095 (89.8%) 2,219 (95.6%) 13,336 (90.0%) 43,969 (92.0%) <0.001 
ACE inhibitors 11,041 (76.9%) 1,982 (86.7%) 10,630 (72.9%) 37,169 (79.5%) <0.001 
Beta-Blockers 11,563 (78.3%) 1,961 (85.2%) 11,785 (78.8%) 39,606 (82.7%) <0.001 
ECG changes= ST –depression, transient ST elevation, T wave inversion, GRACE = Global Registry of Acute Coronary 
Event, ACE= angiotensin converting enzyme PCI= Percutaneous coronary intervention, BMI= body mass index 
 
Appendix Table 7: Missing information on each variable used in the analysis 
 
Variable  Missing information  
Age (y), mean (SD) 0 
Male, n(%) 0 




Hypercholesterolemia (%) 19,947 (5.8%) 
Hypertension (%) 19,946 (5.8%) 
Diabetes (%) 11,863 (3.46%) 
Previous CABG (%) 103,843(30.3%) 
Previous CVA (%) 19,946 (5.8%) 
Peripheral vascular disease (%) 19,947 (5.8%) 
Previous AMI (%) 21,484 (6.3%) 
Previous PCI (%) 10,166 (3%) 
LVSD (%) 157,073 (45.8%) 
Smoking (%) 29,648 (8.6%) 
Renal Failure (%) 20,933 (6.1%) 
Indication for PCI 2,561 (0.75%) 
Operator status 38,761(11.3%) 
Multi vessel PCI (%) 4,467 (1.3%) 
Cardiogenic Shock (%) 124,582 (36.3%) 
Pharmacological Inotropes 18,163 (5.3%) 
Intra-aortic balloon pump device (%) 18,163 (5.3%) 
Left main stem PCI (%) 4,467 (1.3%) 
Mechanical ventilation (%) 45,154 (13.2%) 
PCI to Grafts 4,467 (1.3%) 
Chronic total occlusion PCI 22,449(6.5%) 
Stent Use  12,182(3.5%) 
Bivalirudin (%) 28,913 (8.4%) 
GP2b3a use (%) 28,913 (8.4%) 
Ticagrelor (%) 28,912 (8.4%) 
Prasugrel (%) 28,912 (8.4%) 
Warfarin (%) 28,916 (8.4%) 
In hospital death (%) 8,062 (2.3%) 
MACE (%) 10,558 (3.0%) 
Major Bleeding (%) 10,552 (3.0%) 
In-hospital stroke 10,558 (3.0%) 
30-day mortality (%) 62,282 (19.6%) 
MACE=major adverse cardiovascular events defined as composite of in-hospital mortality, in-hospital myocardial infarction 
or re-infarction and revascularization- emergency PCI or CABG, HTN= hypertension, AMI= acute myocardial infarction, 
LVDS= left ventricular systolic dysfunction, PVD= peripheral vascular disease, PCI= percutaneous coronary intervention, 
CABG= coronary artery bypass graft, IABP= intra-aortic balloon pump,LMS= left main stem, BMS= bare metal stent, DES= 
drug-eluting stent.BMI=body mass index 
Appendix Table 8: Baseline characteristics and procedural details of patients undergoing left and right 
radial percutaneous coronary intervention in the United Kingdom after excluding patients with a 
previous history of coronary artery bypass grafting. 






Age (y), mean (SD) 64.0±11.8 66.4±11.0 <0.001 
Male, n(%) 197,206 (76.4%) 8,143 (74.1%) <0.001 
BMI mean, (SD) 28.5±5.18 29.2±5.61 <0.001 
Hypercholesterolemia (%) 137,880 (55.5%) 7,338 (68.9%) <0.001 
Hypertension (%) 134,098 (54%) 7,167 (67.2%) <0.001 
Diabetes (%) 46,339 (18.5%) 2,970 (27.7%) <0.001 
Previous CVA (%) 9,743 (3.9 %) 780 (7.3%) <0.001 
Peripheral vascular disease 
(%) 
11,140 (4.5%) 1,351 (12.7%) <0.001 
Previous AMI (%) 57,040 (25.3%) 4,726 (45.6%) <0.001 
Previous PCI (%) 50,413 (19.9%) 4,149 (38.4 %%) <0.001 
LVSD (%) 35,858 (27.4%) (30.1%) 2,164 (34.0%) <0.001 
Smoking (%)    
Never smoked 82,779(35.0%) 3,383(33.3%)  
Current smoker 91,013(38.5%) 4,861(48%)  
Ex-smoker 62,475(26.4%) 1,891(18.7%)  
Renal Failure (%) 1,826 (0.7%) 165 (1.6%) <0.001 
Indication for PCI    
Stable Angina (%) 89,065 (34.7%) 5,031(46.4%)  
STEMI (%) 101,107 (39.4%) 4,684 (43.2%)  
UA/NSTEMI 66,095 (25.8%) 1,310 (10.4%)  
Operator status    
Consultant  169,662 (69.4%) 3,433 (67%) <0.001 
Trainee 74,789 (30.6%) 3,433 (33.0%) <0.001 
Multi vessel PCI (%) 34,605 (13.5%) 1,602 (14.8%) <0.001 
Cardiogenic Shock (%) 3,027 (1.8%) 125 (2.1%) 0.07 
Pharmacological Inotropes 1.036 (0.4%) 59 (0.5%) 0.03 
Intra-aortic balloon pump 
device (%) 
1,559 (0.6%) 52 (0.5%) 0.07 
Left main stem PCI (%) 7,070 (2.8%) 633 (5.8%) <0.001 
Mechanical ventilation (%) 2,036 (0.9%) 139 (1.4%) <0.001 
Chronic total occlusion PCI 13,848 (5.7%) 702 (6.7%) <0.001 
Stent Use     
No Stents (%) 16,268 (6.5%) 1,109 (10.4%)  
BMS only (%) 44,989 (18%) 1,709 (16.0%)  
DES only (%) 181,274 (72.4%) 7,531 (70.5%)  
BMS & DES (%) 7,836 (3.1%) 319 (3.0%)  
Bivalirudin (%) 11,738 (4.8%) 189 (1.8%) <0.001 
GP2b3a use (%) 77,681 (25.0%) 2,248 (16.7%) <0.001 
Ticagrelor (%) 19,087 (7.8%) 674 (6.4%) <0.001 
Prasugrel (%) 14,934 (6.1%) 408 (3.9%) <0.001 
Warfarin (%) 2,708(1.1%) 300 (2.9%) <0.001 
In hospital death (%) 1,821 (0.7%) 96 (0.9%) 0.04 
MACE (%) 3,535 (1.4%) 179 (1.6%) 0.02 
Major Bleeding (%) 1,305 (0.41%) 75 (0.54%) 0.02 
In hospital Stroke 311 (0.12%) 9 (0.08%) 0.250 
30-day mortality (%) 3,808 (1.5%) 202 (1.8%) 0.002 
MACE=major adverse cardiovascular events defined as a composite of in-hospital mortality, in-hospital myocardial 
infarction or re-infarction and revascularization- emergency percutaneous coronary intervention or CABG, LVSD= left 
ventricular systolic dysfunction, CABG= coronary artery bypass grafting, AMI= acute myocardial infarction, PCI= 




Appendix Table 9: Adjusted outcomes following Left radial versus right radial access after excluding 
patients with a previous history of CABG 
 
Clinical outcomes Odds ratio (95%CI) p-value 
In hospital death 1.11 (0.85-1.44) 0.82 
Major bleeding 1.01 (0.791.52) 0.56 
In hospital stroke 0.43 (0.15-1.17) 0.10 
MACE 1.03 (0.84-1.26)  0.74 
30- day mortality  1.06 (0.85-1.32)  0.56 
MACE=major adverse cardiovascular events defined as a composite of in-hospital mortality, in-hospital myocardial 
infarction or re-infarction and revascularization- emergency percutaneous coronary intervention or CABG 
 
Appendix Table 10: Predictors of Left radial access after excluding patients with a previous history of 
CABG 
Predictor Odds ratio (95%CI) p-value 
Female  1.01 (1.00-1.01) <0.001 
Repeat Procedures 1.30(1.22-1.37) <0.001 
Previous AMI 1.77 (1.65-1.90) <0.001 
Peripheral vascular disease 2.02 (1.84-2.21) <0.001 
Mechanical ventilation   2.09 (1.71-2.56) <0.001 
Renal Failure 1.57(1.26-1.95) <0.001 
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10.3 Appendix III: Thesis related publications 
June 2018 CME: 
Incidence, determinants and outcomes of left and right radial access use in patients undergoing 
percutaneous coronary intervention in the United Kingdom, a national perspective using the British 




, Mamas A Mamas
1,2 
1. Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care 
and Health Sciences, Keele University, UK 
2. Academic Department of Cardiology, Royal Stoke Hospital, University Hospital North 
Midlands, Stoke-On-Tent, UK 
Learning Objectives: 
 Appraise the risks and benefits associated with different vascular access sites for performing the 
percutaneous coronary intervention. 
  Recognise the anatomical variations associated with left radial access and right radial access. 
 Compare the procedural advantages between left and right radial access and their association 
with clinical benefits.  
Questions:  
1. Radial access is associated with all of the following except: 
a) Reduced access-site related vascular complications 
b) Increased risk of stroke 
c) Reduced length of stay in hospital  
d) Reduced bleeding complications. 
e) Longer learning curve. 
Radial artery is a smaller superficial artery which is easily compressible compared to the femoral artery. 
The most obvious benefits of radial access include the reduced access site related vascular 
complications, bleeding complications and early patient ambulation. Consequently, the length of stay in 
a patient managed via radial access is much shorter compared to those treated via femoral. 
RW.ERROR - 
Unable to find reference:575
 In one the largest trials to date comparing TRA versus TFA, the MATRIX 
(Minimising Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of 
angioX) trial reported a 28% reduction in mortality (1.6% vs. 2.2%; p = 0.045) with a reduction in net 
adverse clinically events (9.8% vs. 11.7%; p = 0.009) mainly driven by a marked reduction in Bleeding 
Academic Research Consortium3 or 5 major bleeding in the TRA group
73
. Shortly afterwards, an 
updated trial sequential analysis of randomized trials reported that radial access significantly reduces 
mortality by 27%, MACE by 14%, access site bleeding by 63% and major bleeding by 40%, with no 
significant effects on recurrent myocardial infarction and stroke in randomised trials of patients managed 
invasively
70
. Given the anatomical challenges such as small artery size, radial loops and tortuosity, radial 
access is associated with a slightly longer learning curve than femoral access particularly early in 
training
226
. Finally, we previously reported that the risk of stroke is actually quite comparable between 








2. Potential benefits of left radial access include all except 
a) Better access to LIMA graft 
b) Lesser tortuosity and radial loops in the arm 
c) Increase operator comfort  
d) Reduced contrast and fluoroscopy time 
e) Faster learning curve 
Left radial access offers better access to LIMA graft compared to right radial access. Studies have shown 
that left radial access has a smaller incidence of radial loops and also offer favourable anatomy similar to 
femoral access particular in shorter patients
210
. Consequently, there is some evidence that left radial 
access may be quicker in the early stages of learning and reduces contrast and fluoroscopy 
time
76,212,215,223
. Sciahbasi at al randomised 1,547 patients to either left radial or right radial access 
whereby procedures were performed by training fellows or senior cardiologists. Six fellows performed 
532 procedures, 260 through the RRA and 272 through the LRA. During the training period, fellows 
showed a progressive significant reduction in fluoroscopy time for the LRA over the 3 stages from 258 
seconds in the first stage to 142 seconds in stage 3, whereas for the RRA, only a slight and non-
significant reduction in fluoroscopy time was observed
227
.  
3. In this study, which of the following was associated with the use of left radial access 
a) Increase vascular complications  
b) Increased risk of stroke 
c) Increased MACE 
d) Increased mortality  
e) Reduced risk of stroke  
Stroke is a very rare but serious complication associated with PCI. In this study, left radial access was 
associated with a significant reduction in in-hospital stroke ((OR 0.52 95%CI 0.37-0.82, p=0.005). This 
is likely due to the fact that in RRA access, the anatomical variations such as increased incidence of 
tortuosity and loops in the arm and subclavian artery may require extra catheter manipulation. 
Additionally, during RRA access the catheter needs to be passed from the innominate artery into the 
ascending aorta where the right carotid comes off resulting in a theoretically increased risk of 
embolization of plaque into the right carotid artery resulting in an embolic stroke. In contrast, LRA 
access offers very similar anatomy to the TFA approach as the left common carotid artery arises directly 
from the aortic arch. 
4. In the current study, switch from right radial access to femoral access was significantly 
higher in  
a) Young men 
b) Men presenting with NSTEMI 
c) Women 
d) Chronic total occlusion procedures 
e) Taller patients 
In this study, we found that when RRA is used at the first procedure, future use of the RRA for PCI 
drops by 28% overall, by 35% in females and 27% in patients aged >75 at a second procedure with a 
concomitant increase mainly in the use TFA access. 




a) Repeat PCI procedure  
b) Vein graft PCI  
c) Renal failure  
d) Previous CABG 
e) Male sex  
In this study, we found that independent predictors of left radial access use repeated PCI procedure, vein 
graft PCI, Previous AMI, peripheral vascular disease, mechanical ventilation, renal failure, previous 
CABG and female gender.  
 









10.4 Application for data approval confirmation  
 The data approval from HQIP is provided below.  
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National Clinical Audit and Patient Outcomes Programme Data: Guidance for Applicants and Data 
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deliver the relevant clinical audit or clinical outcome review programme. The audit or outcome 
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